

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 May 10 PROUSDDR now available on STN  
NEWS 4 May 19 PROUSDDR: One FREE connect hour, per account, in both May  
and June 2004  
NEWS 5 May 12 EXTEND option available in structure searching  
NEWS 6 May 12 Polymer links for the POLYLINK command completed in REGISTRY  
NEWS 7 May 17 FRFULL now available on STN  
NEWS 8 May 27 New UPM (Update Code Maximum) field for more efficient patent  
SDIs in CAplus  
NEWS 9 May 27 CAplus super roles and document types searchable in REGISTRY  
NEWS 10 May 27 Explore APOLLIT with free connect time in June 2004  
NEWS 11 Jun 22 STN Patent Forums to be held July 19-22, 2004  
NEWS 12 Jun 28 Additional enzyme-catalyzed reactions added to CASREACT  
NEWS 13 Jun 28 ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG,  
and WATER from CSA now available on STN(R)

NEWS EXPRESS MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 11:57:23 ON 01 JUL 2004

=> file medline

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.42

0.42

FILE 'MEDLINE' ENTERED AT 11:58:35 ON 01 JUL 2004

FILE LAST UPDATED: 30 JUN 2004 (20040630/UP). FILE COVERS 1951 TO DATE.

On February 29, 2004, the 2004 MeSH terms were loaded. See HELP RLOAD for details. OLDMEDLINE now back to 1951.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2004 vocabulary. See <http://www.nlm.nih.gov/mesh/> and [http://www.nlm.nih.gov/pubs/techbull/nd03/nd03\\_mesh.html](http://www.nlm.nih.gov/pubs/techbull/nd03/nd03_mesh.html) for a description of changes.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s cerebus protein+NT/CT
'CEREBUS PROTEIN' NOT IN RELATIONSHIP FILE
RELATIONSHIP CODE 'NT' IGNORED
L1          0 CEREBUS PROTEIN+NT/CT  (1 TERM)
```

```
=> s cerebus+NT/CT
'CEREBUS' NOT IN RELATIONSHIP FILE
RELATIONSHIP CODE 'NT' IGNORED
L2          0 CEREBUS+NT/CT  (1 TERM)
```

```
=> e cerebus/CN
E#  FREQUENCY  AT  TERM
--  -
E1      3136      CEREBROSPINAL FLUID PROTEINS/CN
E2        0      2  CEREBROSTEROL/CN
E3        0      --> CEREBUS/CN
E4        0      2  CEREBYX/CN
E5       168      3  CEREC/CN
E6        6      1  CEREC CEMENT/CN
E7        0      2  CEREC VITA BLOCKS/CN
E8        0      2  CERECERENE-15,24-DIOL 30-HOTC/CN
E9        0      2  CEREDASE/CN
E10       12      5  CEREOLYSIN/CN
E11        0      2  CEREPORIN/CN
E12        5      2  CERES-18 PROTEIN/CN
```

```
=> e rosen, c/au
E1        2  ROSEN ZVI M/AU
E2        2  ROSEN ZVI MICHAL/AU
E3        0  --> ROSEN, C/AU
E4        2  ROSENADA CEPERO R/AU
E5        1  ROSENAGER L/AU
E6        1  ROSENAK B/AU
E7       33  ROSENAK B D/AU
E8       10  ROSENAK D/AU
E9        1  ROSENAK M J/AU
E10       2  ROSENAK R/AU
E11       2  ROSENAK S/AU
E12       9  ROSENAK S S/AU
```

```
=> e haseltine, w/au
E1       221  HASELTINE W A/AU
E2        1  HASELTINE WILLIAM A/AU
E3        0  --> HASELTINE, W/AU
E4        3  HASELTON A/AU
E5        1  HASELTON B J/AU
E6        3  HASELTON C J/AU
E7        6  HASELTON C L/AU
E8        1  HASELTON D J/AU
E9        5  HASELTON D R/AU
E10       3  HASELTON DEBRA R/AU
E11      31  HASELTON F R/AU
E12       3  HASELTON FREDERICK R/AU
```

=> s e1  
L3 221 "HASELTINE W A"/AU

=> s e2  
L4 1 "HASELTINE WILLIAM A"/AU

=> s l4 and l3  
L5 0 L4 AND L3

=> d l4 ti abs ibib tot

L4 ANSWER 1 OF 1 MEDLINE on STN  
TI A tribute to Dr. William A. Haseltine. Interview by Val J. Halamandaris.  
ACCESSION NUMBER: 2003593338 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 14674196  
TITLE: A tribute to Dr. William A. Haseltine. Interview by Val J. Halamandaris.  
AUTHOR: Haseltine William A  
SOURCE: Caring : National Association for Home Care magazine, (2003 Dec) 22 (12) 54-66.  
Journal code: 8301759. ISSN: 0738-467X.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Biography  
Historical  
(INTERVIEW)  
LANGUAGE: English  
FILE SEGMENT: Health  
ENTRY MONTH: 200402  
ENTRY DATE: Entered STN: 20031217  
Last Updated on STN: 20040218  
Entered Medline: 20040217

=> d his

(FILE 'HOME' ENTERED AT 11:57:23 ON 01 JUL 2004)

FILE 'MEDLINE' ENTERED AT 11:58:35 ON 01 JUL 2004

L1 0 S CEREBUS PROTEIN+NT/CT  
L2 0 S CEREBUS+NT/CT  
E CEREBUS/CN  
E ROSEN, C/AU  
E HASELTINE, W/AU  
L3 221 S E1  
L4 1 S E2  
L5 0 S L4 AND L3

=> s l3 and cerebus protein  
0 CEREBUS  
1283301 PROTEIN  
0 CEREBUS PROTEIN  
(CEREBUS (W) PROTEIN)  
L6 0 L3 AND CEREBUS PROTEIN

=> s cerebus?  
L7 0 CEREBUS?

=> file uspatful, dgene, embase, wpids, fsta, jicst, biosis, biobusiness, cen,  
ceaba, japio, hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	4.73	5.15

FILE 'USPATFULL' ENTERED AT 12:05:35 ON 01 JUL 2004  
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 12:05:35 ON 01 JUL 2004  
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'EMBASE' ENTERED AT 12:05:35 ON 01 JUL 2004  
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'WPIDS' ENTERED AT 12:05:35 ON 01 JUL 2004  
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'FSTA' ENTERED AT 12:05:35 ON 01 JUL 2004  
COPYRIGHT (C) 2004 International Food Information Service

FILE 'JICST-EPLUS' ENTERED AT 12:05:35 ON 01 JUL 2004  
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'BIOSIS' ENTERED AT 12:05:35 ON 01 JUL 2004  
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'BIOBUSINESS' ENTERED AT 12:05:35 ON 01 JUL 2004  
COPYRIGHT (C) 2004 Biological Abstracts, Inc. (BIOSIS)

FILE 'CEN' ENTERED AT 12:05:35 ON 01 JUL 2004  
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CEABA-VTB' ENTERED AT 12:05:35 ON 01 JUL 2004  
COPYRIGHT (c) 2004 DECHEMA eV

FILE 'JAPIO' ENTERED AT 12:05:35 ON 01 JUL 2004  
COPYRIGHT (C) 2004 Japanese Patent Office (JPO)- JAPIO

FILE 'HCAPLUS' ENTERED AT 12:05:35 ON 01 JUL 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

=> d his

(FILE 'HOME' ENTERED AT 11:57:23 ON 01 JUL 2004)

FILE 'MEDLINE' ENTERED AT 11:58:35 ON 01 JUL 2004

L1 0 S CEREBUS PROTEIN+NT/CT  
L2 0 S CEREBUS+NT/CT  
E CEREBUS/CN  
E ROSEN, C/AU  
E HASELTINE, W/AU  
L3 221 S E1  
L4 1 S E2  
L5 0 S L4 AND L3  
L6 0 S L3 AND CEREBUS PROTEIN  
L7 0 S CEREBUS?

FILE 'USPATFULL, DGENE, EMBASE, WPIDS, FSTA, JICST-EPLUS, BIOSIS,  
BIOBUSINESS, CEN, CEABA-VTB, JAPIO, HCAPLUS' ENTERED AT 12:05:35 ON 01  
JUL 2004

=> s cerebus

L8 25 CEREBUS

=> d l8 ti abs ibib tot

L8 ANSWER 1 OF 25 USPATFULL on STN

TI Modified transferrin fusion proteins  
AB Modified fusion proteins of transferrin and therapeutic proteins or peptides with increased serum half-life or serum stability are disclosed. Preferred fusion proteins include those modified so that the transferrin moiety exhibits no or reduced glycosylation, binding to iron and/or binding to the transferrin receptor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:31195 USPATFULL  
TITLE: Modified transferrin fusion proteins  
INVENTOR(S): Prior, Christopher P., Philadelphia, PA, UNITED STATES  
PATENT ASSIGNEE(S): BioRexis Pharmaceutical Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004023334	A1	20040205
APPLICATION INFO.:	US 2002-231494	A1	20020830 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-315745P	20010830 (60)
	US 2001-334059P	20011130 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MORGAN LEWIS & BOCKIUS LLP, 1111 PENNSYLVANIA AVENUE NW, WASHINGTON, DC, 20004	
NUMBER OF CLAIMS:	56	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	14 Drawing Page(s)	
LINE COUNT:	15780	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 2 OF 25 USPATFULL on STN

TI Primitive neural stem cells and method for differentiation of stem cells to neural cells  
AB Described are a novel cell type in the neural lineage, and method of producing the same based on the degree of neural commitment and growth factor responsiveness in vitro and the potential to give rise to neural and non-neural progeny in vivo. The novel cell type of neural lineage and cells derived therefrom have a number of applications including applications regarding tissue engineering, transplantation and gene therapy and drug discovery. Also described are suggested uses of the method and cell type including isolating genes that positively and negatively regulate the transmission from an ES cell to a neural cell and generally for studying ES cell models of mammalian neural development.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:294748 USPATFULL  
TITLE: Primitive neural stem cells and method for differentiation of stem cells to neural cells  
INVENTOR(S): Van Der Kooy, Derek, Toronto, CANADA  
Tropepe, Vincent, Boston, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002164791	A1	20021107
APPLICATION INFO.:	US 2001-966768	A1	20010928 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-236394P	20000929 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	

LEGAL REPRESENTATIVE: DANN DORFMAN HERRELL & SKILLMAN, SUITE 720, 1601 MARKET STREET, PHILADELPHIA, PA, 19103-2307  
NUMBER OF CLAIMS: 46  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 7 Drawing Page(s)  
LINE COUNT: 2456  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 3 OF 25 USPATFULL on STN

TI Transgenic mice containing cerberus gene disruptions

AB The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a cerberus gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:289250 USPATFULL  
TITLE: Transgenic mice containing cerberus gene disruptions  
INVENTOR(S): Leviten, Michael W., Palo Alto, CA, UNITED STATES  
Brennan, Thomas J., South San Francisco, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002162131	A1	20021031
APPLICATION INFO.:	US 2001-887552	A1	20010621 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-213670P	20000621 (60)
	US 2001-266046P	20010201 (60)
	US 2001-282668P	20010409 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: DELTAGEN, INC., 1003 Hamilton Avenue, Menlo Park, CA, 94025

NUMBER OF CLAIMS: 16  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 5 Drawing Page(s)  
LINE COUNT: 2132

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 4 OF 25 USPATFULL on STN

TI Endoderm, cardiac and neural inducing factors-oligonucleotides for expressing murine frazzled (Frzb-1) protein

AB Novel proteins have been designated "cerberus" and "frzb-1," respectively. **Cerebus** is expressed as a secreted peptide during embryogenesis of the Xenopus embryo, and is expressed specifically in the head organizer region. This new molecule has endodermal, cardiac, and neural tissue inducing activity, that should prove useful in therapeutic, diagnostic, and clinical applications requiring regeneration, differentiation, or repair of these and other tissues. Frzb-1 is a soluble antagonist of growth factors of the Wnt family that acts by binding to Wnt growth factors in the extracellular space. A third novel protein is therm PAPC which promotes the formation of dorsal mesoderm and somites in the embryo.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:280799 USPATFULL  
TITLE: Endoderm, cardiac and neural inducing factors-oligonucleotides for expressing murine frazzled

(Frzb-1) protein  
 INVENTOR(S): De Robertis, Edward M., Pacific Palisades, CA, UNITED STATES  
 Bouwmeester, Tewis, Heidelberg, GERMANY, FEDERAL REPUBLIC OF  
 PATENT ASSIGNEE(S): THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002156249	A1	20021024
APPLICATION INFO.:	US 2001-903170	A1	20010711 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-552988, filed on 21 Apr 2000, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-20150P	19960620 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Attention: Charles Berman, OPPENHEIMER WOLFF & DONNELLY, 38th Floor, 2029 Century Park East, Los Angeles, CA, 90067-3024	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	18 Drawing Page(s)	
LINE COUNT:	1198	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L8 ANSWER 5 OF 25 USPATFULL on STN  
 TI Endoderm, cardiac and neural inducing factors - murine frazzled (FRZB-1) protein  
 AB Novel proteins have been designated "cerberus" and "frzb-1," respectively. **Cerebus** is expressed as a secreted peptide during embryogenesis of the Xenopus embryo, and is expressed specifically in the head organizer region. This new molecule has endodermal, cardiac, and neural tissue inducing activity, that should prove useful in therapeutic, diagnostic, and clinical applications requiring regeneration, differentiation, or repair of these and other tissues. Frzb-1 is a soluble antagonist of growth factors of the Wnt family that acts by binding to Wnt growth factors in the extracellular space. A third novel protein is therm PAPC which promotes the formation of dorsal mesoderm and somites in the embryo.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:236237 USPATFULL  
 TITLE: Endoderm, cardiac and neural inducing factors - murine frazzled (FRZB-1) protein  
 INVENTOR(S): De Robertis, Edward M., Pacific Palisades, CA, UNITED STATES  
 Bouwmeester, Tewis, Heidelberg, GERMANY, FEDERAL REPUBLIC OF  
 PATENT ASSIGNEE(S): THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002128441	A1	20020912
APPLICATION INFO.:	US 2001-903325	A1	20010711 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-552988, filed on 21 Apr 2000, PENDING		

NUMBER	DATE
-----	

PRIORITY INFORMATION: US 1996-20150P 19960620 (60)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: Attention: Charles Berman, OPPENHEIMER WOLFF &  
DONNELLY, 38th Floor, 2029 Century Park East, Los  
Angeles, CA, 90067-3024  
NUMBER OF CLAIMS: 15  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 18 Drawing Page(s)  
LINE COUNT: 1199  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 6 OF 25 USPATFULL on STN

TI Endoderm, cardiac and neural inducing factors - oligonucleotides for  
expressing human frazzled (frzb-1) protein  
AB Novel proteins have been designated "cerberus" and "frzb-1,"  
respectively. **Cerebus** is expressed as a secreted peptide  
during embryogenesis of the Xenopus embryo, and is expressed  
specifically in the head organizer region. This new molecule has  
endodermal, cardiac, and neural tissue inducing activity, that should  
prove useful in therapeutic, diagnostic, and clinical applications  
requiring regeneration, differentiation, or repair of these and other  
tissues. Frzb-1 is a soluble antagonist of growth factors of the Wnt  
family that acts by binding to Wnt growth factors in the extracellular  
space. A third novel protein is therm PAPC which promotes the formation  
of dorsal mesoderm and somites in the embryo.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:236236 USPATFULL  
TITLE: Endoderm, cardiac and neural inducing factors -  
oligonucleotides for expressing human frazzled (frzb-1)  
protein  
INVENTOR(S): De Robertis, Edward M., Pacific Palisades, CA, UNITED  
STATES  
Bouwmeester, Tewis, Heidelberg, GERMANY, FEDERAL  
REPUBLIC OF  
PATENT ASSIGNEE(S): THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002128440	A1	20020912
APPLICATION INFO.:	US 2001-903323	A1	20010711 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-552988, filed on 21 Apr 2000, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-20150P	19960620 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Attention: Charles Berman, OPPENHEIMER WOLFF & DONNELLY, 2029 Century Park East, 38th Floor, Los Angeles, CA, 90067-3024	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	18 Drawing Page(s)	
LINE COUNT:	1198	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 7 OF 25 USPATFULL on STN

TI Endoderm, cardiac and neural inducing factors - human frazzled (frzb-1)  
protein  
AB Novel proteins have been designated "cerberus" and "frzb-1,"  
respectively. **Cerebus** is expressed as a secreted peptide



during embryogenesis of the *Xenopus* embryo, and is expressed specifically in the head organizer region. This new molecule has endodermal, cardiac, and neural tissue inducing activity, that should prove useful in therapeutic, diagnostic, and clinical applications requiring regeneration, differentiation, or repair of these and other tissues. Frzb-1 is a soluble antagonist of growth factors of the Wnt family that acts by binding to Wnt growth factors in the extracellular space. A third novel protein is termed PAPC which promotes the formation of dorsal mesoderm and somites in the embryo.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:236235 USPATFULL  
TITLE: Endoderm, cardiac and neural inducing factors - human frazzled (frzb-1) protein  
INVENTOR(S): De Robertis, Edward M., Pacific Palisades, CA, UNITED STATES  
Bouwmeester, Tewis, Heidelberg, GERMANY, FEDERAL REPUBLIC OF  
PATENT ASSIGNEE(S): THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002128439	A1	20020912
APPLICATION INFO.:	US 2001-903188	A1	20010711 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-552988, filed on 21 Apr 2000, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-20150P	19960620 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Attention : Charles Berman, OPPENHEIMER WOLFF & DONNELLY, 38th Floor, 2029 Century Park East, Los Angeles, CA, 90067-3024	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	18 Drawing Page(s)	
LINE COUNT:	1199	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 8 OF 25 USPATFULL on STN

TI Endoderm, cardiac and neural inducing factors - oligonucleotides for expressing *xenopus* frazzled (frzb-1) protein

AB Novel proteins have been designated "cerberus" and "frzb-1," respectively. **Cerebus** is expressed as a secreted peptide during embryogenesis of the *Xenopus* embryo, and is expressed specifically in the head organizer region. This new molecule has endodermal, cardiac, and neural tissue inducing activity, that should prove useful in therapeutic, diagnostic, and clinical applications requiring regeneration, differentiation, or repair of these and other tissues. Frzb-1 is a soluble antagonist of growth factors of the Wnt family that acts by binding to Wnt growth factors in the extracellular space. A third novel protein is termed PAPC which promotes the formation of dorsal mesoderm and somites in the embryo.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:228450 USPATFULL  
TITLE: Endoderm, cardiac and neural inducing factors - oligonucleotides for expressing *xenopus* frazzled (frzb-1) protein  
INVENTOR(S): De Robertis, Edward M., Pacific Palisades, CA, UNITED STATES

PATENT ASSIGNEE(S) : Bouwmeester, Tewis, Heidelberg, GERMANY, FEDERAL  
REPUBLIC OF  
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002123613	A1	20020905
APPLICATION INFO.:	US 2001-903171	A1	20010711 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-552988, filed on 21 Apr 2000, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-20150P	19960620 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Attention of Charles Berman, OPPENHEIMER WOLFF & DONNELLY, 38th Floor, 2029 Century Park East, Los Angeles, CA, 90067-3024	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	18 Drawing Page(s)	
LINE COUNT:	1198	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L8 ANSWER 9 OF 25 USPATFULL on STN

TI ENDODERM, CARDIAC AND NEURAL INDUCING FACTORS - XENOPUS PARAXIAL  
PROTOCOLADHERIN PROTEIN

AB Novel proteins have been designated "cerberus" and "frzb-1," respectively. **Cerebus** is expressed as a secreted peptide during embryogenesis of the Xenopus embryo, and is expressed specifically in the head organizer region. This new molecule has endodermal, cardiac, and neural tissue inducing activity, that should prove useful in therapeutic, diagnostic, and clinical applications requiring regeneration, differentiation, or repair of these and other tissues. Frzb-1 is a soluble antagonist of growth factors of the Wnt family that acts by binding to Wnt growth factors in the extracellular space. A third novel protein is therm PAPC which promotes the formation of dorsal mesoderm and somites in the embryo.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:186249 USPATFULL  
TITLE: ENDODERM, CARDIAC AND NEURAL INDUCING FACTORS - XENOPUS  
PARAXIAL PROTOCOLADHERIN PROTEIN  
INVENTOR(S): Robertis, Edward M. De, Pacific Palisades, CA, UNITED  
STATES  
Bouwmeester, Tewis, Heidelberg, GERMANY, FEDERAL  
REPUBLIC OF  
PATENT ASSIGNEE(S) : THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002099172	A1	20020725
APPLICATION INFO.:	US 2001-903187	A1	20010711 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-552988, filed on 21 Apr 2000, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-20150P	19960620 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	

LEGAL REPRESENTATIVE: Attention of Charles Berman, OPPENHEIMER WOLFF &  
DONNELLY, 38th Floor, 2029 Century Park East, Los  
Angeles, CA, 90067-3024

NUMBER OF CLAIMS: 15  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 18 Drawing Page(s)  
LINE COUNT: 1209  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 10 OF 25 USPATFULL on STN

TI ENDODERM, CARDIAC AND NEURAL INDUCING FACTORS - XENOPUS FRAZZLED  
(FRZB-1) PROTEIN

AB Novel proteins have been designated "cerberus" and "frzb-1,"  
respectively. **Cerebus** is expressed as a secreted peptide  
during embryogenesis of the Xenopus embryo, and is expressed  
specifically in the head organizer region. This new molecule has  
endodermal, cardiac, and neural tissue inducing activity, that should  
prove useful in therapeutic, diagnostic, and clinical applications  
requiring regeneration, differentiation, or repair of these and other  
tissues. Frzb-1 is a soluble antagonist of growth factors of the Wnt  
family that acts by binding to Wnt growth factors in the extracellular  
space. A third novel protein is therm PAPC which promotes the formation  
of dorsal mesoderm and somites in the embryo.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:186248 USPATFULL  
TITLE: ENDODERM, CARDIAC AND NEURAL INDUCING FACTORS - XENOPUS  
FRAZZLED (FRZB-1) PROTEIN  
INVENTOR(S): De Robertis, Edward M., Pacific Palisades, CA, UNITED  
STATES  
Bouwmeester, Tewis, Heidelberg, GERMANY, FEDERAL  
REPUBLIC OF  
PATENT ASSIGNEE(S): THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002099171	A1	20020725
APPLICATION INFO.:	US 2001-903180	A1	20010711 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-552988, filed on 21 Apr 2000, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-20150P	19960620 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Attention of Charles Berman, OPPENHEIMER WOLFF & DONNELLY LLP, 38th Floor, 2029 Century Park East, Los Angeles, CA, 90067-3024	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	18 Drawing Page(s)	
LINE COUNT:	1210	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L8 ANSWER 11 OF 25 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN

TI Human and murine **cerebus**-like proteins - used for treating  
tissue defects and degenerative nerve conditions

AN AAW96212 Protein DGENE

AB Compositions containing cerberus like proteins can be used for inducing  
the formation of neurons and related neural cells and tissues, such as  
Schwann cells, glial cells, and astrocytes, as well as liver, pancreas,  
lung, heart, kidney, spleen, stomach, and cardiac tissue and cells. They

may also be used to treat precursor or stem cells. The compositions can also be used for treating tissue defects, and healing and maintenance of various types of tissues and wounds. The cerberus protein containing compositions may also be used to treat or prevent degenerate nerve conditions such as Parkinson's disease, Alzheimer's disease, and Lou Gehrig's disease. They can also be used to treat osteoporosis, rheumatoid arthritis, osteoarthritis, and other abnormalities of connective tissue, or of other organs or tissues.

ACCESSION NUMBER: AAW96212 Protein DGENE  
TITLE: Human and murine **cerberus**-like proteins - used for treating tissue defects and degenerative nerve conditions  
INVENTOR: Derobertis E M; Follettie M  
PATENT ASSIGNEE: (GEMY)GENETICS INST INC.  
(REGC) UNIV CALIFORNIA.  
PATENT INFO: WO 9901553 A1 19990114 50p  
APPLICATION INFO: WO 1998-US11462 19980603  
PRIORITY INFO: US 1997-887997 19970703  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
OTHER SOURCE: 1999-106054 [09]  
CROSS REFERENCES: N-PSDB: AAX08989  
DESCRIPTION: Human cerberus like protein.

L8 ANSWER 12 OF 25 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
TI Human and murine **cerberus**-like proteins - used for treating tissue defects and degenerative nerve conditions  
AN AAW96211 Protein DGENE  
AB Compositions containing cerberus like proteins can be used for inducing the formation of neurons and related neural cells and tissues, such as Schwann cells, glial cells, and astrocytes, as well as liver, pancreas, lung, heart, kidney, spleen, stomach, and cardiac tissue and cells. They may also be used to treat precursor or stem cells. The compositions can also be used for treating tissue defects, and healing and maintenance of various types of tissues and wounds. The cerberus protein containing compositions may also be used to treat or prevent degenerate nerve conditions such as Parkinson's disease, Alzheimer's disease, and Lou Gehrig's disease. They can also be used to treat osteoporosis, rheumatoid arthritis, osteoarthritis, and other abnormalities of connective tissue, or of other organs or tissues.

ACCESSION NUMBER: AAW96211 Protein DGENE  
TITLE: Human and murine **cerberus**-like proteins - used for treating tissue defects and degenerative nerve conditions  
INVENTOR: Derobertis E M; Follettie M  
PATENT ASSIGNEE: (GEMY)GENETICS INST INC.  
(REGC) UNIV CALIFORNIA.  
PATENT INFO: WO 9901553 A1 19990114 50p  
APPLICATION INFO: WO 1998-US11462 19980603  
PRIORITY INFO: US 1997-887997 19970703  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
OTHER SOURCE: 1999-106054 [09]  
CROSS REFERENCES: N-PSDB: AAX08984  
DESCRIPTION: Murine cerberus like protein.

L8 ANSWER 13 OF 25 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN  
TI Human and murine **cerberus**-like proteins - used for treating tissue defects and degenerative nerve conditions  
AN AAX08989 DNA DGENE  
AB Compositions containing cerberus like proteins can be used for inducing the formation of neurons and related neural cells and tissues, such as Schwann cells, glial cells, and astrocytes, as well as liver, pancreas, lung, heart, kidney, spleen, stomach, and cardiac tissue and cells. They may also be used to treat precursor or stem cells. The compositions can also be used for treating tissue defects, and healing and maintenance of

various types of tissues and wounds. The cerberus protein containing compositions may also be used to treat or prevent degenerate nerve conditions such as Parkinson's disease, Alzheimer's disease, and Lou Gehrig's disease. They can also be used to treat osteoporosis, rheumatoid arthritis, osteoarthritis, and other abnormalities of connective tissue, or of other organs or tissues.

ACCESSION NUMBER: AAX08989 DNA DGENE  
TITLE: Human and murine **cerebus**-like proteins - used for treating tissue defects and degenerative nerve conditions  
INVENTOR: Derobertis E M; Follettie M  
PATENT ASSIGNEE: (GEMY)GENETICS INST INC.  
(REGC) UNIV CALIFORNIA.  
PATENT INFO: WO 9901553 A1 19990114 50p  
APPLICATION INFO: WO 1998-US11462 19980603  
PRIORITY INFO: US 1997-887997 19970703  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
OTHER SOURCE: 1999-106054 [09]  
CROSS REFERENCES: P-PSDB: AAW96212  
DESCRIPTION: Sequence encoding human cerberus like protein.

L8 ANSWER 14 OF 25 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN

TI Human and murine **cerebus**-like proteins - used for treating tissue defects and degenerative nerve conditions

AN AAX08988 DNA DGENE

AB Compositions containing cerberus like proteins can be used for inducing the formation of neurons and related neural cells and tissues, such as Schwann cells, glial cells, and astrocytes, as well as liver, pancreas, lung, heart, kidney, spleen, stomach, and cardiac tissue and cells. They may also be used to treat precursor or stem cells. The compositions can also be used for treating tissue defects, and healing and maintenance of various types of tissues and wounds. The cerberus protein containing compositions may also be used to treat or prevent degenerate nerve conditions such as Parkinson's disease, Alzheimer's disease, and Lou Gehrig's disease. They can also be used to treat osteoporosis, rheumatoid arthritis, osteoarthritis, and other abnormalities of connective tissue, or of other organs or tissues.

ACCESSION NUMBER: AAX08988 DNA DGENE  
TITLE: Human and murine **cerebus**-like proteins - used for treating tissue defects and degenerative nerve conditions  
INVENTOR: Derobertis E M; Follettie M  
PATENT ASSIGNEE: (GEMY)GENETICS INST INC.  
(REGC) UNIV CALIFORNIA.  
PATENT INFO: WO 9901553 A1 19990114 50p  
APPLICATION INFO: WO 1998-US11462 19980603  
PRIORITY INFO: US 1997-887997 19970703  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
OTHER SOURCE: 1999-106054 [09]  
DESCRIPTION: Sequence encoding human cerberus like protein.

L8 ANSWER 15 OF 25 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN

TI Human and murine **cerebus**-like proteins - used for treating tissue defects and degenerative nerve conditions

AN AAX08987 cDNA DGENE

AB Compositions containing cerberus like proteins can be used for inducing the formation of neurons and related neural cells and tissues, such as Schwann cells, glial cells, and astrocytes, as well as liver, pancreas, lung, heart, kidney, spleen, stomach, and cardiac tissue and cells. They may also be used to treat precursor or stem cells. The compositions can also be used for treating tissue defects, and healing and maintenance of various types of tissues and wounds. The cerberus protein containing compositions may also be used to treat or prevent degenerate nerve conditions such as Parkinson's disease, Alzheimer's disease, and Lou

Gehrig's disease. They can also be used to treat osteoporosis, rheumatoid arthritis, osteoarthritis, and other abnormalities of connective tissue, or of other organs or tissues. Three regions of nucleic acid homology within the cysteine rich domains of cerberus-like genes provide consensus sequences which can be used as probes for other mammalian cerberus-like genes. See AAX08985-X08987.

ACCESSION NUMBER: AAX08987 cDNA DGENE  
TITLE: Human and murine **cerberus**-like proteins - used for treating tissue defects and degenerative nerve conditions  
INVENTOR: Derobertis E M; Follettie M  
PATENT ASSIGNEE: (GEMY)GENETICS INST INC.  
(REGC) UNIV CALIFORNIA.  
PATENT INFO: WO 9901553 A1 19990114 50p  
APPLICATION INFO: WO 1998-US11462 19980603  
PRIORITY INFO: US 1997-887997 19970703  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
OTHER SOURCE: 1999-106054 [09]  
DESCRIPTION: Probe for mammalian cerberus like protein.

L8 ANSWER 16 OF 25 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN

TI Human and murine **cerberus**-like proteins - used for treating tissue defects and degenerative nerve conditions

AN AAX08986 cDNA DGENE

AB Compositions containing cerberus like proteins can be used for inducing the formation of neurons and related neural cells and tissues, such as Schwann cells, glial cells, and astrocytes, as well as liver, pancreas, lung, heart, kidney, spleen, stomach, and cardiac tissue and cells. They may also be used to treat precursor or stem cells. The compositions can also be used for treating tissue defects, and healing and maintenance of various types of tissues and wounds. The cerberus protein containing compositions may also be used to treat or prevent degenerate nerve conditions such as Parkinson's disease, Alzheimer's disease, and Lou Gehrig's disease. They can also be used to treat osteoporosis, rheumatoid arthritis, osteoarthritis, and other abnormalities of connective tissue, or of other organs or tissues. Three regions of nucleic acid homology within the cysteine rich domains of cerberus-like genes provide consensus sequences which can be used as probes for other mammalian cerberus-like genes. See AAX08985-X08987.

ACCESSION NUMBER: AAX08986 cDNA DGENE  
TITLE: Human and murine **cerberus**-like proteins - used for treating tissue defects and degenerative nerve conditions  
INVENTOR: Derobertis E M; Follettie M  
PATENT ASSIGNEE: (GEMY)GENETICS INST INC.  
(REGC) UNIV CALIFORNIA.  
PATENT INFO: WO 9901553 A1 19990114 50p  
APPLICATION INFO: WO 1998-US11462 19980603  
PRIORITY INFO: US 1997-887997 19970703  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
OTHER SOURCE: 1999-106054 [09]  
DESCRIPTION: Probe for mammalian cerberus like protein.

L8 ANSWER 17 OF 25 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN

TI Human and murine **cerberus**-like proteins - used for treating tissue defects and degenerative nerve conditions

AN AAX08985 cDNA DGENE

AB Compositions containing cerberus like proteins can be used for inducing the formation of neurons and related neural cells and tissues, such as Schwann cells, glial cells, and astrocytes, as well as liver, pancreas, lung, heart, kidney, spleen, stomach, and cardiac tissue and cells. They may also be used to treat precursor or stem cells. The compositions can also be used for treating tissue defects, and healing and maintenance of various types of tissues and wounds. The cerberus protein containing

compositions may also be used to treat or prevent degenerate nerve conditions such as Parkinson's disease, Alzheimer's disease, and Lou Gehrig's disease. They can also be used to treat osteoporosis, rheumatoid arthritis, osteoarthritis, and other abnormalities of connective tissue, or of other organs or tissues. Three regions of nucleic acid homology within the cysteine rich domains of cerberus-like genes provide consensus sequences which can be used as probes for other mammalian cerberus-like genes. See AAX08985-X08987.

ACCESSION NUMBER: AAX08985 cDNA DGENE  
TITLE: Human and murine **cerberus**-like proteins - used for treating tissue defects and degenerative nerve conditions  
INVENTOR: Derobertis E M; Follettie M  
PATENT ASSIGNEE: (GEMY)GENETICS INST INC.  
(REGC) UNIV CALIFORNIA.  
PATENT INFO: WO 9901553 A1 19990114 50p  
APPLICATION INFO: WO 1998-US11462 19980603  
PRIORITY INFO: US 1997-887997 19970703  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
OTHER SOURCE: 1999-106054 [09]  
DESCRIPTION: Probe for mammalian cerberus like protein.

L8 ANSWER 18 OF 25 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN

TI Human and murine **cerberus**-like proteins - used for treating tissue defects and degenerative nerve conditions

AN AAX08984 cDNA DGENE

AB Compositions containing cerberus like proteins can be used for inducing the formation of neurons and related neural cells and tissues, such as Schwann cells, glial cells, and astrocytes, as well as liver, pancreas, lung, heart, kidney, spleen, stomach, and cardiac tissue and cells. They may also be used to treat precursor or stem cells. The compositions can also be used for treating tissue defects, and healing and maintenance of various types of tissues and wounds. The cerberus protein containing compositions may also be used to treat or prevent degenerate nerve conditions such as Parkinson's disease, Alzheimer's disease, and Lou Gehrig's disease. They can also be used to treat osteoporosis, rheumatoid arthritis, osteoarthritis, and other abnormalities of connective tissue, or of other organs or tissues.

ACCESSION NUMBER: AAX08984 cDNA DGENE  
TITLE: Human and murine **cerberus**-like proteins - used for treating tissue defects and degenerative nerve conditions  
INVENTOR: Derobertis E M; Follettie M  
PATENT ASSIGNEE: (GEMY)GENETICS INST INC.  
(REGC) UNIV CALIFORNIA.  
PATENT INFO: WO 9901553 A1 19990114 50p  
APPLICATION INFO: WO 1998-US11462 19980603  
PRIORITY INFO: US 1997-887997 19970703  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
OTHER SOURCE: 1999-106054 [09]  
CROSS REFERENCES: P-PSDB: AAW96211  
DESCRIPTION: Sequence encoding murine cerberus like protein.

L8 ANSWER 19 OF 25 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN

TI Producing neuronal cell lines based on the degree of neural commitment and growth factor responsiveness, and the potential to produce neural and non-neural progeny.

AN 2002-315799 [35] WPIDS

AB WO 200226941 A UPAB: 20020603

NOVELTY - A novel neuronal cell line (III) and a method for producing it based on the degree of neural commitment and growth factor responsiveness in vitro and the potential to produce neural and non-neural progeny in vivo, are new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the

following:

(1) a method (I) for differentiating embryonic stem cells to cells with markers characteristic of neural cells comprising:

(a) culturing the embryonic stem cells in a serum free media at low cell density selected to minimize embryonic stem (ES) cell aggregation or embryoid body (EB) formation; and

(b) allowing the cells to differentiate;

(2) a method (II) for producing secondary neural stem cell colonies, comprising:

(a) culturing ES cells in low cell density completely defined serum-free media under conditions in which the ES cells differentiate;

(b) dissociating and sub-cloning primary neural cell colonies generated from the ES cells; and

(c) administering a growth factor to the dissociated cell neural cells;

(3) cells (III) expressing 1 or more neural precursor cell markers and/or one or more neural-specific mRNA molecules and which have multilineage potential;

(4) a method (IV) of producing a pre-selected cell type derived from (III), comprising culturing the cells under differentiating conditions that promote formation of the cell type;

(5) a method (V) for screening for modulators of cellular differentiation, comprising:

(a) culturing pluripotent cells in serum-free media under low density conditions in the presence of the potential modulator;

(b) allowing for differentiation of the cells; and

(c) detecting any differentiation of the cells and cell types generated (if any);

(6) a method (VI) for screening for differentiation factors of cellular development, comprising:

(a) culturing the cells in serum free media at low cell density in the presence of the differentiation factor;

(b) allowing the cells to differentiate; and

(c) detecting differentiation of the cells (if any)

(7) a method (VII) of screening for modulators or differentiation factors of neural development;

(8) a method (VIII) for screening for differentiation factors of cellular development, comprising:

(a) culturing (III) in serum free media and in the presence of a differentiation factor; and

(b) detecting any differentiation of the cells; and

(9) a modulator or differentiation factor (IX) detected by (V) - (VIII).

USE - (I) Is used for analyzing the role of genes in the regulation of neural fate specification and/or for obtaining a homogenous uniform neural cell base. (III) Are used as a supply of cells for transplantation, for treatment of neurodegenerative disorders, for the treatment of diseases and conditions resulting from cell loss or function in the neural system and in gene therapy (the cell is modified to express a gene of interest) (claimed). The neural line cells have a number of uses such as tissue engineering, transplantation, gene therapy and drug discovery.

ADVANTAGE - It has been discovered that in low density cell culture assayed, in the absence of serum-derived or feeder cell-derived factors and in the absence of embryoid body formation, embryonic stem cells directly differentiate into neural cells. The transition from ES cell to neural cell can be enhanced by the inhibition of TGF beta -related signaling, in a manner that is consistent with a default model of neural fate specification, but one which is distinct from Xenopus default neuralization.

Dwg.0/7

ACCESSION NUMBER: 2002-315799 [35] WPIDS

DOC. NO. CPI: C2002-092027

TITLE: Producing neuronal cell lines based on the degree of neural commitment and growth factor responsiveness, and



the potential to produce neural and non-neural progeny.

DERWENT CLASS: B04 D16

INVENTOR(S): TROPEPE, V; VAN DER KOOY, D

PATENT ASSIGNEE(S): (TROP-I) TROPEPE V; (VKOO-I) VAN DER KOOY D

COUNTRY COUNT: 97

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2002026941	A2	20020404	(200235)*	EN	84
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ					
NL OA PT SD SE SL SZ TR TZ UG ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK					
DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR					
KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO					
RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW					
AU 2001093586	A	20020408	(200252)		
US 2002164791	A1	20021107	(200275)		

#### APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2002026941	A2	WO 2001-CA1383	20010928
AU 2001093586	A	AU 2001-93586	20010928
US 2002164791	A1 Provisional	US 2000-236394P	20000929
		US 2001-966768	20010928

#### FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2001093586	A Based on	WO 2002026941

PRIORITY APPLN. INFO: US 2000-236394P 20000929; US  
2001-966768 20010928

L8 ANSWER 20 OF 25 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN

TI Human and murine **cerebus**-like proteins - used for treating tissue defects and degenerative nerve conditions.

AN 1999-106054 [09] WPIDS

CR 2003-298696 [29]

AB WO 9901553 A UPAB: 20040426

A novel isolated DNA sequence comprises a DNA sequence selected from: (a) nucleotides beginning at # 1, 52, 55, 58, 61, 64, 67, 70, 73, 121, 256, 259, 262, 265, 268, 171, or 484 and ending at # 723 or 801 of the 804 bp DNA sequence given in the specification; and (b) sequences which hybridise to (a) under stringent hybridisation conditions and encode a protein which exhibits **cerebus** activity. Also claimed are: (1) an isolated DNA sequence comprising nucleotides encoding amino acids beginning at #1, 18 to 25, 41, 85 to 91 or 152, and ending at #241 or 267 of the 267 amino acid sequence given in the specification; (2) a vector comprising either of the above DNA molecules in operative association with an expression control sequence; (3) an isolated DNA molecule comprising nucleotides 268-801 of the 272 amino acid sequence given in the specification (sic), or naturally occurring allelic sequences of it; (4) a vector comprising the DNA of (4) in operative association with an expression control sequence; (5) an isolated DNA molecule encoding mammalian **cerebus** protein, comprising nucleotides 268-801 of the 804 bp DNA sequence given in the specification; (6) a vector comprising the DNA of (5) in operative association with an expression control sequence; (7) a host cell transformed with the vector of (2), (4) or (6); (8) a purified mammalian **cerebus** protein comprising the 267 amino acid sequence given in the specification; (9) a purified mammalian **cerebus** protein

comprising residues 90-267 of the 272 amino acid sequence given in the specification; and (10) antibodies to the **cerebus** protein of (8) or (9).

USE - The host cell of (7) can be used to produce the mammalian **cerebus** proteins (claimed). Compositions containing the protein can be used in the formation of neurons and related neural cells and tissues, such as Schwann cells, glial cells, and astrocytes, as well as liver, pancreas, lung, heart, kidney, spleen, stomach, and cardiac tissue and cells. They may also be used to treat precursor or stem cells. The compositions can also be used for treating tissue defects, and healing and maintenance of various types of tissues and wounds. The mammalian **cerebus** protein containing compositions may also be used to treat or prevent degenerate nerve conditions such as Parkinson's disease, Alzheimer's disease, and Lou Gehrig's disease. They can also be used to treat osteoporosis, rheumatoid arthritis, osteoarthritis, and other abnormalities of connective tissue, or of other organs or tissues.

Dwg.0/0

ACCESSION NUMBER: 1999-106054 [09] WPIDS  
 CROSS REFERENCE: 2003-298696 [29]  
 DOC. NO. CPI: C1999-031758  
 TITLE: Human and murine **cerebus**-like proteins - used for treating tissue defects and degenerative nerve conditions.  
 DERWENT CLASS: B04 D16  
 INVENTOR(S): DEROBERTIS, E M; FOLLETTIE, M  
 PATENT ASSIGNEE(S): (GEMY) GENETICS INST INC; (REGC) UNIV CALIFORNIA  
 COUNTRY COUNT: 83  
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9901553	A1	19990114	(199909)*	EN	50
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG ZW W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW					
AU 9878140	A	19990125	(199923)		
US 5935852	A	19990810	(199938)		
EP 1012278	A1	20000628	(200035)	EN	
R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE					
MX 2000000242	A1	20010601	(200235)		
JP 2002511762	W	20020416	(200242)		57
AU 749031	B	20020620	(200252)		
AU 2002301117	A1	20030227	(200427)#		

# APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9901553	A1	WO 1998-US11462	19980603
AU 9878140	A	AU 1998-78140	19980603
US 5935852	A	US 1997-887997	19970703
EP 1012278	A1	EP 1998-926263	19980603
		WO 1998-US11462	19980603
MX 2000000242	A1	MX 2000-242	20000105
JP 2002511762	W	WO 1998-US11462	19980603
		JP 1999-507147	19980603
AU 749031	B	AU 1998-78140	19980603
AU 2002301117	A1 Div ex	AU 1998-78140	19980603
		AU 2002-301117	20020920

# FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 9878140	A Based on	WO 9901553
EP 1012278	A1 Based on	WO 9901553
JP 2002511762	W Based on	WO 9901553
AU 749031	B Previous Publ. Based on	AU 9878140 WO 9901553

PRIORITY APPLN. INFO: US 1997-887997 19970703; AU  
2002-301117 20020920

L8 ANSWER 21 OF 25 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN  
 TI Analysis of Spemann organizer formation in Xenopus embryos by cDNA  
 macroarrays.  
 AB The understanding of vertebrate development has greatly benefited from the  
 study of gastrulation in the Xenopus embryo. Over the years, the  
 molecular dissection of the Spemann organizer has proven to be a very  
 fruitful source for gene discovery. Here, we report a comprehensive  
 screen of gene expression in the Xenopus gastrula using cDNA macroarrays.  
 Nylon filters containing more than 72,000 cDNAs from a gastrula stage  
 library were hybridized with differential probes from embryos in which  
 organizer induction had been inhibited by reducing Nodal-related or  
 maternal beta-Catenin signaling. Combining the changes in gene expression  
 levels caused by these two major signaling pathways in a single graph  
 identified both known and novel dorsoventral regulated genes. The most  
 highly enriched organizer-specific genes were the secreted molecules  
 chordin and Xnr-3, followed by the transmembrane protein paraxial  
 protocadherin (PAPC). Ventral-specific abundant cDNAs included S10-40-H5,  
 members of the Hyaluronan synthase family, Xvent-2 and XFD2/FoxI1. A  
 differential probe of dorsal and ventral lips identified many more  
 organizer-specific cDNAs than the screens inhibiting Nodal-related and  
 beta-Catenin signaling, suggesting that additional, as yet uncharacterized  
 signaling pathways, contribute to organizer formation. Finally, extension  
 of this approach to the blastula preorganizer signaling center identified  
 the transcription factor pintallavis/FoxA2 as a new preorganizer  
 component. Copyright 2004 Elsevier Inc. All rights reserved.

ACCESSION NUMBER: 2004:289326 BIOSIS  
 DOCUMENT NUMBER: PREV200400288002  
 TITLE: Analysis of Spemann organizer formation in Xenopus embryos  
 by cDNA macroarrays.  
 AUTHOR(S): Wessely, Oliver; Kim, James I.; Geissert, Douglas; Tran,  
 Uyen; De Robertis, E. M. [Reprint Author]  
 CORPORATE SOURCE: Howard Hughes Med Inst, Univ Calif Los Angeles, 675 Charles  
 Young Dr S, 5-748 MRL, Los Angeles, CA, 90095, USA  
 derobert@hhmi.ucla.edu  
 SOURCE: Developmental Biology, (May 13 2004) Vol. 269, No. 2, pp.  
 552-566. print.  
 ISSN: 0012-1606 (ISSN print).  
 DOCUMENT TYPE: Article  
 LANGUAGE: English  
 ENTRY DATE: Entered STN: 16 Jun 2004  
 Last Updated on STN: 16 Jun 2004

L8 ANSWER 22 OF 25 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN  
 TI Activity of spinal neural circuitry underlying motor primitives.  
 AB Modular control of motor activity in spinal bullfrogs is evidenced as  
 force-field motor primitives, and modular electromyogram (EMG)  
 composition. Whether this observed modularity reflects an underlying  
 modularity of spinal circuitry is unknown. For example, apparently  
 distinct motor behaviors may simply reflect different underlying modes of  
 the same neural circuitry (Galiana and Green, 2001). To determine the  
 degree to which behavioral modularity in spinal frogs reflects dedicated  
 modularity of circuits, we have begun to use simultaneous EMG recording

and multi-unit recordings in the spinal cord using a Bionic Technologies 128 channel **Cerebus** system. Our data will allow us to determine the degree to which sets of spinal neurons recorded participate in one or more motor primitives in dedicated or distributed fashion. Putative premotor drives (representing distinct primitives) are extracted from EMG activity using an independent components analysis. Drives and raw EMG are related to spinal neuronal activity using cross-correlational and information theoretic techniques. Cells recorded are also classified by conventional reflex testing techniques. We examine several possible outcomes of these analysis for a neuron: 1) recorded neurons may fire in one-to-one relationship with the activation of particular synergies 2) neurons may fire in a one to one relation with specific muscles or reflex pathways 3) neurons may be distributed between several synergies, muscles or reflexes, firing with the activation of some, but not with others, or 4) there may be some combination of (1), (2) or (3). An assessment of the degree to which modular behaviors are developed through modular or distributed circuitry will depend on how cleanly cells can be classified and assigned to such roles, the numbers of cells assigned to each classification, and the classification techniques. Simultaneous multi-neuron recording allows in depth examination of these issues.

ACCESSION NUMBER: 2004:195263 BIOSIS  
DOCUMENT NUMBER: PREV200400195822  
TITLE: Activity of spinal neural circuitry underlying motor primitives.  
AUTHOR(S): Giszter, S. F. [Reprint Author]; Hart, C. B. [Reprint Author]  
CORPORATE SOURCE: Dept. Neurobiol and Anat, Drexel Univ. Col. of Med., Philadelphia, PA, USA  
SOURCE: Society for Neuroscience Abstract Viewer and Itinerary Planner, (2003) Vol. 2003, pp. Abstract No. 186.17.  
<http://sfn.scholarone.com>. e-file.  
Meeting Info.: 33rd Annual Meeting of the Society of Neuroscience. New Orleans, LA, USA. November 08-12, 2003. Society of Neuroscience.  
DOCUMENT TYPE: Conference; (Meeting)  
Conference; Abstract; (Meeting Abstract)  
LANGUAGE: English  
ENTRY DATE: Entered STN: 14 Apr 2004  
Last Updated on STN: 14 Apr 2004

L8 ANSWER 23 OF 25 HCAPLUS COPYRIGHT 2004 ACS on STN  
TI Primitive neural stem cells and method for differentiation of stem cells to neural cells  
AB Described are a novel cell type in the neural lineage, and method of producing the same based on the degree of neural commitment and growth factor responsiveness in vitro and the potential to give rise to neural and non-neural progeny in vivo. The novel cell type of neural lineage and cells derived therefrom have a number of applications including applications regarding tissue engineering, transplantation and gene therapy and drug discovery. Also described are suggested uses of the method and cell type including isolating genes that pos. and neg. regulate the transition from an ES cell to a neural cell and generally for studying ES cell models of mammalian neural development.

ACCESSION NUMBER: 2002:256435 HCAPLUS  
DOCUMENT NUMBER: 136:275702  
TITLE: Primitive neural stem cells and method for differentiation of stem cells to neural cells  
INVENTOR(S): Van der Kooy, Derek; Tropepe, Vincent  
PATENT ASSIGNEE(S): Can.  
SOURCE: PCT Int. Appl., 84 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002026941	A2	20020404	WO 2001-CA1383	20010928
WO 2002026941	A3	20021212		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002164791	A1	20021107	US 2001-966768	20010928
PRIORITY APPLN. INFO.:			US 2000-236394P	P 20000929

L8 ANSWER 24 OF 25 HCAPLUS COPYRIGHT 2004 ACS on STN

TI Albumin fusion proteins with therapeutic proteins for improved shelf-life

AB The present invention encompasses fusion proteins of albumin with various therapeutic proteins. Therapeutic proteins may be stabilized to extend the shelf-life, and/or to retain the therapeutic protein's activity for extended periods of time in solution, in vitro and/or in vivo, by genetically or chemical fusing or conjugating the therapeutic protein to albumin or a fragment or variant of albumin. Use of albumin fusion proteins may also reduce the need to formulate the protein solns. with large excesses of carrier proteins to prevent loss of therapeutic proteins due to factors such as binding to the container. Nucleic acid mols. encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Thus, plasmid vectors are constructed in which DNA encoding the desired therapeutic protein may be inserted for expression of the albumin fusion proteins in yeast (pPPC0005) and mammalian cells (pC4:HSA). Yeast-derived signal sequences from *Saccharomyces cerevisiae* invertase SUC2 gene, or the stanniocalcin or native human serum albumin signal peptides, are used for secretion in yeast or mammalian systems, resp. Thus, the fusion product of human growth hormone with residues 1-387 of human serum albumin retains essentially intact biol. activity after 5 wk of incubation in tissue culture media at 37°, whereas recombinant human growth hormone used as control lost its biol. activity in the first week. Although the potency of the albumin fusion proteins is slightly lower than the unfused counterparts in rapid bioassays, their biol. stability results in much higher biol. activity in the longer term in vitro assay or in vivo assays. Addnl., the present invention encompasses pharmaceutical compns. comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

ACCESSION NUMBER: 2001:781079 HCAPLUS

DOCUMENT NUMBER: 135:348851

TITLE: Albumin fusion proteins with therapeutic proteins for improved shelf-life

INVENTOR(S): Rosen, Craig A.; Haseltine, William A.

PATENT ASSIGNEE(S): Human Genome Sciences, Inc, USA

SOURCE: PCT Int. Appl., 606 pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 7

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2001079444	A2	20011025	WO 2001-US12013	20010412
WO 2001079444	A3	20020523		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001074809	A5	20011020	AU 2001-74809	20010412
EP 1278544	A2	20030129	EP 2001-941457	20010412
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003125247	A1	20030703	US 2001-833041	20010412
US 2003171267	A1	20030911	US 2001-833117	20010412
JP 2003530847	T2	20031021	JP 2001-577428	20010412
US 2003199043	A1	20031023	US 2001-832501	20010412
US 2003219875	A1	20031127	US 2001-833118	20010412
US 2004010134	A1	20040115	US 2001-833245	20010412
PRIORITY APPLN. INFO.:			US 2000-229358P	P 20000412
			US 2000-199384P	P 20000425
			US 2000-256931P	P 20001221
			WO 2001-US12013	W 20010412

L8 ANSWER 25 OF 25 HCAPLUS COPYRIGHT 2004 ACS on STN  
TI Endoderm, cardiac and neural inducing factors from Xenopus dorsal lip  
AB The dorsal lip or Spemann's organizer of the Xenopus embryo is an ideal tissue for seeking novel growth and neurotrophic factors. Cloning of cerberus, frzb-1 (frizzled), and PAPC (paraxial protocadherin) resulted from a comprehensive, subtractive differential screen for cDNAs enriched in Spemann's organizer with secretory signal signals. Novel proteins designated "cerberus", "frzb-1", and PAPC are provided. **Cerebus** is expressed as a secreted peptide during embryogenesis of the Xenopus embryo, and is expressed specifically in the head organizer region. This new mol. has endodermal, cardiac, and neural tissue inducing activity, that should prove useful in therapeutic, diagnostic, and clin. applications requiring regeneration, differentiation, or repair of these and other tissues. Frzb-1 is a soluble antagonist of growth factors of the Wnt family that acts by binding to Wnt growth factors in the extracellular space. Murine and human analogs of Frzb-1 were also isolated and characterized. PAPC promotes the formation of dorsal mesoderm and somites in the embryo.

ACCESSION NUMBER: 1998:25129 HCAPLUS  
DOCUMENT NUMBER: 128:98574  
TITLE: Endoderm, cardiac and neural inducing factors from Xenopus dorsal lip  
INVENTOR(S): De Robertis, Edward M.; Bouwmeester, Tewis  
PATENT ASSIGNEE(S): The Regents of the University of California, USA  
SOURCE: PCT Int. Appl., 47 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9748275	A1	19971224	WO 1997-US10942	19970619
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 6133232	A	20001017	US 1997-878474	19970618

CA 2258789	AA	19971224	CA 1997-2258789	19970619
AU 9735765	A1	19980107	AU 1997-35765	19970619
AU 723210	B2	20000817		
EP 973391	A1	20000126	EP 1997-932262	19970619
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI				
JP 2002514043	T2	20020514	JP 1998-503467	19970619
US 2002099171	A1	20020725	US 2001-903180	20010711
US 2002099172	A1	20020725	US 2001-903187	20010711
US 2002123613	A1	20020905	US 2001-903171	20010711
US 2002128439	A1	20020912	US 2001-903188	20010711
US 2002128440	A1	20020912	US 2001-903323	20010711
US 2002128441	A1	20020912	US 2001-903325	20010711
US 2002156249	A1	20021024	US 2001-903170	20010711
PRIORITY APPLN. INFO.:			US 1996-20150P	P 19960620
			US 1997-878474	A 19970618
			WO 1997-US10942	W 19970619
			US 2000-552988	A3 20000421

=> s fusion protein

L9 180419 FUSION PROTEIN

=> s albumin and l9

L10 26400 ALBUMIN AND L9

=> s albumin fusion protein

L11 8366 ALBUMIN FUSION PROTEIN

=> s l10 and l11

L12 8365 L10 AND L11

=> d his

(FILE 'HOME' ENTERED AT 11:57:23 ON 01 JUL 2004)

FILE 'MEDLINE' ENTERED AT 11:58:35 ON 01 JUL 2004

L1 0 S CEREBUS PROTEIN+NT/CT  
L2 0 S CEREBUS+NT/CT  
E CEREBUS/CN  
E ROSEN, C/AU  
E HASELTINE, W/AU  
L3 221 S E1  
L4 1 S E2  
L5 0 S L4 AND L3  
L6 0 S L3 AND CEREBUS PROTEIN  
L7 0 S CEREBUS?

FILE 'USPATFULL, DGENE, EMBASE, WPIDS, FSTA, JICST-EPLUS, BIOSIS, BIOBUSINESS, CEN, CEABA-VTB, JAPIO, HCAPLUS' ENTERED AT 12:05:35 ON 01 JUL 2004

L8 25 S CEREBUS  
L9 180419 S FUSION PROTEIN  
L10 26400 S ALBUMIN AND L9  
L11 8366 S ALBUMIN FUSION PROTEIN  
L12 8365 S L10 AND L11

=> s l12 and l8

L13 0 L12 AND L8

=> s l3 and l11

L14 8007 L3 AND L11

=> s l14 and l8

L15 0 L14 AND L8





Dialing COMPUERVE (19200 baud) at 9,9342267

The modem is not responding to modem commands.

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal653hxp

PASSWORD:

THIS LOGINID IS CURRENTLY IN USE.

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal653hxp

PASSWORD:

THIS LOGINID IS CURRENTLY IN USE.

DO YOU WISH TO RESUME THE PREVIOUS SESSION? Y/(N)/?:

Invalid response, please try again

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal653hxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 09	CA/CAPlus records now contain indexing from 1907 to the present
NEWS	4	DEC 08	INPADOC: Legal Status data reloaded
NEWS	5	SEP 29	DISSABS now available on STN
NEWS	6	OCT 10	PCTFULL: Two new display fields added
NEWS	7	OCT 21	BIOSIS file reloaded and enhanced
NEWS	8	OCT 28	BIOSIS file segment of TOXCENTER reloaded and enhanced
NEWS	9	NOV 24	MSDS-CCOHS file reloaded
NEWS	10	DEC 08	CABA reloaded with left truncation
NEWS	11	DEC 08	IMS file names changed
NEWS	12	DEC 09	Experimental property data collected by CAS now available in REGISTRY
NEWS	13	DEC 09	STN Entry Date available for display in REGISTRY and CA/CAPlus

NEWS 14 DEC 17 DGENE: Two new display fields added  
 NEWS 15 DEC 18 BIOTECHNO no longer updated  
 NEWS 16 DEC 19 CROPU no longer updated; subscriber discount no longer available  
 NEWS 17 DEC 22 Additional INPI reactions and pre-1907 documents added to CAS databases  
 NEWS 18 DEC 22 IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields  
 NEWS 19 DEC 22 ABI-INFORM now available on STN  
 NEWS 20 JAN 27 Source of Registration (SR) information in REGISTRY updated and searchable  
 NEWS 21 JAN 27 A new search aid, the Company Name Thesaurus, available in CA/Caplus

NEWS EXPRESS DECEMBER 28 CURRENT WINDOWS VERSION IS V7.00, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
 NEWS INTER General Internet Information  
 NEWS LOGIN Welcome Banner and News Items  
 NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
 NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 18:21:39 ON 29 JAN 2004

=> file medline, uspatful, dgene, embase, wpids, fsta  
 COST IN U.S. DOLLARS                      SINCE FILE              TOTAL  
    ENTRY              SESSION  
 FULL ESTIMATED COST                      0.21              0.21

FILE 'MEDLINE' ENTERED AT 18:21:55 ON 29 JAN 2004

FILE 'USPATFULL' ENTERED AT 18:21:55 ON 29 JAN 2004  
 CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 18:21:55 ON 29 JAN 2004  
 COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'EMBASE' ENTERED AT 18:21:55 ON 29 JAN 2004  
 COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'WPIDS' ENTERED AT 18:21:55 ON 29 JAN 2004  
 COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'FSTA' ENTERED AT 18:21:55 ON 29 JAN 2004  
 COPYRIGHT (C) 2004 International Food Information Service

=> s TIMP-1  
 L1              5340 TIMP-1

=> s cerebus protein  
 L2              1 CEREBUS PROTEIN

=> s brain derived neurotrophic factor or BDNF  
 L3              10853 BRAIN DERIVED NEUROTROPHIC FACTOR OR BDNF

=> s interferon alpha  
L4 41802 INTERFERON ALPHA

=> s interferon beta  
L5 14602 INTERFERON BETA

=> s albumin  
L6 258098 ALBUMIN

=> s l6 and fusion  
L7 30354 L6 AND FUSION

=> s l7 and l1  
L8 214 L7 AND L1

=> s l7 and l2  
L9 0 L7 AND L2

=> s l7 and l3  
L10 636 L7 AND L3

=> s l7 and l4  
L11 1550 L7 AND L4

=> s l7 and l5  
L12 1361 L7 AND L5

=> s l6 and l2  
L13 0 L6 AND L2

=> d l8 ti abs ibib 1-20

L8 ANSWER 1 OF 214 USPATFULL on STN

TI Molecules for diagnostics and therapeutics

AB The present invention provides purified human polynucleotides for diagnostics and therapeutics (dithp). Also encompassed are the polypeptides (DITHP) encoded by dithp. The invention also provides for the use of dithp, or complements, oligonucleotides, or fragments thereof in diagnostic assays. The invention further provides for vectors and host cells containing dithp for the expression of DITHP. The invention additionally provides for the use of isolated and purified DITHP to induce antibodies and to screen libraries of compounds and the use of anti-DITHP antibodies in diagnostic assays. Also provided are microarrays containing dithp and methods of use.

ACCESSION NUMBER: 2004:18785 USPATFULL

TITLE: Molecules for diagnostics and therapeutics

INVENTOR(S): Hodgson, David M., Ann Arbor, MI, UNITED STATES  
Lincoln, Stephen E., Potomac, MD, UNITED STATES  
Russo, Frank D., Sunnyvale, CA, UNITED STATES  
Albany, Peter A., Berkeley, CA, UNITED STATES  
Banville, Steve C., Sunnyvale, CA, UNITED STATES  
Bratcher, Shawn R., Mountain View, CA, UNITED STATES  
Dufour, Gerard E., Castro Valley, CA, UNITED STATES  
Cohen, Howard J., Palo Alto, CA, UNITED STATES  
Rosen, Bruce H., Menlo Park, CA, UNITED STATES  
Chalup, Michael S., Livingston, TX, UNITED STATES  
Jackson, Jennifer L., Santa Cruz, CA, UNITED STATES  
Jones, Anissa L., San Jose, CA, UNITED STATES  
Yu, Jimmy Y., Fremont, CA, UNITED STATES  
Greenawalt, Lila B., San Jose, CA, UNITED STATES  
Panzer, Scott R., Sunnyvale, CA, UNITED STATES  
Roseberry Lincoln, Ann M., Potomac, MD, UNITED STATES  
Wright, Rachel J., Merivale, NEW ZEALAND

PATENT ASSIGNEE(S): Daniels, Susan E., Mountain View, CA, UNITED STATES  
Incyte Corporation, Palo Alto, CA, UNITED STATES (U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004014087	A1	20040122
APPLICATION INFO.:	US 2003-378029	A1	20030228 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-980285, filed on 30 Nov 2001, PENDING A 371 of International Ser. No. WO 2000-US15404, filed on 31 May 2000, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-147500P	19990805 (60)
	US 1999-147542P	19990805 (60)
	US 1999-147541P	19990805 (60)
	US 1999-147824P	19990805 (60)
	US 1999-147547P	19990805 (60)
	US 1999-147530P	19990805 (60)
	US 1999-147536P	19990805 (60)
	US 1999-147520P	19990805 (60)
	US 1999-147527P	19990805 (60)
	US 1999-147549P	19990805 (60)
	US 1999-147377P	19990804 (60)
	US 1999-147436P	19990804 (60)
	US 1999-137411P	19990603 (60)
	US 1999-137396P	19990603 (60)
	US 1999-137417P	19990603 (60)
	US 1999-137337P	19990603 (60)
	US 1999-137173P	19990602 (60)
	US 1999-137114P	19990602 (60)
	US 1999-137259P	19990602 (60)
	US 1999-137113P	19990602 (60)
	US 1999-137260P	19990602 (60)
	US 1999-137258P	19990602 (60)
	US 1999-137109P	19990602 (60)
	US 1999-137161P	19990601 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	INCYTE CORPORATION (formerly known as Incyte, Genomics, Inc.), 3160 PORTER DRIVE, PALO ALTO, CA, 94304	
NUMBER OF CLAIMS:	19	
EXEMPLARY CLAIM:	1	
LINE COUNT:	14819	

L8 ANSWER 2 OF 214 USPATFULL on STN  
TI Nucleic acids, proteins, and antibodies  
AB The present invention relates to novel proteins. More specifically,  
isolated nucleic acid molecules are provided encoding novel  
polypeptides. Novel polypeptides and antibodies that bind to these  
polypeptides are provided. Also provided are vectors, host cells, and  
recombinant and synthetic methods for producing human polynucleotides  
and/or polypeptides, and antibodies. The invention further relates to  
diagnostic and therapeutic methods useful for diagnosing, treating,  
preventing and/or prognosing disorders related to these novel  
polypeptides. The invention further relates to screening methods for  
identifying agonists and antagonists of polynucleotides and polypeptides  
of the invention. The present invention further relates to methods  
and/or compositions for inhibiting or enhancing the production and  
function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:18737 USPATFULL  
TITLE: Nucleic acids, proteins, and antibodies  
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES

PATENT ASSIGNEE(S) : Ruben, Steven M., Olney, MD, UNITED STATES  
 Barash, Steven C., Rockville, MD, UNITED STATES  
 Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004014039	A1	20040122
APPLICATION INFO.:	US 2002-158057	A1	20020531 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-764890, filed on 17 Jan 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)
	US 2000-228924P	20000830 (60)
	US 2000-224518P	20000814 (60)
	US 2000-236369P	20000929 (60)
	US 2000-224519P	20000814 (60)
	US 2000-220964P	20000726 (60)
	US 2000-241809P	20001020 (60)
	US 2000-249299P	20001117 (60)
	US 2000-236327P	20000929 (60)
	US 2000-241785P	20001020 (60)
	US 2000-244617P	20001101 (60)
	US 2000-225268P	20000814 (60)
	US 2000-236368P	20000929 (60)
	US 2000-251856P	20001208 (60)
	US 2000-251868P	20001208 (60)
	US 2000-229344P	20000901 (60)
	US 2000-234997P	20000925 (60)
	US 2000-229343P	20000901 (60)
	US 2000-229345P	20000901 (60)
	US 2000-229287P	20000901 (60)
	US 2000-229513P	20000905 (60)
	US 2000-231413P	20000908 (60)
	US 2000-229509P	20000905 (60)
	US 2000-236367P	20000929 (60)
	US 2000-237039P	20001002 (60)
	US 2000-237038P	20001002 (60)
	US 2000-236370P	20000929 (60)
	US 2000-236802P	20001002 (60)
	US 2000-237037P	20001002 (60)
	US 2000-237040P	20001002 (60)
	US 2000-240960P	20001020 (60)
	US 2000-239935P	20001013 (60)
	US 2000-239937P	20001013 (60)

US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)

US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850  
NUMBER OF CLAIMS: 24  
EXEMPLARY CLAIM: 1  
LINE COUNT: 26776

L8 ANSWER 3 OF 214 USPATFULL on STN

TI **Albumin fusion** proteins

AB The present invention encompasses **albumin fusion** proteins. Nucleic acid molecules encoding the **albumin fusion** proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the **albumin fusion** proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising **albumin fusion** proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using **albumin fusion** proteins of the invention.

ACCESSION NUMBER: 2004:13611 USPATFULL  
TITLE: **Albumin fusion** proteins  
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010134	A1	20040115
APPLICATION INFO.:	US 2001-833245	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850  
NUMBER OF CLAIMS: 29  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 18 Drawing Page(s)  
LINE COUNT: 25066

L8 ANSWER 4 OF 214 USPATFULL on STN

TI 7 Human ovarian and ovarian cancer associated proteins

AB This invention relates to newly identified ovarian or ovarian cancer related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "ovarian cancer antigens", and the use of such ovarian antigens for detecting disorders of the reproductive system, particularly the presence of ovarian cancer and ovarian cancer metastases. This invention relates to ovarian cancer antigens as well as vectors, host cells, antibodies directed to ovarian cancer antigens and the recombinant methods and synthetic methods for producing the same. Also provided are diagnostic methods for detecting, treating, preventing and/or prognosing disorders related to the ovary, including ovarian cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of ovarian cancer antigens of the invention. The present invention further relates to inhibiting the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:13598 USPATFULL

TITLE: 7 Human ovarian and ovarian cancer associated proteins

INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES

Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010121	A1	20040115
APPLICATION INFO.:	US 2003-333900	A1	20030124 (10)
	WO 2001-US8585		20010316
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850		
NUMBER OF CLAIMS:	23		
EXEMPLARY CLAIM:	1		
LINE COUNT:	16023		

L8 ANSWER 5 OF 214 USPATFULL on STN

TI Use of bioactive glass compositions to stimulate osteoblast production

AB Compositions comprising bioactive glass compositions or extracts thereof which include ions in an appropriate concentration and ratio that they enhance osteoblast production, and methods of preparation and use thereof, are disclosed. The compositions can be included in implantable devices that are capable of inducing tissue formation in autogeneic, allogeneic and xenogeneic implants, for example as coatings and/or matrix materials. Examples of such devices include prosthetic implants, sutures, stents, screws, plates, tubes, and the like. Aqueous extracts of the bioactive glass compositions, which extracts are capable of stimulating osteoblast production, are also disclosed. The compositions can be used, for example, to induce local tissue formation from a progenitor cell in a mammal, for accelerating allograft repair in a mammal, for promoting in vivo integration of an implantable prosthetic device to enhance the bond strength between the prosthesis and the existing target tissue at the joining site, and for treating tissue degenerative conditions.

ACCESSION NUMBER: 2004:13078 USPATFULL

TITLE: Use of bioactive glass compositions to stimulate osteoblast production

INVENTOR(S): Hench, Larry L, London, UNITED KINGDOM

Polak, Julia M, London, UNITED KINGDOM

Buttery, Lee D.k., London, UNITED KINGDOM

Xynos, Ioannis D, Nafplion, GREECE

Maroothernaden, Jason, London, UNITED KINGDOM



	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009598	A1	20040115
APPLICATION INFO.:	US 2003-332731	A1	20030707 (10)
	WO 2001-US21801		20010711
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	BURNS DOANE SWECKER & MATHIS L L P, POST OFFICE BOX 1404, ALEXANDRIA, VA, 22313-1404		
NUMBER OF CLAIMS:	34		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1301		

L8 ANSWER 6 OF 214 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel polynucleotides associated with the plasma membrane, the polypeptides encoded by these polynucleotides herein collectively referred to as "plasma membrane associated antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such plasma membrane associated polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders related to these novel polypeptides. More specifically, isolated nucleic acid molecules are provided encoding novel plasma membrane associated polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing these plasma membrane associated polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the novel polypeptides of the invention. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

ACCESSION NUMBER: 2004:12971 USPATFULL  
 TITLE: Nucleic acids, proteins, and antibodies  
 INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES  
 Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009491	A1	20040115
APPLICATION INFO.:	US 2002-264237	A1	20021004 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2001-US16450, filed on 18 May 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-205515P	20000519 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
LINE COUNT:	18144	

L8 ANSWER 7 OF 214 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel musculoskeletal system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "musculoskeletal system antigens," and the use of such musculoskeletal system antigens for detecting disorders of

the musculoskeletal system, particularly the presence of cancer and cancer metastases. More specifically, isolated musculoskeletal system associated nucleic acid molecules are provided encoding novel musculoskeletal system associated polypeptides. Novel musculoskeletal system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human musculoskeletal system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the musculoskeletal system, including cancer of musculoskeletal tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:12968 USPATFULL  
 TITLE: Nucleic acids, proteins, and antibodies  
 INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
 Ruben, Steven M., Olney, MD, UNITED STATES  
 Barash, Steven C., Rockville, MD, UNITED STATES  
 PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009488	A1	20040115
APPLICATION INFO.:	US 2002-242515	A1	20020913 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-764877, filed on 17 Jan 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)
	US 2000-228924P	20000830 (60)
	US 2000-224518P	20000814 (60)
	US 2000-236369P	20000929 (60)
	US 2000-224519P	20000814 (60)
	US 2000-220964P	20000726 (60)
	US 2000-241809P	20001020 (60)
	US 2000-249299P	20001117 (60)
	US 2000-236327P	20000929 (60)
	US 2000-241785P	20001020 (60)
	US 2000-244617P	20001101 (60)
	US 2000-225268P	20000814 (60)
	US 2000-236368P	20000929 (60)

US 2000-251856P	20001208 (60)
US 2000-251868P	20001208 (60)
US 2000-229344P	20000901 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-229345P	20000901 (60)
US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)

US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850  
NUMBER OF CLAIMS: 24  
EXEMPLARY CLAIM: 1  
LINE COUNT: 32038

L8 ANSWER 8 OF 214 USPATFULL on STN  
TI Methods for the treatment of carcinoma  
AB The invention concerns compositions and methods for the diagnosis and treatment of neoplastic cell growth and proliferation in mammals, including humans. The invention is based upon the identification of genes that are amplified in the genome of tumor cells, such as renal cell carcinoma. Such gene amplification is expected to be associated with the overexpression of the gene product as compared to normal cells of the same tissue type and contribute to tumorigenesis. Accordingly, the proteins encoded by the amplified genes are believed to be useful targets for the diagnosis and/or treatment (including prevention) of certain cancers, such as renal cell carcinoma, and may act as predictors of the prognosis of tumor treatment. The present invention is directed to novel methods of diagnosing and treating tumor, such as renal cell carcinoma or Wilms tumor.

ACCESSION NUMBER: 2004:12653 USPATFULL

TITLE: Methods for the treatment of carcinoma  
INVENTOR(S): Gerritsen, Mary E., San Mateo, CA, UNITED STATES  
Peale, Franklin V., JR., San Carlos, CA, UNITED STATES  
Wu, Thomas D., San Francisco, CA, UNITED STATES  
PATENT ASSIGNEE(S): GENENTECH, INC. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009171	A1	20040115
APPLICATION INFO.:	US 2003-372683	A1	20030221 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-271690, filed on 16 Oct 2002, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-344534P	20011018 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080	
NUMBER OF CLAIMS:	57	
EXEMPLARY CLAIM:	1	
LINE COUNT:	6662	

L8 ANSWER 9 OF 214 USPATFULL on STN  
TI Nucleic acids, proteins, and antibodies  
AB The present invention relates to novel ovarian related polynucleotides, the polypeptides encoded by these polynucleotides herein collectively referred to as "ovarian antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such ovarian polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders of the reproductive system, particularly disorders of the ovaries and/or breast, including, but not limited to, the presence of ovarian and/or breast cancer and ovarian and/or breast cancer metastases. More specifically, isolated ovarian nucleic acid molecules are provided encoding novel ovarian polypeptides. Novel ovarian polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human ovarian polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the ovaries and/or breast, including ovarian and/or breast cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

ACCESSION NUMBER: 2004:7345 USPATFULL  
TITLE: Nucleic acids, proteins, and antibodies  
INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES  
Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005579	A1	20040108
APPLICATION INFO.:	US 2002-264049	A1	20021004 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2001-US18569, filed on 7 Jun 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-209467P	20000607 (60)
DOCUMENT TYPE:	Utility	

FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
 ROCKVILLE, MD, 20850  
 NUMBER OF CLAIMS: 24  
 EXEMPLARY CLAIM: 1  
 LINE COUNT: 18130

L8 ANSWER 10 OF 214 USPATFULL on STN  
 TI Nucleic acids, proteins, and antibodies  
 AB The present invention relates to novel proteins. More specifically,  
 isolated nucleic acid molecules are provided encoding novel  
 polypeptides. Novel polypeptides and antibodies that bind to these  
 polypeptides are provided. Also provided are vectors, host cells, and  
 recombinant and synthetic methods for producing human polynucleotides  
 and/or polypeptides, and antibodies. The invention further relates to  
 diagnostic and therapeutic methods useful for diagnosing, treating,  
 preventing and/or prognosing disorders related to these novel  
 polypeptides. The invention further relates to screening methods for  
 identifying agonists and antagonists of polynucleotides and polypeptides  
 of the invention. The present invention further relates to methods  
 and/or compositions for inhibiting or enhancing the production and  
 function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:7343 USPATFULL  
 TITLE: Nucleic acids, proteins, and antibodies  
 INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
 Ruben, Steven M., Olney, MD, UNITED STATES  
 Barash, Steven C., Rockville, MD, UNITED STATES  
 PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED  
 STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005577	A1	20040108
APPLICATION INFO.:	US 2002-242747	A1	20020913 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-764881, filed on 17 Jan 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)
	US 2000-228924P	20000830 (60)
	US 2000-224518P	20000814 (60)
	US 2000-236369P	20000929 (60)
	US 2000-224519P	20000814 (60)
	US 2000-220964P	20000726 (60)

US 2000-241809P	20001020 (60)
US 2000-249299P	20001117 (60)
US 2000-236327P	20000929 (60)
US 2000-241785P	20001020 (60)
US 2000-244617P	20001101 (60)
US 2000-225268P	20000814 (60)
US 2000-236368P	20000929 (60)
US 2000-251856P	20001208 (60)
US 2000-251868P	20001208 (60)
US 2000-229344P	20000901 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-229345P	20000901 (60)
US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)

US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850  
NUMBER OF CLAIMS: 24  
EXEMPLARY CLAIM: 1  
LINE COUNT: 27694  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 11 OF 214 USPATFULL on STN  
TI Nucleic acids, proteins, and antibodies  
AB The present invention relates to novel cardiovascular system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "cardiovascular system antigens," and the use of such cardiovascular system antigens for detecting disorders of the cardiovascular system, particularly the presence of cancer of cardiovascular system tissues and cancer metastases. More specifically, isolated cardiovascular system associated nucleic acid molecules are



provided encoding novel cardiovascular system associated polypeptides. Novel cardiovascular system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human cardiovascular system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the cardiovascular system, including cancer of cardiovascular system tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:7341 USPATFULL  
 TITLE: Nucleic acids, proteins, and antibodies  
 INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
 Ruben, Steven M., Olney, MD, UNITED STATES  
 Barash, Steven C., Rockville, MD, UNITED STATES  
 PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005575	A1	20040108
APPLICATION INFO.:	US 2002-227577	A1	20020826 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2002-91504, filed on 7 Mar 2002, PENDING Continuation of Ser. No. US 2001-764869, filed on 17 Jan 2001, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)
	US 2000-228924P	20000830 (60)
	US 2000-224518P	20000814 (60)
	US 2000-236369P	20000929 (60)
	US 2000-224519P	20000814 (60)
	US 2000-220964P	20000726 (60)
	US 2000-241809P	20001020 (60)
	US 2000-249299P	20001117 (60)
	US 2000-236327P	20000929 (60)
	US 2000-241785P	20001020 (60)
	US 2000-244617P	20001101 (60)
	US 2000-225268P	20000814 (60)
	US 2000-236368P	20000929 (60)

US 2000-251856P	20001208 (60)
US 2000-251868P	20001208 (60)
US 2000-229344P	20000901 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-229345P	20000901 (60)
US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)

US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
 ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 24  
 EXEMPLARY CLAIM: 1  
 LINE COUNT: 28742

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 12 OF 214 USPATFULL on STN  
 TI Functional MRI agents for cancer imaging  
 AB The invention relates to novel magnetic resonance imaging contrast  
 agents for imaging cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:4285 USPATFULL  
 TITLE: Functional MRI agents for cancer imaging  
 INVENTOR(S): Meade, Thomas J., Altadena, CA, United States  
 Fraser, Scott, La Canada, CA, United States  
 Jacobs, Russell, Arcadia, CA, United States  
 PATENT ASSIGNEE(S): Research Corporation Technologies, Inc., Tucson, AZ,  
 United States (U.S. corporation)

NUMBER	KIND	DATE
-----	-----	-----

PATENT INFORMATION: US 6673333 B1 20040106  
APPLICATION INFO.: US 2000-715859 20001117 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-201816P	20000504 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Hartley, Michael G.	
LEGAL REPRESENTATIVE:	Dorsey & Whitney LLP, Silva, Robin M., Kossiak, Renee M.	
NUMBER OF CLAIMS:	10	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	7 Drawing Figure(s); 5 Drawing Page(s)	
LINE COUNT:	2422	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L8 ANSWER 13 OF 214 USPATFULL on STN  
TI 50 human secreted proteins  
AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:2568 USPATFULL  
TITLE: 50 human secreted proteins  
INVENTOR(S): Moore, Paul A., Germantown, MD, UNITED STATES  
Ruben, Steven M., Olney, MD, UNITED STATES  
LaFleur, David W., Washington, DC, UNITED STATES  
Shi, Yanggu, Gaithersburg, MD, UNITED STATES  
Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Olsen, Henrik S., Gaithersburg, MD, UNITED STATES  
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES  
Brewer, Laurie A., St. Paul, MN, UNITED STATES  
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004002591	A1	20040101
APPLICATION INFO.:	US 2002-47021	A1	20020117 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-722329, filed on 28 Nov 2000, PENDING Continuation of Ser. No. US 1999-262109, filed on 4 Mar 1999, ABANDONED Continuation-in-part of Ser. No. WO 1998-US18360, filed on 3 Sep 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-262066P	20010118 (60)
	US 1997-57626P	19970905 (60)
	US 1997-57663P	19970905 (60)
	US 1997-57669P	19970905 (60)
	US 1997-58666P	19970912 (60)
	US 1997-58667P	19970912 (60)
	US 1997-58973P	19970912 (60)
	US 1997-58974P	19970912 (60)
	US 1998-90112P	19980622 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,	

ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 23  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 2 Drawing Page(s)  
LINE COUNT: 33379  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 14 OF 214 USPATFULL on STN

TI Novel human gene relating to respiratory diseases, obesity, and inflammatory bowel disease  
AB This invention relates to genes identified from human chromosome 20p13-p12, which are associated with various diseases, including asthma. The invention also relates to the nucleotide sequences of these genes, isolated nucleic acids comprising these nucleotide sequences, and isolated polypeptides or peptides encoded thereby. The invention further relates to vectors and host cells comprising the disclosed nucleotide sequences, or fragments thereof, as well as antibodies that bind to the encoded polypeptides or peptides. Also related are ligands that modulate the activity of the disclosed genes or gene products. In addition, the invention relates to methods and compositions employing the disclosed nucleic acids, polypeptides or peptides, antibodies, and/or ligands for use in diagnostics and therapeutics for asthma and other diseases.

ACCESSION NUMBER: 2004:2447 USPATFULL  
TITLE: Novel human gene relating to respiratory diseases, obesity, and inflammatory bowel disease  
INVENTOR(S): Keith, Tim, Bedford, MA, UNITED STATES  
Little, Randall D., Newtonville, MA, UNITED STATES  
Eerdewegh, Paul Van, Weston, MA, UNITED STATES  
Dupuis, Josee, Newton, MA, UNITED STATES  
Del Mastro, Richard G., Norfolk, MA, UNITED STATES  
Simon, Jason, Westfield, NJ, UNITED STATES  
Allen, Kristin, Hopkinton, MA, UNITED STATES  
Pandit, Sunil, Gaithersburg, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004002470	A1	20040101
APPLICATION INFO.:	US 2002-277216	A1	20021017 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-126022, filed on 19 Apr 2002, PENDING Continuation-in-part of Ser. No. US 2001-834597, filed on 13 Apr 2001, PENDING Continuation-in-part of Ser. No. US 2000-548797, filed on 13 Apr 2000, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	MORGAN & FINNEGAN, L.L.P., 345 PARK AVENUE, NEW YORK, NY, 10154		
NUMBER OF CLAIMS:	45		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	162 Drawing Page(s)		
LINE COUNT:	15810		

L8 ANSWER 15 OF 214 USPATFULL on STN

TI Detection and modulation of Slit and roundabout (Robo) mediated angiogenesis and uses thereof  
AB This invention is generally in the field of methods for diagnosis, treatment and prevention of various disorders involving the Slit2 mediated angiogenesis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:335332 USPATFULL  
TITLE: Detection and modulation of Slit and roundabout (Robo) mediated angiogenesis and uses thereof  
INVENTOR(S): Geng, Jian-Guo, Portage, MI, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003236210	A1	20031225
APPLICATION INFO.:	US 2003-386386	A1	20030310 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-362485P	20020308 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Peng Chen, Morrison & Foerster LLP, Suite 500, 3811 Valley Centre Drive, San Diego, CA, 92130-2332	
NUMBER OF CLAIMS:	29	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Page(s)	
LINE COUNT:	1337	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L8 ANSWER 16 OF 214 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel excretory system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "excretory system antigens," and the use of such excretory system antigens for detecting disorders of the excretory system, particularly the presence of cancer of excretory system tissues and cancer metastases. More specifically, isolated excretory system associated nucleic acid molecules are provided encoding novel excretory system associated polypeptides. Novel excretory system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human excretory system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the excretory system, including cancer of excretory system tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:334955 USPATFULL

TITLE: Nucleic acids, proteins, and antibodies

INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
 Ruben, Steven M., Olney, MD, UNITED STATES  
 Barash, Steven C., Rockville, MD, UNITED STATES

PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003235831	A1	20031225
APPLICATION INFO.:	US 2002-242355	A1	20020913 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-764897, filed on 17 Jan 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)

US 2000-220963P	20000726 (60)
US 2000-217496P	20000711 (60)
US 2000-225447P	20000814 (60)
US 2000-218290P	20000714 (60)
US 2000-225757P	20000814 (60)
US 2000-226868P	20000822 (60)
US 2000-216647P	20000707 (60)
US 2000-225267P	20000814 (60)
US 2000-216880P	20000707 (60)
US 2000-225270P	20000814 (60)
US 2000-251869P	20001208 (60)
US 2000-235834P	20000927 (60)
US 2000-234274P	20000921 (60)
US 2000-234223P	20000921 (60)
US 2000-228924P	20000830 (60)
US 2000-224518P	20000814 (60)
US 2000-236369P	20000929 (60)
US 2000-224519P	20000814 (60)
US 2000-220964P	20000726 (60)
US 2000-241809P	20001020 (60)
US 2000-249299P	20001117 (60)
US 2000-236327P	20000929 (60)
US 2000-241785P	20001020 (60)
US 2000-244617P	20001101 (60)
US 2000-225268P	20000814 (60)
US 2000-236368P	20000929 (60)
US 2000-251856P	20001208 (60)
US 2000-251868P	20001208 (60)
US 2000-229344P	20000901 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-229345P	20000901 (60)
US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)

US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)



US 2001-259678P 20010105 (60)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850  
NUMBER OF CLAIMS: 24  
EXEMPLARY CLAIM: 1  
LINE COUNT: 22457  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 17 OF 214 USPATFULL on STN  
TI Nucleic acids, proteins, and antibodies  
AB The present invention relates to novel proteins. More specifically,  
isolated nucleic acid molecules are provided encoding novel  
polypeptides. Novel polypeptides and antibodies that bind to these  
polypeptides are provided. Also provided are vectors, host cells, and  
recombinant and synthetic methods for producing human polynucleotides  
and/or polypeptides, and antibodies. The invention further relates to  
diagnostic and therapeutic methods useful for diagnosing, treating,  
preventing and/or prognosing disorders related to these novel  
polypeptides. The invention further relates to screening methods for  
identifying agonists and antagonists of polynucleotides and polypeptides  
of the invention. The present invention further relates to methods  
and/or compositions for inhibiting or enhancing the production and  
function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:334953 USPATFULL  
TITLE: Nucleic acids, proteins, and antibodies  
INVENTOR(S): Ruben, Steven M., Olney, MD, UNITED STATES  
Barash, Steven C., Rockville, MD, UNITED STATES  
Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Birse, Charles E., North Potomac, MD, UNITED STATES  
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED  
STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003235829	A1	20031225
APPLICATION INFO.:	US 2002-227646	A1	20020826 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-860670, filed on 21 May 2001, PENDING Continuation-in-part of Ser. No. WO 2001-US1346, filed on 17 Jan 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-205515P	20000519 (60)
	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-216880P	20000707 (60)
	US 2000-234997P	20000925 (60)
	US 2000-229343P	20000901 (60)
	US 2000-236367P	20000929 (60)
	US 2000-239937P	20001013 (60)
	US 2000-249210P	20001117 (60)
	US 2000-249211P	20001117 (60)
	US 2000-249214P	20001117 (60)
	US 2000-231243P	20000908 (60)
	US 2000-246477P	20001108 (60)
	US 2000-246528P	20001108 (60)
	US 2000-246525P	20001108 (60)
	US 2000-246476P	20001108 (60)
	US 2000-246526P	20001108 (60)

US 2000-249265P	20001117 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-179065P	20000131 (60)
US 2000-180628P	20000204 (60)
US 2000-214886P	20000628 (60)
US 2000-217487P	20000711 (60)
US 2000-225758P	20000814 (60)
US 2000-220963P	20000726 (60)
US 2000-217496P	20000711 (60)
US 2000-225447P	20000814 (60)
US 2000-218290P	20000714 (60)
US 2000-225757P	20000814 (60)
US 2000-226868P	20000822 (60)
US 2000-216647P	20000707 (60)
US 2000-225267P	20000814 (60)
US 2000-216880P	20000707 (60)
US 2000-225270P	20000814 (60)
US 2000-251869P	20001208 (60)
US 2000-235834P	20000927 (60)
US 2000-234274P	20000921 (60)
US 2000-234223P	20000921 (60)
US 2000-228924P	20000830 (60)
US 2000-224518P	20000814 (60)
US 2000-236369P	20000929 (60)
US 2000-224519P	20000814 (60)
US 2000-220964P	20000726 (60)
US 2000-241809P	20001020 (60)
US 2000-249299P	20001117 (60)
US 2000-236327P	20000929 (60)
US 2000-241785P	20001020 (60)
US 2000-244617P	20001101 (60)
US 2000-225268P	20000814 (60)
US 2000-236368P	20000929 (60)
US 2000-251856P	20001208 (60)
US 2000-251868P	20001208 (60)
US 2000-229344P	20000901 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-229345P	20000901 (60)
US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)

US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)

US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)
US 2000-179065P	20000131 (60)
US 2000-180628P	20000204 (60)
US 2000-214886P	20000628 (60)
US 2000-217487P	20000711 (60)
US 2000-225758P	20000814 (60)
US 2000-220963P	20000726 (60)
US 2000-217496P	20000711 (60)
US 2000-225447P	20000814 (60)
US 2000-218290P	20000714 (60)
US 2000-225757P	20000814 (60)
US 2000-226868P	20000822 (60)
US 2000-216647P	20000707 (60)
US 2000-225267P	20000814 (60)
US 2000-216880P	20000707 (60)
US 2000-225270P	20000814 (60)
US 2000-251869P	20001208 (60)
US 2000-235834P	20000927 (60)
US 2000-234274P	20000921 (60)
US 2000-234223P	20000921 (60)
US 2000-228924P	20000830 (60)
US 2000-224518P	20000814 (60)
US 2000-236369P	20000929 (60)
US 2000-224519P	20000814 (60)
US 2000-220964P	20000726 (60)
US 2000-241809P	20001020 (60)
US 2000-249299P	20001117 (60)
US 2000-236327P	20000929 (60)
US 2000-241785P	20001020 (60)
US 2000-244617P	20001101 (60)
US 2000-225268P	20000814 (60)
US 2000-236368P	20000929 (60)
US 2000-251856P	20001208 (60)
US 2000-251868P	20001208 (60)
US 2000-229344P	20000901 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-229345P	20000901 (60)
US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)

US 2000-240960P	20001020	(60)
US 2000-239935P	20001013	(60)
US 2000-239937P	20001013	(60)
US 2000-241787P	20001020	(60)
US 2000-246474P	20001108	(60)
US 2000-246532P	20001108	(60)
US 2000-249216P	20001117	(60)
US 2000-249210P	20001117	(60)
US 2000-226681P	20000822	(60)
US 2000-225759P	20000814	(60)
US 2000-225213P	20000814	(60)
US 2000-227182P	20000822	(60)
US 2000-225214P	20000814	(60)
US 2000-235836P	20000927	(60)
US 2000-230438P	20000906	(60)
US 2000-215135P	20000630	(60)
US 2000-225266P	20000814	(60)
US 2000-249218P	20001117	(60)
US 2000-249208P	20001117	(60)
US 2000-249213P	20001117	(60)
US 2000-249212P	20001117	(60)
US 2000-249207P	20001117	(60)
US 2000-249245P	20001117	(60)
US 2000-249244P	20001117	(60)
US 2000-249217P	20001117	(60)
US 2000-249211P	20001117	(60)
US 2000-249215P	20001117	(60)
US 2000-249264P	20001117	(60)
US 2000-249214P	20001117	(60)
US 2000-249297P	20001117	(60)
US 2000-232400P	20000914	(60)
US 2000-231242P	20000908	(60)
US 2000-232081P	20000908	(60)
US 2000-232080P	20000908	(60)
US 2000-231414P	20000908	(60)
US 2000-231244P	20000908	(60)
US 2000-233064P	20000914	(60)
US 2000-233063P	20000914	(60)
US 2000-232397P	20000914	(60)
US 2000-232399P	20000914	(60)
US 2000-232401P	20000914	(60)
US 2000-241808P	20001020	(60)
US 2000-241826P	20001020	(60)
US 2000-241786P	20001020	(60)
US 2000-241221P	20001020	(60)
US 2000-246475P	20001108	(60)
US 2000-231243P	20000908	(60)
US 2000-233065P	20000914	(60)
US 2000-232398P	20000914	(60)
US 2000-234998P	20000925	(60)
US 2000-246477P	20001108	(60)
US 2000-246528P	20001108	(60)
US 2000-246525P	20001108	(60)
US 2000-246476P	20001108	(60)
US 2000-246526P	20001108	(60)
US 2000-249209P	20001117	(60)
US 2000-246527P	20001108	(60)
US 2000-246523P	20001108	(60)
US 2000-246524P	20001108	(60)
US 2000-246478P	20001108	(60)
US 2000-246609P	20001108	(60)
US 2000-246613P	20001108	(60)
US 2000-249300P	20001117	(60)
US 2000-249265P	20001117	(60)
US 2000-246610P	20001108	(60)

US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850  
NUMBER OF CLAIMS: 24  
EXEMPLARY CLAIM: 1  
LINE COUNT: 20415  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 18 OF 214 USPATFULL on STN  
TI Compositions and methods for systemic inhibition of cartilage  
degradation  
AB Methods and compositions for inhibiting articular cartilage degradation.  
The compositions preferably include multiple chondroprotective agents,  
including at least one agent that promotes cartilage anabolic activity  
and at least one agent that inhibits cartilage catabolism. The  
compositions may also include one or more pain and inflammation  
inhibitory agents. The compositions may be administered systemically,  
such as to treat patients at risk of cartilage degradation at multiple  
joints, and suitably may be formulated in a carrier or delivery vehicle  
that is targeted to the joints. Alternatively the compositions may be  
injected or infused directly into the joint.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:334713 USPATFULL  
TITLE: Compositions and methods for systemic inhibition of  
cartilage degradation  
INVENTOR(S): Demopoulos, Gregory A., Mercer Island, WA, UNITED STATES  
Palmer, Pamela Pierce, San Francisco, CA, UNITED STATES  
Herz, Jeffrey M., Mill Creek, WA, UNITED STATES  
PATENT ASSIGNEE(S): Omeros Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003235589	A1	20031225
APPLICATION INFO.:	US 2003-356649	A1	20030131 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-31546, filed on 18 Jan 2002, PENDING A 371 of International Ser. No. WO 2000-US19864, filed on 21 Jul 2000, PENDING Continuation-in-part of Ser. No. US 2001-839633, filed on 20 Apr 2001, PENDING Continuation-in-part of Ser. No. WO 1999-US26330, filed on 5 Nov 1999, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-353552P	20020201 (60)
	US 1999-144904P	19990721 (60)
	US 1998-107256P	19981105 (60)
	US 1998-105026P	19981020 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	OMEROS MEDICAL SYSTEMS, INC., 1420 FIFTH AVENUE, SUITE 2675, SEATTLE, WA, 98101	
NUMBER OF CLAIMS:	155	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	9 Drawing Page(s)	
LINE COUNT:	6575	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 19 OF 214 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel endocrine related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "endocrine antigens," and the use of such endocrine antigens for detecting disorders of the endocrine system, particularly the presence of cancers of the endocrine system and endocrine cancer metastases. More specifically, isolated endocrine associated nucleic acid molecules are provided encoding novel endocrine associated polypeptides. Novel endocrine polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human endocrine associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the endocrine system, including cancers of the endocrine system, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:330759 USPATFULL

TITLE: Nucleic acids, proteins, and antibodies

INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Ruben, Steven M., Olney, MD, UNITED STATES  
Barash, Steven C., Rockville, MD, UNITED STATES

PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003232975	A1	20031218
APPLICATION INFO.:	US 2002-74024	A1	20020214 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-764895, filed on 17 Jan 2001, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)

US 2000-217496P	20000711 (60)
US 2000-225447P	20000814 (60)
US 2000-218290P	20000714 (60)
US 2000-225757P	20000814 (60)
US 2000-226868P	20000822 (60)
US 2000-216647P	20000707 (60)
US 2000-225267P	20000814 (60)
US 2000-216880P	20000707 (60)
US 2000-225270P	20000814 (60)
US 2000-251869P	20001208 (60)
US 2000-235834P	20000927 (60)
US 2000-234274P	20000921 (60)
US 2000-234223P	20000921 (60)
US 2000-228924P	20000830 (60)
US 2000-224518P	20000814 (60)
US 2000-236369P	20000929 (60)
US 2000-224519P	20000814 (60)
US 2000-220964P	20000726 (60)
US 2000-241809P	20001020 (60)
US 2000-249299P	20001117 (60)
US 2000-236327P	20000929 (60)
US 2000-241785P	20001020 (60)
US 2000-244617P	20001101 (60)
US 2000-225268P	20000814 (60)
US 2000-236368P	20000929 (60)
US 2000-251856P	20001208 (60)
US 2000-251868P	20001208 (60)
US 2000-229344P	20000901 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-229345P	20000901 (60)
US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)



US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850  
NUMBER OF CLAIMS: 24  
EXEMPLARY CLAIM: 1  
LINE COUNT: 21828  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 20 OF 214 USPATFULL on STN

TI Proteases

AB The invention provides human proteases (PRTS) and polynucleotides which identify and encode PRTS. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of PRTS.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:330138 USPATFULL

TITLE: Proteases

INVENTOR(S): Delegeane, Angelo M., Milpitas, CA, UNITED STATES  
Gandhi, Ameena R., San Francisco, CA, UNITED STATES  
Hafalia, April J. A., Santa Clara, CA, UNITED STATES  
Lu, Dyung Aina M., San Jose, CA, UNITED STATES  
Arvizu, Chandra S., San Jose, CA, UNITED STATES  
Tribouley, Catherine M., San Francisco, CA, UNITED STATES  
Das, Debopriya, Mountain View, CA, UNITED STATES  
Kallick, Deborah A., Portola Valley, CA, UNITED STATES  
Nguyen, Danniell B., San Jose, CA, UNITED STATES  
Lee, Ernestine A., Castro Valley, CA, UNITED STATES  
Khan, Farrah A., Glen View, IL, UNITED STATES  
Yue, Henry, Sunnyvale, CA, UNITED STATES  
Au-Young, Janice, Brisbane, CA, UNITED STATES  
Griffin, Jennifer A., Fremont, CA, UNITED STATES  
Policky, Jennifer L., San Jose, CA, UNITED STATES  
Ramkumar, Jayalaxmi, Fremont, CA, UNITED STATES  
Yang, Junming, San Jose, CA, UNITED STATES  
Thangavelu, Kavitha, Mountain View, CA, UNITED STATES  
Ding, Li, Creve Coeur, MO, UNITED STATES  
Kearney, Liam, San Francisco, CA, UNITED STATES  
Baughn, Mariah R., San Leandro, CA, UNITED STATES  
Borowsky, Mark L., Redwood City, CA, UNITED STATES  
Sanjanwala, Madhusudan, Los Altos, CA, UNITED STATES  
Yao, Monique G., Carmel, IN, UNITED STATES  
Burford, Neil, Durham, CT, UNITED STATES  
Chawla, Narinder K., Union City, CA, UNITED STATES  
Lal, Preeti G., Santa Clara, CA, UNITED STATES  
Lee, Sally, San Jose, CA, UNITED STATES  
Todd, Stephen, San Francisco, CA, UNITED STATES  
Lo, Terence P., Foster City, CA, UNITED STATES  
Tang, Y. Tom, San Jose, CA, UNITED STATES  
Elliott, Vicki S., San Jose, CA, UNITED STATES  
Azimzai, Yalda, Oakland, CA, UNITED STATES  
Lu, Yan, Palo Alto, CA, UNITED STATES  
PATENT ASSIGNEE(S): Incyte Genomics, Inc., Palo Alto, CA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003232349	A1	20031218
APPLICATION INFO.:	US 2002-274639	A1	20021018 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 2001-US22397, filed on 17 Jul 2001, PENDING		

NUMBER	DATE
--------	------

```

-----
PRIORITY INFORMATION:  US 2000-220063P      20000721 (60)
                       US 2000-221680P      20000728 (60)
                       US 2000-223544P      20000804 (60)
                       US 2000-224717P      20000811 (60)
                       US 2000-225988P      20000816 (60)
                       US 2000-227568P      20000823 (60)

DOCUMENT TYPE:         Utility
FILE SEGMENT:          APPLICATION
LEGAL REPRESENTATIVE:  INCYTE CORPORATION (formerly known as Incyte, Genomics,
                       Inc.), 3160 PORTER DRIVE, PALO ALTO, CA, 94304
NUMBER OF CLAIMS:      86
EXEMPLARY CLAIM:       1
LINE COUNT:            8959
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

```

=> d his

(FILE 'HOME' ENTERED AT 18:21:39 ON 29 JAN 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA' ENTERED AT 18:21:55  
ON 29 JAN 2004

```

L1      5340 S TIMP-1
L2      1 S CEREBUS PROTEIN
L3      10853 S BRAIN DERIVED NEUROTROPHIC FACTOR OR BDNF
L4      41802 S INTERFERON ALPHA
L5      14602 S INTERFERON BETA
L6      258098 S ALBUMIN
L7      30354 S L6 AND FUSION
L8      214 S L7 AND L1
L9      0 S L7 AND L2
L10     636 S L7 AND L3
L11     1550 S L7 AND L4
L12     1361 S L7 AND L5
L13     0 S L6 AND L2

```

=> d l10 ti abs ibib 1-20

```

L10 ANSWER 1 OF 636  USPATFULL on STN
TI    Modulation of neural stem cells and neural progenitor cells
AB    The invention relates generally to methods of influencing central
      nervous system cells to produce progeny useful in the treatment of CNS
      disorders. More specifically, the invention includes methods of exposing
      a patient suffering from such a disorder to a reagent that modulates the
      proliferation, migration, differentiation and survival of central
      nervous system cells via S1P or LPA signaling. These methods are useful
      for reducing at least one symptom of the disorder.

```

```

ACCESSION NUMBER:      2004:19358  USPATFULL
TITLE:                 Modulation of neural stem cells and neural progenitor
                       cells
INVENTOR(S):           Lindquist, Per, Staltradsvagen 21, SWEDEN
                       Mercer, Alex, Staltradsvagen 15, SWEDEN
                       Ronnholm, Harriet, Tornslingan 8, 1tr, SWEDEN
                       Wikstrom, Lilian, Stjarnfallsvagen 9, SWEDEN

```

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004014662	A1	20040122
APPLICATION INFO.:	US 2003-434943	A1	20030508 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-379114P	20020508 (60)

US 2002-393159P 20020702 (60)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: Ivor R. Elrifi, Mintz, Levin, Cohn, Ferris,, Glovsky  
and Popeo, P.C., 666 Third Avenue, 24th Floor, New  
York, NY, 10017  
NUMBER OF CLAIMS: 66  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 12 Drawing Page(s)  
LINE COUNT: 3175

L10 ANSWER 2 OF 636 USPATFULL on STN

TI Novel carcinoma-related genes and polypeptides and methods of use  
thereof  
AB Novel nucleic acids and polypeptides encoded thereby are provided that  
are highly duplicated and overexpressed in squamous cell carcinomas of a  
variety of tissues. Antibodies specific for binding the novel  
polypeptides are also provided. The invention further discloses several  
assays for gene duplication and overexpression of the novel gene and  
excessive production of the novel polypeptide in a sample. These assays  
permit assessing copy number in a sample from a subject, and contribute  
to the diagnosis, prognosis and development of therapeutic strategy for  
a pathology such as squamous cell carcinoma in a subject.

ACCESSION NUMBER: 2004:13021 USPATFULL  
TITLE: Novel carcinoma-related genes and polypeptides and  
methods of use thereof  
INVENTOR(S): Singh, Bhuvanesh, New York, NY, UNITED STATES  
Reddy, Pabbathi Gopal, Gangadhara Mandal, INDIA  
Reddy, Pabbathi Thirumal, Gangadhara Mandal, INDIA LR  
PATENT ASSIGNEE(S): Memorial Sloan-Kettering Cancer Center (U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009541	A1	20040115
APPLICATION INFO.:	US 2003-361725	A1	20030210 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-355009P	20020208 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Proteus Patent Practice LLC, P. O. Box 1867, New Haven, CT, 06508	
NUMBER OF CLAIMS:	86	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	9 Drawing Page(s)	
LINE COUNT:	6217	

L10 ANSWER 3 OF 636 USPATFULL on STN

TI Methods and reagents for dendritic localization of polynucleotides  
AB The present invention provides for a recombinant nucleic acid molecule  
comprising a region of a calcium-calmodulin dependent kinase II $\alpha$   
promoter operatively linked to a gene of interest. The region of a  
calcium-calmodulin dependent kinase II $\alpha$  promoter may comprise an  
8.5 kilobase nucleic acid sequence which corresponds to the nucleic acid  
sequence of ATCC Accession Number \_\_\_\_\_, designated pMM281. The present  
invention also provides a human cell line which has been stably  
transformed by a recombinant nucleic acid molecule comprising a gene of  
interest operatively linked to a nucleic acid encoding a  
calcium-calmodulin dependent kinase II $\alpha$  promoter region which has  
a nucleotide sequence corresponding to the sequence of ATCC Accession  
Number \_\_\_\_\_, designated pMM281. The present invention also provides for a  
transgenic nonhuman mammal whose germ or somatic cells contain a nucleic

acid molecule which encodes a gene of interest under the control of a CaMKII $\alpha$  promoter (ATCC Accession Number \_\_\_\_\_), introduced into the mammal, or an ancestor thereof, at an embryonic stage. Another embodiment of the present invention is a method of evaluating whether a compound is effective in treating symptoms of a neurological disorder in a subject which comprises: (a) administering the compound to the transgenic nonhuman mammal whose germ or somatic cells contain a nucleic acid molecule which encodes a gene of interest under the control of a CaMKII $\alpha$  promoter, and (b) comparing the neurological function the mammal in step (a) with neurological function of the transgenic mammal in the absence of the compound, thereby determining whether the compound is effective in treating symptoms of the neurological disorder in a subject.

ACCESSION NUMBER: 2004:12977 USPATFULL  
 TITLE: Methods and reagents for dendritic localization of polynucleotides  
 INVENTOR(S): Kandel, Eric R., Riverdale, NY, UNITED STATES  
 Mayford, Mark, San Diego, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009497	A1	20040115
APPLICATION INFO.:	US 2003-341999	A1	20030114 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1997-969137, filed on 12 Nov 1997, GRANTED, Pat. No. US 6509190		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	John P. White, Esq., Cooper & Dunham LLP, 1185 Avenue of the Americas, New York, NY, 10036		
NUMBER OF CLAIMS:	20		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	56 Drawing Page(s)		
LINE COUNT:	4900		

L10 ANSWER 4 OF 636 USPATFULL on STN  
 TI Compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer  
 AB The invention relates to compositions, kits, and methods for diagnosing, staging, prognosing, monitoring and treating human prostate cancers. A variety of marker genes are provided, wherein changes in the levels of expression of one or more of the marker genes is correlated with the presence of prostate cancer.

ACCESSION NUMBER: 2004:12961 USPATFULL  
 TITLE: Compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer  
 INVENTOR(S): Schlegel, Robert, Auburndale, MA, UNITED STATES  
 Endege, Wilson O., Norwood, MA, UNITED STATES  
 PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., Cambridge, MA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009481	A1	20040115
APPLICATION INFO.:	US 2002-166883	A1	20020611 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-297285P	20010611 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	LAHIVE & COCKFIELD, 28 STATE STREET, BOSTON, MA, 02109	
NUMBER OF CLAIMS:	27	

EXEMPLARY CLAIM: 1  
LINE COUNT: 15572

L10 ANSWER 5 OF 636 USPATFULL on STN

TI Cardiostrophin and uses therefor

AB Isolated CT-1, isolated DNA encoding CT-1, and recombinant or synthetic methods of preparing CT-1 are disclosed. CT-1 is shown to bind to and activate the receptor, LIFR $\beta$ . These CT-1 molecules are shown to influence hypertrophic activity, neurological activity, and other activities associated with receptor LIFR $\beta$ . Accordingly, these compounds or their antagonists may be used for treatment of heart failure, arrhythmic disorders, inotropic disorders, neurological disorders, and other disorders associated with the LIFR $\beta$ .

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:7778 USPATFULL

TITLE: Cardiostrophin and uses therefor

INVENTOR(S): Baker, Joffre, El Granada, CA, UNITED STATES

Chien, Kenneth, La Jolla, CA, UNITED STATES

King, Kathleen, Pacifica, CA, UNITED STATES

Pennica, Diane, Burlingame, CA, UNITED STATES

Wood, William, San Mateo, CA, UNITED STATES

PATENT ASSIGNEE(S): Genentech, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004006018	A1	20040108
APPLICATION INFO.:	US 2003-407303	A1	20030403 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-724772, filed on 28 Nov 2000, PENDING Continuation of Ser. No. US 1997-797014, filed on 7 Feb 1997, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-49998P	19960214 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080	
NUMBER OF CLAIMS:	25	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	22 Drawing Page(s)	
LINE COUNT:	5602	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 6 OF 636 USPATFULL on STN

TI Materials and methods relating to therapy and diagnosis using targeting of cells that express DCAL-Hy polypeptides

AB The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to novel human DCAL-Hy polypeptides. Other aspects of the invention include vectors containing processes for producing novel human DCAL-Hy polypeptides, and antibodies specific for such polypeptides. Targeting DCAL-Hy using DCAL-Hy polypeptides, nucleic acids encoding for DCAL-Hy polypeptides, anti-DCAL-Hy antibodies, and other binding peptides and small molecules provides a method of killing or inhibiting that growth of cancer cells that express the DCAL-Hy protein. Methods of therapy and diagnosis of disorders associated with DCAL-Hy protein-expressing cells, such as DCAL-Hy, are described.

ACCESSION NUMBER: 2004:7358 USPATFULL

TITLE: Materials and methods relating to therapy and diagnosis using targeting of cells that express DCAL-Hy polypeptides

INVENTOR(S): Emtage, Peter C.R., Sunnyvale, CA, UNITED STATES

Drmanac, Radoje T., Palo Alto, CA, UNITED STATES  
Goodrich, Ryle W., Los Angeles, CA, UNITED STATES  
Tang, Y. Tom, San Jose, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005592	A1	20040108
APPLICATION INFO.:	US 2003-379127	A1	20030303 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-799451, filed on 5 Mar 2001, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	NUVELO, 675 ALMANOR AVE., SUNNYVALE, CA, 94085		
NUMBER OF CLAIMS:	51		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	8 Drawing Page(s)		
LINE COUNT:	7657		

L10 ANSWER 7 OF 636 USPATFULL on STN

TI Method for treating inflammation

AB A method for treating IL-20 induced inflammation. An antagonist to IL-20 is administered to treat inflammation and associated diseases. The antagonist can be an antibody that binds to IL-20 or its receptor or a soluble receptor that binds to IL-20. Examples of such diseases are adult respiratory disease, psoriasis, eczema, contact dermatitis, atopic dermatitis, septic shock, multiple organ failure, inflammatory lung injury, bacterial pneumonia, inflammatory bowel disease, rheumatoid arthritis, asthma, ulcerative colitis and Crohn's disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:7087 USPATFULL  
TITLE: Method for treating inflammation  
INVENTOR(S): Thompson, Penny, Snohomish, WA, UNITED STATES  
Foster, Donald C., Lake Forest Park, WA, UNITED STATES  
Xu, Wenfeng, Mukilteo, WA, UNITED STATES  
Madden, Karen L., Bellevue, WA, UNITED STATES  
Kelly, James D., Mercer Island, WA, UNITED STATES  
Sprecher, Cindy A., Seattle, WA, UNITED STATES  
Blumberg, Hal, Seattle, WA, UNITED STATES  
Eagan, Maribeth A., Seattle, WA, UNITED STATES  
Jaspers, Stephen R., Edmonds, WA, UNITED STATES  
Chandrasekher, Yasmin A., Mercer Island, WA, UNITED STATES  
Novak, Julia E., Bainbridge Island, WA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005320	A1	20040108
APPLICATION INFO.:	US 2003-424658	A1	20030428 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-746359, filed on 22 Dec 2000, GRANTED, Pat. No. US 6610286		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-171969P	19991223 (60)
	US 2000-213341P	20000622 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Shelby J. Walker, ZymoGenetics, Inc., 1201 Eastlake Avenue East, Seattle, WA, 98102	
NUMBER OF CLAIMS:	29	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	
LINE COUNT:	3489	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 8 OF 636 USPATFULL on STN

TI Methods of therapy and diagnosis using immunotargeting of  
CD84Hyl-expressing cells  
AB Certain cells, including types of cancer cells such as lymphomas, are  
capable of expressing high levels of CD84Hyl. Immunotargeting using  
CD84Hyl polypeptides, nucleic acids encoding for CD84Hyl polypeptides  
and anti-CD84Hyl antibodies provides a method of killing or inhibiting  
that growth of CD84HY1Protein-expressing cancer cells. Methods of  
immunotherapy and diagnosis of disorders associated with  
CD84Hylprotein-expressing cells are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:7084 USPATFULL  
TITLE: Methods of therapy and diagnosis using immunotargeting  
of CD84Hyl-expressing cells  
INVENTOR(S): Deder, Douglas, Castro Valley, CA, UNITED STATES  
Wang, Jian-Rui, Cupertino, CA, UNITED STATES  
Emtage, Peter C.R., Sunnyvale, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005317	A1	20040108
APPLICATION INFO.:	US 2002-327413	A1	20021219 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-78080, filed on 15 Feb 2002, PENDING Continuation-in-part of Ser. No. WO 2001-US2613, filed on 25 Jan 2001, PENDING Continuation-in-part of Ser. No. US 2000-645476, filed on 24 Aug 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-491404, filed on 25 Jan 2000, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Luisa Bigornia, HYSEQ, INC., 670 Almanor Avenue, Sunnyvale, CA, 94085		
NUMBER OF CLAIMS:	21		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Page(s)		
LINE COUNT:	2703		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 9 OF 636 USPATFULL on STN

TI Fc region variants  
AB The present invention provides polypeptide Fe region variants and  
oligonucleotides encoding Fc region variants. Specifically, the present  
invention provides compositions comprising novel Fc region variants,  
methods for identifying useful Fc region variants, and methods for  
employing Fc region variants for treating disease.

ACCESSION NUMBER: 2004:2564 USPATFULL  
TITLE: Fc region variants  
INVENTOR(S): Watkins, Jeffrey D., Olivenhain, CA, UNITED STATES  
Allan, Barrett, Encinitas, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004002587	A1	20040101
APPLICATION INFO.:	US 2003-370749	A1	20030220 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-358161P	20020220 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MEDLEN & CARROLL, LLP, Suite 350, 101 Howard Street, San Francisco, CA, 94105	



NUMBER OF CLAIMS: 20  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 12 Drawing Page(s)  
LINE COUNT: 5292

L10 ANSWER 10 OF 636 USPATFULL on STN

TI Methods for making recombinant proteins using apoptosis inhibitors  
AB The invention provided improved methods of making and producing recombinant proteins in in vitro cultures of host cells using apoptosis inhibitors. The use of one or more apoptosis inhibitors in the methods can reduce apoptosis in the cell cultures and markedly improve yield of the desired recombinant proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:2118 USPATFULL  
TITLE: Methods for making recombinant proteins using apoptosis inhibitors  
INVENTOR(S): Dixit, Vishva, Los Altos Hills, CA, UNITED STATES  
Hamilton, Robert W., San Carlos, CA, UNITED STATES  
Goor, Jana van de, Foster City, CA, UNITED STATES  
PATENT ASSIGNEE(S): Genentech, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004002139	A1	20040101
APPLICATION INFO.:	US 2003-607882	A1	20030627 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-668924, filed on 25 Sep 2000, GRANTED, Pat. No. US 6586206		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-156232P	19990927 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Genentech, Inc., Attn: Diane L. Marschang, 1 DNA Way, South San Francisco, CA, 94080-4990	
NUMBER OF CLAIMS:	37	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	15 Drawing Page(s)	
LINE COUNT:	1549	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 11 OF 636 USPATFULL on STN

TI Prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents  
AB The present invention relates to methods and compositions designed for the treatment, management or prevention of cancer. The methods of the invention comprise the administration of an effective amount of one or more antagonists of Integrin  $\alpha$ .sub.V $\beta$ .sub.3 alone or in combination with the administration of an effective amount of one or more other agents useful for cancer therapy. The invention also provides pharmaceutical compositions comprising one or more antagonists of Integrin  $\alpha$ .sub.V $\beta$ .sub.3 and/or one or more other agents useful for cancer therapy. In particular, the invention is directed to methods of treatment and prevention of cancer by the administration of a therapeutically or prophylactically effective amount of one or more antagonists of Integrin  $\alpha$ .sub.V $\beta$ .sub.3 alone or in combination with standard and experimental therapies for treatment or prevention of cancer. Also included are methods for screening for epitope-specific Integrin  $\alpha$ .sub.V $\beta$ .sub.3 antagonists which can be used according to the methods of the invention. In addition, methods for facilitating the use of Integrin  $\alpha$ .sub.V $\beta$ .sub.3 antagonists in the analysis of Integrin  $\alpha$ .sub.V $\beta$ .sub.3 expression in biopsies of animal model and clinical study samples are also contemplated.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:1816 USPATFULL  
TITLE: Prevention or treatment of cancer using integrin  
alphavbeta3 antagonists in combination with other  
agents  
INVENTOR(S): Woessner, Richard, Lafayette, CO, UNITED STATES  
Kiener, Peter, Doylestown, PA, UNITED STATES  
Dormitzer, Melissa, Germantown, MD, UNITED STATES  
Walsh, William, Sharpsburg, MD, UNITED STATES  
Heinrichs, Jon, North Potomac, MD, UNITED STATES  
PATENT ASSIGNEE(S): MedImmune, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004001835	A1	20040101
APPLICATION INFO.:	US 2003-379189	A1	20030304 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-361859P	20020304 (60)
	US 2002-370398P	20020405 (60)
	US 2003-444265P	20030130 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PENNIE AND EDMONDS, 1155 AVENUE OF THE AMERICAS, NEW YORK, NY, 100362711	
NUMBER OF CLAIMS:	44	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	
LINE COUNT:	6588	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 12 OF 636 USPATFULL on STN

TI Methods of treatment using specific binding agents of human  
angiopoietin-2  
AB Disclosed are peptides that bind to Ang-2. Also disclosed are  
peptibodies comprising the peptides, methods of making such peptides and  
peptibodies, and methods of treatment using such peptides and  
peptibodies.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:335315 USPATFULL  
TITLE: Methods of treatment using specific binding agents of  
human angiopoietin-2  
INVENTOR(S): Oliner, Jonathan Daniel, Newbury Park, CA, UNITED  
STATES  
Min, Hosung, Newbury Park, CA, UNITED STATES  
PATENT ASSIGNEE(S): Amgen Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003236193	A1	20031225
APPLICATION INFO.:	US 2003-410998	A1	20030409 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-269695, filed on 10 Oct 2002, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-414155P	20020927 (60)
	US 2001-328624P	20011011 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	U.S. Patent Operations/[SNB], AMGEN, INC., Dept. 4300, M/S 27-4-A, One Amgen Center Drive, Thousand Oaks, CA,	

91320-1799  
NUMBER OF CLAIMS: 41  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 22 Drawing Page(s)  
LINE COUNT: 9524  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 13 OF 636 USPATFULL on STN

TI Vascularized organized tissues and uses thereof  
AB The invention relates to organized tissues that are implanted into an organism wherein they become vascularized. The invention also relates to methods of using an organized tissue that is vascularized following implantation into an organism, for delivery of a bioactive compound. The invention also relates to methods of producing an organized tissue that is vascularized following implantation into an organism.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:334686 USPATFULL  
TITLE: Vascularized organized tissues and uses thereof  
INVENTOR(S): Vandenburg, Herman H., Providence, RI, UNITED STATES  
Valentini, Robert F., Cranston, RI, UNITED STATES  
Wang, Xiao, Providence, RI, UNITED STATES  
Shansky, Janet, Barrington, RI, UNITED STATES  
Ferland, Paulette, Tiverton, RI, UNITED STATES  
DeTatto, Michael, Bristol, RI, UNITED STATES  
PATENT ASSIGNEE(S): Cell Based Delivery Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003235561	A1	20031225
APPLICATION INFO.:	US 2002-281765	A1	20021028 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-391330P	20020625 (60)
	US 2002-399605P	20020730 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PALMER & DODGE, LLP, KATHLEEN M. WILLIAMS, 111 HUNTINGTON AVENUE, BOSTON, MA, 02199	
NUMBER OF CLAIMS:	85	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	9 Drawing Page(s)	
LINE COUNT:	5322	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 14 OF 636 USPATFULL on STN

TI Central airway administration for systemic delivery of therapeutics  
AB The present invention relates to methods and products for the transepithelial systemic delivery of therapeutics. In particular, the invention relates to methods and compositions for the systemic delivery of therapeutics by administering an aerosol containing antibodies or conjugates of a therapeutic agent with an FcRn binding partner to epithelium of central airways of the lung. The methods and products are adaptable to a wide range of therapeutic agents, including proteins and polypeptides, nucleic acids, drugs, and others. The methods and products have the advantage of not requiring administration to the deep lung in order to effect systemic delivery.

ACCESSION NUMBER: 2003:334661 USPATFULL  
TITLE: Central airway administration for systemic delivery of therapeutics  
INVENTOR(S): Blumberg, Richard S., Chestnut Hill, MA, UNITED STATES  
Lencer, Wayne I., Jamaica Plain, MA, UNITED STATES  
Simister, Neil E., Wellesley, MA, UNITED STATES

PATENT ASSIGNEE(S): Bitonti, Alan J., Acton, MA, UNITED STATES  
The Brigham and Women's Hospital, Inc., Boston, MA,  
UNITED STATES, 02115 (U.S. corporation)  
Children's Medical Center Corporation, Boston, MA,  
UNITED STATES, 02115 (U.S. corporation)  
Brandeis University, Waltham, MA, UNITED STATES, 02254  
(U.S. corporation)  
Syntonix Pharmaceuticals, Inc., Waltham, MA, UNITED  
STATES, 02451 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003235536	A1	20031225
APPLICATION INFO.:	US 2003-435608	A1	20030509 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2002-US21335, filed on 3 Jul 2002, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-364482P	20020315 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA, 600 ATLANTIC AVENUE, BOSTON, MA, 02210-2211	
NUMBER OF CLAIMS:	127	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	17 Drawing Page(s)	
LINE COUNT:	4042	

L10 ANSWER 15 OF 636 USPATFULL on STN

TI Perlecan transgenic animals and methods of identifying compounds for the  
treatment of amyloidoses

AB The invention provides a transgenic non-human animal expressing a  
perlecan encoding transgene. Also provided is a double-transgenic  
non-human animal expressing a perlecan and an amyloid encoding  
transgene. A method of screening for a compound which alters the rate or  
extent of amyloid deposition is additionally provided. The method  
consists of: (a) constructing a perlecan transgenic animal; (b)  
administering an effective amount of a test compound to said perlecan  
transgenic animal; and (c) determining whether said test compound alters  
the extent or rate of amyloid deposition. Finally, the invention  
provides a method of screening for a compound which alters the rate or  
extent of amyloid deposition. The method consists of: (a) constructing a  
perlecan/amyloid double-transgenic animal; (b) administering an  
effective amount of a test compound to said perlecan/amyloid  
double-transgenic animal; and (c) determining whether said test compound  
alters the extent o rate of amyloid deposition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:331452 USPATFULL

TITLE: Perlecan transgenic animals and methods of identifying  
compounds for the treatment of amyloidoses

INVENTOR(S): Snow, Alan D., Lynnwood, WA, UNITED STATES  
Fukuchi, Ken-Ichiro, Birmingham, AL, UNITED STATES  
Hassell, John, Tampa, FL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003233669	A1	20031218
APPLICATION INFO.:	US 2003-384172	A1	20030305 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-536231, filed on 27 Mar 2000, GRANTED, Pat. No. US 6563016 Continuation of Ser. No. US 1997-870987, filed on 6 Jun 1997, ABANDONED		

NUMBER	DATE
--------	------

-----  
PRIORITY INFORMATION: US 1996-17830P 19960606 (60)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: PATRICK M. DWYER, PROTEOTECH, INC, SUITE 114, 1818  
WESTLAKE AVENUE N, SEATTLE, WA, 98109  
NUMBER OF CLAIMS: 14  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 25 Drawing Page(s)  
LINE COUNT: 2761  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 16 OF 636 USPATFULL on STN

TI Method for identifying compounds which affect synaptogenesis  
AB A method is provided for identifying a compound which affects the formation of AMPA receptors into aggregates. A method is also provided for identifying a compound which affects the formation of synaptic connections. A method is provided for identifying a compound that modulates immediate early gene expression. A method is further provided for increasing the number of excitory synapses of a neuron, including introducing into the neuron a polynucleotide sequence encoding a Narp operatively linked to a promoter, or a Narp polypeptide, thereby increasing the number of excitory synapses of the neuron. A method is provided for treating a subject with a disorder associated with a decrease in a function or expression of Narp, including administering to the subject a therapeutically effective amount of a compound that augments Narp function or expression. A method is provided for treating a subject with a disorder associated with an increase in a function or expression of Narp, including administering to the subject a therapeutically effective amount of a compound that inhibits Narp function or expression. A method is provided for treating a patient having or at risk of having a disorder associated with decreased Narp expression. The method includes introducing into a cell of a patient having a disorder associated with decreased Narp expression or function a polynucleotide sequence encoding a Narp polypeptide operatively linked to a promoter. A method is provided for treating a subject having a deficiency in a neuron's immediate early gene responsiveness to a stimulus. The method includes administering a nucleic acid encoding a Narp polypeptide to said subject, wherein the administration results in amelioration of the deficiency.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:330561 USPATFULL  
TITLE: Method for identifying compounds which affect synaptogenesis  
INVENTOR(S): Worley, Paul, Baltimore, MD, UNITED STATES  
O'Brien, Richard, Baltimore, MD, UNITED STATES  
Xu, DeSheng, Towson, MD, UNITED STATES  
Huganir, Richard L., Baltimore, MD, UNITED STATES  
PATENT ASSIGNEE(S): THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003232776	A1	20031218
APPLICATION INFO.:	US 2002-299957	A1	20021118 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-328710, filed on 9 Jun 1999, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	GRAY CARY WARE & FREIDENRICH LLP, 4365 EXECUTIVE DRIVE, SUITE 1100, SAN DIEGO, CA, 92121-2133		
NUMBER OF CLAIMS:	32		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	2 Drawing Page(s)		

LINE COUNT: 1889  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 17 OF 636 USPATFULL on STN  
TI Treatment of inner ear hair cells  
AB Compositions, methods, and devices are provided for inducing or enhancing the growth, proliferation, regeneration of inner ear tissue, particularly inner ear hair cells. In addition, provided are compositions and methods for prophylactic or therapeutic treatment of a mammal afflicted with an inner ear disorder or condition, particularly for hearing impairments involving hair cell damage, loss, or degeneration, by administration of a therapeutically effective amount of IGF-1 or FGF-2, or their agonists, alone or in combination.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
ACCESSION NUMBER: 2003:330544 USPATFULL  
TITLE: Treatment of inner ear hair cells  
INVENTOR(S): Gao, Wei-Qiang, Foster City, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003232759	A1	20031218
APPLICATION INFO.:	US 2003-458039	A1	20030609 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-644368, filed on 23 Aug 2000, PENDING Division of Ser. No. US 1997-963596, filed on 31 Oct 1997, GRANTED, Pat. No. US 6156728		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	HELLER EHRMAN WHITE & MCAULIFFE LLP, 275 MIDDLEFIELD ROAD, MENLO PARK, CA, 94025-3506		
NUMBER OF CLAIMS:	20		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	7 Drawing Page(s)		
LINE COUNT:	2082		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 18 OF 636 USPATFULL on STN  
TI Proliferated cell lines and uses thereof  
AB The subject invention pertains to tumor cell lines useful for increasing the proliferation potential of any human or animal cell in culture, thereby providing immortalized or continuous cell lines and cultures. The invention also concerns proliferation factors, and compositions containing the factors, which are capable of increasing the proliferation potential of any human or other animal cell in culture. The subject invention further pertains to a method for proliferation cells in culture by contacting cells with the proliferation factors. The proliferated cells can range in plasticity and can include, for example, blast cells, fertilized ova, non-fertilized gametes, embryonic stem cells, adult stem cells, precursor or progenitor cells, and highly specialized cells. Optionally, the cells can be induced to cease proliferation. The proliferation cells of the subject invention are useful for cell therapy, cell/gene therapy, biological production of molecules, and as in vitro models for research, toxicity testing, and drug development.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
ACCESSION NUMBER: 2003:330537 USPATFULL  
TITLE: Proliferated cell lines and uses thereof  
INVENTOR(S): Freeman, Thomas B., Tampa, FL, UNITED STATES  
Caviedes, Pablo, Santiago, CHILE  
Caviedes, Raul, Santiago, CHILE  
Sanberg, Paul R., Spring Hill, FL, UNITED STATES  
Cameron, Don F., Lutz, FL, UNITED STATES

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 2003232752 A1 20031218  
APPLICATION INFO.: US 2003-359854 A1 20030207 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-355157P	20020208 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL ASSOCIATION, 2421 N.W. 41ST STREET, SUITE A-1, GAINESVILLE, FL, 326066669	
NUMBER OF CLAIMS:	93	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	30 Drawing Page(s)	
LINE COUNT:	4025	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 19 OF 636 USPATFULL on STN  
TI Molecules interacting with CASL (MICAL) polynucleotides, polypeptides, and methods of using the same  
AB The present invention provides MICAL and MICAL-Like polypeptides and polynucleotides. Also provided are methods that for identifying agents that affect axon growth and placement. Furthermore, provided herein are methods for affecting axon growth and placement.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:330208 USPATFULL  
TITLE: Molecules interacting with CASL (MICAL) polynucleotides, polypeptides, and methods of using the same  
INVENTOR(S): Kolodkin, Alex L., Baltimore, MD, UNITED STATES  
Terman, Jon R., Baltimore, MD, UNITED STATES  
Mao, Tiany, Parkville, MD, UNITED STATES  
Pasterkamp, Ronald J., Baltimore, MD, UNITED STATES  
Yu, Hung-Hsiang, Lynnwood, WA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003232419	A1	20031218
APPLICATION INFO.:	US 2003-359012	A1	20030204 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-354178P	20020204 (60)
	US 2002-384302P	20020530 (60)
	US 2002-388325P	20020613 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	LISA A. HAILE, J.D., PH.D., GRAY CARY WARE & FREIDENRICH LLP, Suite 1100, 4365 Executive Drive, San Diego, CA, 92121-2133	
NUMBER OF CLAIMS:	153	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	45 Drawing Page(s)	
LINE COUNT:	10590	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 20 OF 636 USPATFULL on STN  
TI Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis  
AB Isolated nucleic acid molecules are disclosed, comprising an alphavirus nonstructural protein gene which, when operably incorporated into a recombinant alphavirus particle, eukaryotic layered vector initiation system, or RNA vector replicon, has a reduced level of vector-specific

RNA synthesis, as compared to wild-type, and the same or greater level of proteins encoded by RNA transcribed from the viral junction region promoter, as compared to a wild-type recombinant alphavirus particle. Also disclosed are RNA vector replicons, alphavirus vector constructs, and eukaryotic layered vector initiation systems which contain the above-identified nucleic acid molecules.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:329847 USPATFULL  
TITLE: Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis  
INVENTOR(S): Dubensky, Thomas W., JR., Del Mar, CA, UNITED STATES  
Polo, John M., Encinitas, CA, UNITED STATES  
Belli, Barbara A., San Diego, CA, UNITED STATES  
Schlesinger, Sondra, St. Louis, MO, UNITED STATES  
Drvga, Sergey A., Fort Collins, CO, UNITED STATES  
Frolov, Ilya, St. Louis, MO, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003232058	A1	20031218
APPLICATION INFO.:	US 2003-391441	A1	20030317 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-507362, filed on 18 Feb 2000, GRANTED, Pat. No. US 6592874 Division of Ser. No. US 1997-944465, filed on 6 Oct 1997, GRANTED, Pat. No. US 6451592 Continuation-in-part of Ser. No. US 1997-833148, filed on 4 Apr 1997, ABANDONED Continuation-in-part of Ser. No. US 1996-679640, filed on 12 Jul 1996, ABANDONED Continuation-in-part of Ser. No. US 1996-668953, filed on 24 Jun 1996, ABANDONED Continuation-in-part of Ser. No. US 1996-628594, filed on 5 Apr 1996, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Chiron Corporation, Intellectual Property - R440, P.O. Box 8097, Emeryville, CA, 94662-8097		
NUMBER OF CLAIMS:	33		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	63 Drawing Page(s)		
LINE COUNT:	8258		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 18:21:39 ON 29 JAN 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA' ENTERED AT 18:21:55 ON 29 JAN 2004

L1 5340 S TIMP-1  
L2 1 S CEREBUS PROTEIN  
L3 10853 S BRAIN DERIVED NEUROTROPHIC FACTOR OR BDNF  
L4 41802 S INTERFERON ALPHA  
L5 14602 S INTERFERON BETA  
L6 258098 S ALBUMIN  
L7 30354 S L6 AND FUSION  
L8 214 S L7 AND L1  
L9 0 S L7 AND L2  
L10 636 S L7 AND L3  
L11 1550 S L7 AND L4  
L12 1361 S L7 AND L5  
L13 0 S L6 AND L2

=> d l11 ti abs ibib 1-20



L11 ANSWER 1 OF 1550 MEDLINE on STN

TI Pharmacokinetic and pharmacodynamic studies of a human serum  
**albumin-interferon-alpha fusion**  
protein in cynomolgus monkeys.

AB **Interferon-alpha** (IFN-alpha) is indicated for the treatment of certain viral infections including hepatitis B and C, and cancers such as melanoma. The short circulating half-life of unmodified IFN-alpha makes frequent dosing (daily or three times weekly) over an extended period (6-12 months or more) necessary. To improve the pharmacokinetics of IFN-alpha and decrease dosing frequency, IFN-alpha was fused to human serum **albumin** producing a new protein, Albuferon. In vitro comparisons of Albuferon and IFN-alpha showed similar antiviral and antiproliferative activities, although Albuferon was less potent on a molar basis than IFN-alpha. Pharmacokinetic and pharmacodynamic properties of the **fusion** protein were enhanced in monkeys. After a single intravenous injection (30 microg/kg,) clearance was 0.9 ml/h/kg, and the terminal half-life was 68 h. After 30 microg/kg subcutaneous injection, apparent clearance (clearance divided by bioavailability) was 1.4 ml/h/kg, the terminal half-life was 93 h, and bioavailability was 64%. The rate of clearance of Albuferon was approximately 140-fold slower, and the half-life 18-fold longer, than for IFN-alpha given by the subcutaneous route in other monkey studies. Sera from Albuferon-treated monkeys demonstrated dose-related antiviral activity for > or =8 days based on an in vitro bioassay, whereas antiviral activity from IFN-alpha-treated animals was only slightly elevated relative to vehicle on day 0. Significant increases in 2',5'-oligoadenylate synthetase mRNA relative to IFN-alpha- or vehicle-treated animals were maintained for > or =10 days after subcutaneous dosing. The improved pharmacokinetics of Albuferon are accompanied by an improved pharmacodynamic response suggesting that Albuferon may offer the benefits of less frequent dosing and a potentially improved efficacy profile compared with IFN-alpha.

ACCESSION NUMBER: 2002641106 MEDLINE

DOCUMENT NUMBER: 22276264 PubMed ID: 12388634

TITLE: Pharmacokinetic and pharmacodynamic studies of a human serum **albumin-interferon-alpha fusion** protein in cynomolgus monkeys.

AUTHOR: Osborn Blaire L; Olsen Henrik S; Nardelli Bernardetta; Murray James H; Zhou Joe X H; Garcia Andrew; Moody Gordon; Zaritskaya Liubov S; Sung Cynthia

CORPORATE SOURCE: Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850, USA.. blaire\_osborn@hgsi.com

SOURCE: JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, (2002 Nov) 303 (2) 540-8.  
Journal code: 0376362. ISSN: 0022-3565.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200211

ENTRY DATE: Entered STN: 20021029

Last Updated on STN: 20021211

Entered Medline: 20021122

L11 ANSWER 2 OF 1550 USPATFULL on STN

TI Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto

AB The present invention is a novel cytokine protein called IL-12 or Cytotoxic Lymphocyte Maturation Factor (CLMF) which is produced and synthesized by human NC-37 B lymphoblastoid cells (American Type Culture Collection, Rockville, Md.). CLMF synergistically induces with low concentrations of IL-2 the cytolytic activity of Lymphokine Activated Killer (LAK) cells, and CLMF is capable of stimulating T-cell growth. Also claimed are the cloned gene for CLMF, its recombination in a suitable vector, the transformed cells containing said vector, the

recombinant protein produced by the transformed cells and antibodies to CLMF.

ACCESSION NUMBER: 2004:21589 USPATFULL  
TITLE: Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto  
INVENTOR(S): Gately, Maurice Kent, Montville, NJ, United States  
Gubler, Ulrich Andreas, Glen Ridge, NJ, United States  
Hulmes, Jeffrey David, Ringwood, NJ, United States  
Podlaski, Frank John, New City, NY, United States  
Stern, Alvin Seth, Passaic Park, NJ, United States  
Chizzonite, Richard Anthony, South Kent, CT, United States  
Pan, Yu-Ching Eugene, Pine Brook, NJ, United States  
PATENT ASSIGNEE(S): Hoffmann-La Roche Inc., Nutley, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6683046	B1	20040127
APPLICATION INFO.:	US 1995-459151		19950602 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-205011, filed on 2 Mar 1994, now abandoned Division of Ser. No. US 1992-857023, filed on 24 Mar 1992, now abandoned Continuation-in-part of Ser. No. US 1990-572284, filed on 27 Aug 1990, now abandoned Continuation-in-part of Ser. No. US 1990-520935, filed on 9 May 1990, now abandoned Continuation-in-part of Ser. No. US 1989-455708, filed on 22 Dec 1989, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Romeo, David S.		
ASSISTANT EXAMINER:	Murphy, Joseph F.		
LEGAL REPRESENTATIVE:	Pennie & Edmonds LLP		
NUMBER OF CLAIMS:	2		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	44 Drawing Figure(s); 44 Drawing Page(s)		
LINE COUNT:	2745		

L11 ANSWER 3 OF 1550 USPATFULL on STN

TI Methods and compositions for interferon therapy  
AB Methods and pharmaceutical compositions for administering interferon therapy to tissues or organs having an epithelial cell layer are provided. A recombinant adenoviral vector encoding an interferon gene is administered to the target tissue or organ in combination with treatment with a delivery enhancing agent which increases the transduction of the cells of the target tissues or organs by the vector. The methods and combinations are useful in the treatment of cancers and other conditions responsive to interferon therapy. An exemplary method comprises the transurethral intravesical administration to the bladder of a therapeutically effective amount of a pharmaceutical composition comprising an adenoviral vector encoding alpha-interferon and SYN3 or a SYN3 homolog or analog. In the urinary bladder, as much as a 1,000 to 10,000 fold increase in interferon gene expression has been achieved by use of the combination of SYN3 with the recombinant adenoviral vector as compared to the use of the vector without SYN3.

ACCESSION NUMBER: 2004:19405 USPATFULL  
TITLE: Methods and compositions for interferon therapy  
INVENTOR(S): Engler, Heidrun, San Diego, CA, UNITED STATES  
Nagabhushan, Tattanahalli L., Parsippany, NJ, UNITED STATES  
Youngster, Stephen, Piscataway, NJ, UNITED STATES  
PATENT ASSIGNEE(S): Canji, Inc., San Diego, CA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004014709	A1	20040122
APPLICATION INFO.:	US 2003-455215	A1	20030604 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-55863, filed on 22 Jan 2002, PENDING Continuation of Ser. No. US 1998-112074, filed on 8 Jul 1998, GRANTED, Pat. No. US 6392069 Continuation-in-part of Ser. No. US 1997-889355, filed on 8 Jul 1997, PENDING Continuation-in-part of Ser. No. US 1996-584077, filed on 8 Jan 1996, GRANTED, Pat. No. US 5789244 Continuation-in-part of Ser. No. US 2003-454662, filed on 3 Jun 2003, PENDING Continuation of Ser. No. US 2000-650359, filed on 28 Aug 2000, ABANDONED Continuation of Ser. No. US 1997-779627, filed on 7 Jan 1997, GRANTED, Pat. No. US 6165779 Continuation-in-part of Ser. No. US 1996-584077, filed on 8 Jan 1996, GRANTED, Pat. No. US 5789244		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834		
NUMBER OF CLAIMS:	58		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	7 Drawing Page(s)		
LINE COUNT:	2411		

L11 ANSWER 4 OF 1550 USPATFULL on STN

TI Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a B-cell associated protein

AB The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a BAP-37 as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.

ACCESSION NUMBER: 2004:19345 USPATFULL

TITLE: Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a B-cell associated protein

INVENTOR(S): Masuda, Esteban, Menlo Park, CA, UNITED STATES  
Kinsella, Todd M., Fayetteville, NC, UNITED STATES  
Warner, Justin E., San Francisco, CA, UNITED STATES  
Kinoshita, Taisei, San Mateo, CA, UNITED STATES  
Bennett, Mark K., Moraga, CA, UNITED STATES  
Anderson, David C., San Bruno, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004014649	A1	20040122
APPLICATION INFO.:	US 2002-197919	A1	20020716 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	DORSEY & WHITNEY LLP, INTELLECTUAL PROPERTY DEPARTMENT, 4 EMBARCADERO CENTER, SUITE 3400, SAN FRANCISCO, CA, 94111		
NUMBER OF CLAIMS:	54		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	13 Drawing Page(s)		
LINE COUNT:	3468		

L11 ANSWER 5 OF 1550 USPATFULL on STN

TI Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a CLLD8 protein

AB The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a CLLD8 protein as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.

ACCESSION NUMBER: 2004:19334 USPATFULL  
TITLE: Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a CLLD8 protein

INVENTOR(S): Masuda, Esteban, Menlo Park, CA, UNITED STATES  
Kinsella, Todd M., Fayetteville, NC, UNITED STATES  
Warner, Justin E., San Francisco, CA, UNITED STATES  
Kinoshita, Taisei, San Mateo, CA, UNITED STATES  
Bennett, Mark K., Moraga, CA, UNITED STATES  
Anderson, David C., San Bruno, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004014638	A1	20040122
APPLICATION INFO.:	US 2002-197368	A1	20020716 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	DORSEY & WHITNEY LLP, INTELLECTUAL PROPERTY DEPARTMENT, 4 EMBARCADERO CENTER, SUITE 3400, SAN FRANCISCO, CA, 94111		
NUMBER OF CLAIMS:	54		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	12 Drawing Page(s)		
LINE COUNT:	3569		

L11 ANSWER 6 OF 1550 USPATFULL on STN

TI Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a thioredoxin-like 32 kDa protein

AB The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a thioredoxin-like 32 kDa protein (TXNL) as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.

ACCESSION NUMBER: 2004:18847 USPATFULL  
TITLE: Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a thioredoxin-like 32 kDa protein

INVENTOR(S): Masuda, Esteban, Menlo Park, CA, UNITED STATES  
Kinsella, Todd M., Fayetteville, NC, UNITED STATES  
Warner, Justin E., San Francisco, CA, UNITED STATES  
Kinoshita, Taisei, San Mateo, CA, UNITED STATES  
Bennett, Mark K., Moraga, CA, UNITED STATES  
Anderson, David C., San Bruno, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004014149	A1	20040122
APPLICATION INFO.:	US 2002-197962	A1	20020716 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	DORSEY & WHITNEY LLP, INTELLECTUAL PROPERTY DEPARTMENT, 4 EMBARCADERO CENTER, SUITE 3400, SAN FRANCISCO, CA, 94111		
NUMBER OF CLAIMS:	53		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	12 Drawing Page(s)		
LINE COUNT:	3529		

L11 ANSWER 7 OF 1550 USPATFULL on STN

TI Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a chloride intracellular channel 1 protein

AB The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a chloride intracellular channel 1 (CLIC1) as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.

ACCESSION NUMBER: 2004:18846 USPATFULL

TITLE: Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a chloride intracellular channel 1 protein

INVENTOR(S): Masuda, Esteban, Menlo Park, CA, UNITED STATES  
Kinsella, Todd M., Fayetteville, NC, UNITED STATES  
Warner, Justin E., San Francisco, CA, UNITED STATES  
Kinoshita, Taisei, San Mateo, CA, UNITED STATES  
Bennett, Mark K., Moraga, CA, UNITED STATES  
Anderson, David C., San Bruno, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004014148	A1	20040122
APPLICATION INFO.:	US 2002-197945	A1	20020716 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	DORSEY & WHITNEY LLP, INTELLECTUAL PROPERTY DEPARTMENT, 4 EMBARCADERO CENTER, SUITE 3400, SAN FRANCISCO, CA, 94111		
NUMBER OF CLAIMS:	57		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	12 Drawing Page(s)		
LINE COUNT:	3609		

L11 ANSWER 8 OF 1550 USPATFULL on STN

TI Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing an adenosine kinase

AB The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize an adenosine kinase as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.

ACCESSION NUMBER: 2004:18845 USPATFULL

TITLE: Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing an adenosine kinase

INVENTOR(S): Masuda, Esteban, Menlo Park, CA, UNITED STATES  
Kinsella, Todd M., Fayetteville, NC, UNITED STATES  
Warner, Justin E., San Francisco, CA, UNITED STATES  
Kinoshita, Taisei, San mateo, CA, UNITED STATES  
Bennett, Mark K., Moraga, CA, UNITED STATES  
Anderson, David C., San Bruno, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004014147	A1	20040122
APPLICATION INFO.:	US 2002-197381	A1	20020716 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	DORSEY & WHITNEY LLP, INTELLECTUAL PROPERTY DEPARTMENT, 4 EMBARCADERO CENTER, SUITE 3400, SAN FRANCISCO, CA,		

94111  
NUMBER OF CLAIMS: 52  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 12 Drawing Page(s)  
LINE COUNT: 3513

L11 ANSWER 9 OF 1550 USPTFULL on STN

TI Polynucleotide encoding a novel cysteine protease of the calpain superfamily, Protease-42

AB The present invention provides novel polynucleotides encoding Protease-42 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel Protease-42 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

ACCESSION NUMBER: 2004:18791 USPTFULL  
TITLE: Polynucleotide encoding a novel cysteine protease of the calpain superfamily, Protease-42  
INVENTOR(S): Duclos, Franck, Washington Crossing, PA, UNITED STATES  
Chen, Jian, Princeton, NJ, UNITED STATES  
Feder, John N., Belle Mead, NJ, UNITED STATES  
Nayeem, Akbar, Newtown, PA, UNITED STATES  
Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004014093	A1	20040122
APPLICATION INFO.:	US 2003-390585	A1	20030314 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-364941P	20020314 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	19 Drawing Page(s)	
LINE COUNT:	19269	

L11 ANSWER 10 OF 1550 USPTFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:18737 USPTFULL  
TITLE: Nucleic acids, proteins, and antibodies  
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES

PATENT ASSIGNEE(S): Ruben, Steven M., Olney, MD, UNITED STATES  
 Barash, Steven C., Rockville, MD, UNITED STATES  
 Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004014039	A1	20040122
APPLICATION INFO.:	US 2002-158057	A1	20020531 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-764890, filed on 17 Jan 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)
	US 2000-228924P	20000830 (60)
	US 2000-224518P	20000814 (60)
	US 2000-236369P	20000929 (60)
	US 2000-224519P	20000814 (60)
	US 2000-220964P	20000726 (60)
	US 2000-241809P	20001020 (60)
	US 2000-249299P	20001117 (60)
	US 2000-236327P	20000929 (60)
	US 2000-241785P	20001020 (60)
	US 2000-244617P	20001101 (60)
	US 2000-225268P	20000814 (60)
	US 2000-236368P	20000929 (60)
	US 2000-251856P	20001208 (60)
	US 2000-251868P	20001208 (60)
	US 2000-229344P	20000901 (60)
	US 2000-234997P	20000925 (60)
	US 2000-229343P	20000901 (60)
	US 2000-229345P	20000901 (60)
	US 2000-229287P	20000901 (60)
	US 2000-229513P	20000905 (60)
	US 2000-231413P	20000908 (60)
	US 2000-229509P	20000905 (60)
	US 2000-236367P	20000929 (60)
	US 2000-237039P	20001002 (60)
	US 2000-237038P	20001002 (60)
	US 2000-236370P	20000929 (60)
	US 2000-236802P	20001002 (60)
	US 2000-237037P	20001002 (60)
	US 2000-237040P	20001002 (60)
	US 2000-240960P	20001020 (60)
	US 2000-239935P	20001013 (60)
	US 2000-239937P	20001013 (60)

US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)



US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850  
NUMBER OF CLAIMS: 24  
EXEMPLARY CLAIM: 1  
LINE COUNT: 26776

L11 ANSWER 11 OF 1550 USPATFULL on STN

TI Treatment with anti-ErbB2 antibodies  
AB The present application describes methods for treating cancer with  
anti-ErbB2 antibodies, such as anti-ErbB2 antibodies that block ligand  
activation of an ErbB receptor.

ACCESSION NUMBER: 2004:18365 USPATFULL  
TITLE: Treatment with anti-ErbB2 antibodies  
INVENTOR(S): Kelsey, Stephen M., Montara, CA, UNITED STATES  
Sliwkowski, Mark X., San Carlos, CA, UNITED STATES  
PATENT ASSIGNEE(S): GENENTECH, INC. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004013667	A1	20040122
APPLICATION INFO.:	US 2003-608626	A1	20030627 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-268501, filed on 10 Oct 2002, PENDING Continuation-in-part of Ser. No. US 2000-602812, filed on 23 Jun 2000, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-141316P	19990625 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080	
NUMBER OF CLAIMS:	12	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	14 Drawing Page(s)	
LINE COUNT:	4076	

L11 ANSWER 12 OF 1550 USPATFULL on STN

TI Tumor necrosis factor receptors 6 alpha & 6 beta  
AB The present invention relates to novel Tumor Necrosis Factor Receptor  
proteins. In particular, isolated nucleic acid molecules are provided  
encoding the human TNFR-6 $\alpha$  & -6 $\beta$  proteins. TNFR-6 $\alpha$  &

-6 $\beta$  polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TNFR-6 $\alpha$  & -6 $\beta$  activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.

ACCESSION NUMBER: 2004:18362 USPATFULL  
 TITLE: Tumor necrosis factor receptors 6 alpha & 6 beta  
 INVENTOR(S): Gentz, Reiner L., Belo Horizonte-Mg, BRAZIL  
 Yu, Guo-Liang, Berkeley, CA, UNITED STATES  
 Ni, Jian, Germantown, MD, UNITED STATES  
 Ebner, Reinhard, Gaithersburg, MD, UNITED STATES  
 Feng, Ping, Germantown, MD, UNITED STATES  
 Ruben, Steven M., Brookeville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004013664	A1	20040122
APPLICATION INFO.:	US 2003-418242	A1	20030418 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-935727, filed on 24 Aug 2001, PENDING Continuation-in-part of Ser. No. US 2000-518931, filed on 3 Mar 2000, PENDING Continuation-in-part of Ser. No. US 1998-6352, filed on 13 Jan 1998, PENDING Continuation-in-part of Ser. No. US 2000-518931, filed on 3 Mar 2000, PENDING Continuation-in-part of Ser. No. US 1998-6352, filed on 13 Jan 1998, PENDING Continuation-in-part of Ser. No. US 1998-6352, filed on 13 Jan 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-373604P	20020419 (60)
	US 2001-303224P	20010706 (60)
	US 2000-252131P	20001121 (60)
	US 2000-227598P	20000825 (60)
	US 1999-168235P	19991201 (60)
	US 1999-146371P	19990802 (60)
	US 1999-131964P	19990430 (60)
	US 1999-131279P	19990427 (60)
	US 1999-124092P	19990312 (60)
	US 1999-121774P	19990304 (60)
	US 1997-35496P	19970114 (60)
	US 1999-168235P	19991201 (60)
	US 1999-146371P	19990802 (60)
	US 1999-131964P	19990430 (60)
	US 1999-131279P	19990427 (60)
	US 1999-124092P	19990312 (60)
	US 1999-121774P	19990304 (60)
	US 1997-35496P	19970114 (60)
	US 1997-35496P	19970114 (60)

DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850  
 NUMBER OF CLAIMS: 40  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 23 Drawing Page(s)  
 LINE COUNT: 13403

L11 ANSWER 13 OF 1550 USPATFULL on STN  
 TI Novel nucleic acids and polypeptides  
 AB The present invention provides novel nucleic acids, novel polypeptide sequences encoded by these nucleic acids and uses thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:18355 USPATFULL  
TITLE: Novel nucleic acids and polypeptides  
INVENTOR(S): Tang, Y. Tom, San Jose, CA, UNITED STATES  
Asundi, Vinod, Foster City, CA, UNITED STATES  
Wehrman, Tom, Stanford, CA, UNITED STATES  
Yang, Yonghong, San Jose, CA, UNITED STATES  
Zhang, Jie, Campbell, CA, UNITED STATES  
Zhou, Ping, Cupertino, CA, UNITED STATES  
Drmanac, Radoje T., Palo Alto, CA, UNITED STATES  
Goodrich, Ryle, Los Angeles, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004013657	A1	20040122
APPLICATION INFO.:	US 2002-294006	A1	20021112 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2002-US8964, filed on 20 Mar 2002, PENDING Continuation of Ser. No. US 2001-815925, filed on 22 Mar 2001, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	NUVELO, 675 ALMANOR AVE., SUNNYVALE, CA, 94085		
NUMBER OF CLAIMS:	27		
EXEMPLARY CLAIM:	1		
LINE COUNT:	10481		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 14 OF 1550 USPATFULL on STN

TI Interferon beta-like molecules

AB The invention relates to a conjugate exhibiting interferon  $\beta$  (IFNB) activity and comprising at least one first non-polypeptide moiety covalently attached to an IFNB polypeptide, the amino acid sequence of which differs from that of wildtype human IFNB in at least one introduced and at least one removed amino acid residue comprising an attachment group for said first non-polypeptide moiety. The first non-polypeptide moiety is e.g. a polymer molecule or a sugar moiety. The conjugate finds particular use in therapy. The invention also relates to a glycosylated variant of a parent IFNB polypeptide comprising at least one in vivo glycosylation site, wherein an amino acid residue of said parent polypeptide located close to said glycosylation site has been modified to obtain the variant polypeptide having an increased glycosylation as compared to the glycosylation of the parent polypeptide.

ACCESSION NUMBER: 2004:18342 USPATFULL  
TITLE: Interferon beta-like molecules  
INVENTOR(S): Rasmussen, Poul Baad, Soeberg, DENMARK  
Drustrup, Joern, Farum, DENMARK  
Rasmussen, Grethe, Farum, DENMARK  
Pedersen, Anders Hjelholt, Lyngby, DENMARK  
Schambye, Hans Thalsgard, Frederiksberg C., DENMARK  
Andersen, Kim Vilbour, Broenshoej, DENMARK  
Bornaes, Claus, Hellerup, DENMARK  
PATENT ASSIGNEE(S): Maxygen ApS (non-U.S. corporation)  
Maxygen Holdings Ltd. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004013644	A1	20040122
APPLICATION INFO.:	US 2003-609296	A1	20030627 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2002-84706, filed on 26 Feb 2002, PENDING		

NUMBER	DATE
-----	-----

PRIORITY INFORMATION: DK 2001-333 20010301  
 DK 1999-1197 19990827  
 DK 1999-1691 19991126  
 DK 2000-194 20000207  
 US 2001-272116P 20010227 (60)  
 US 2001-343436P 20011221 (60)  
 US 2001-302140P 20010629 (60)  
 US 2001-316170P 20010830 (60)  
 US 2002-357945P 20020219 (60)

DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: CANDESCENT TECHNOLOGIES, 6320 SAN IGNACIO AVE., SAN JOSE, CA, 95119

NUMBER OF CLAIMS: 87  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 3 Drawing Page(s)  
 LINE COUNT: 5448

L11 ANSWER 15 OF 1550 USPATFULL on STN

TI **Albumin fusion** proteins  
 AB The present invention encompasses **albumin fusion** proteins. Nucleic acid molecules encoding the **albumin fusion** proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the **albumin fusion** proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising **albumin fusion** proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using **albumin fusion** proteins of the invention.

ACCESSION NUMBER: 2004:13611 USPATFULL  
 TITLE: **Albumin fusion** proteins  
 INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
 Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010134	A1	20040115
APPLICATION INFO.:	US 2001-833245	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 29  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 18 Drawing Page(s)  
 LINE COUNT: 25066

L11 ANSWER 16 OF 1550 USPATFULL on STN

TI 53 human secreted proteins  
 AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

ACCESSION NUMBER: 2004:13609 USPATFULL  
 TITLE: 53 human secreted proteins  
 INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
 Brewer, Laurie A., St. Paul, MN, UNITED STATES  
 Duan, Roxanne D., Bethesda, MD, UNITED STATES  
 Ruben, Steven M., Olney, MD, UNITED STATES  
 Florence, Kimberly A., Rockville, MD, UNITED STATES  
 Greene, John M., Gaithersburg, MD, UNITED STATES  
 Young, Paul E., Gaithersburg, MD, UNITED STATES  
 Ferrie, Ann M., Painted Post, NY, UNITED STATES  
 Yu, Guo-Liang, Berkeley, CA, UNITED STATES  
 Florence, Charles, Rockville, MD, UNITED STATES  
 Ebner, Reinhard, Gaithersburg, MD, UNITED STATES  
 Olsen, Henrik, Gaithersburg, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010132	A1	20040115
APPLICATION INFO.:	US 2001-984429	A1	20011030 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-288143, filed on 8 Apr 1999, GRANTED, Pat. No. US 6433139		
	Continuation-in-part of Ser. No. WO 1998-US21142, filed on 8 Oct 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-244591P	20001101 (60)
	US 1997-61463P	19971009 (60)
	US 1997-61529P	19971009 (60)
	US 1997-71498P	19971009 (60)
	US 1997-61527P	19971009 (60)
	US 1997-61536P	19971009 (60)
	US 1997-61532P	19971009 (60)

DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850  
 NUMBER OF CLAIMS: 24  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 4 Drawing Page(s)  
 LINE COUNT: 27480

L11 ANSWER 17 OF 1550 USPATFULL on STN  
 TI Recombinant gene containing inverted repeat sequence and utilization thereof  
 AB The object of the present invention is to improve a method for introducing dsRNA in such a way that RNAi effect is sustained in mammalian (mainly mouse) cells for a long period of time. The present invention provides a recombinant gene which contains inverted repeats of a target gene which can be expressed in mammalian cells.

ACCESSION NUMBER: 2004:13607 USPATFULL  
 TITLE: Recombinant gene containing inverted repeat sequence and utilization thereof  
 INVENTOR(S): Katsuki, Motoya, Tokyo, JAPAN  
 Ishida, Mitsuyoshi, Tokyo, JAPAN  
 Kato, Minoru, Tokyo, JAPAN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010130	A1	20040115
APPLICATION INFO.:	US 2003-296243	A1	20030616 (10)
	WO 2002-JP1554		20020221

	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	JP 2001-46089	20010222
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GREENBLUM & BERNSTEIN, P.L.C., 1950 ROLAND CLARKE PLACE, RESTON, VA, 20191	
NUMBER OF CLAIMS:	10	
EXEMPLARY CLAIM:	3	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	
LINE COUNT:	876	

L11 ANSWER 18 OF 1550 USPATFULL on STN

TI 7 Human ovarian and ovarian cancer associated proteins

AB This invention relates to newly identified ovarian or ovarian cancer related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "ovarian cancer antigens", and the use of such ovarian antigens for detecting disorders of the reproductive system, particularly the presence of ovarian cancer and ovarian cancer metastases. This invention relates to ovarian cancer antigens as well as vectors, host cells, antibodies directed to ovarian cancer antigens and the recombinant methods and synthetic methods for producing the same. Also provided are diagnostic methods for detecting, treating, preventing and/or prognosing disorders related to the ovary, including ovarian cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of ovarian cancer antigens of the invention. The present invention further relates to inhibiting the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:13598 USPATFULL  
 TITLE: 7 Human ovarian and ovarian cancer associated proteins  
 INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES  
 Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
	-----	-----	-----
PATENT INFORMATION:	US 2004010121	A1	20040115
APPLICATION INFO.:	US 2003-333900	A1	20030124 (10)
	WO 2001-US8585		20010316
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850		
NUMBER OF CLAIMS:	23		
EXEMPLARY CLAIM:	1		
LINE COUNT:	16023		

L11 ANSWER 19 OF 1550 USPATFULL on STN

TI Methods of enhancing immune induction involving MDA-7

AB The present invention relates to compositions and methods for the enhancing or inducing an immune response against an immunogenic molecule by indirectly activating PKR. More specifically, immunotherapy is improved by co-administering a MDA-7 polypeptide with an immunogenic molecule against which an immune response is desired. Such immunotherapies include cancer vaccines, and compositions thereof are described.

ACCESSION NUMBER: 2004:13417 USPATFULL  
 TITLE: Methods of enhancing immune induction involving MDA-7  
 INVENTOR(S): Chada, Sunil, Missouri City, TX, UNITED STATES  
 Pataer, Abujiang, Houston, TX, UNITED STATES  
 Mhashilkar, Abner, Houston, TX, UNITED STATES  
 Ramesh, Rajagopal, Sugarland, TX, UNITED STATES  
 Roth, Jack, Houston, TX, UNITED STATES

PATENT ASSIGNEE(S): Swisher, Steve, Fresno, TX, UNITED STATES  
Board of Regent, The University of Texas System (U.S. corporation)  
Introgen Therapeutics, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009939	A1	20040115
APPLICATION INFO.:	US 2003-378590	A1	20030303 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-404932P	20020821 (60)
	US 2002-370335P	20020405 (60)
	US 2002-361755P	20020305 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Gina N. Shishima, Fulbright & Jaworski L.L.P., Suite 2400, 600 Congress Avenue, Austin, TX, 78701	
NUMBER OF CLAIMS:	76	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	73 Drawing Page(s)	
LINE COUNT:	6371	

L11 ANSWER 20 OF 1550 USPATFULL on STN  
TI Macroaggregated **albumin**-polyethyleneimine (MAA-PEI)  
lung-targeted delivery of respiratory syncytial virus DNA vaccines  
AB The present invention provides a composition comprising: 1)  
macroaggregated **albumin**, 2) a nucleic acid comprising a  
nucleotide sequence encoding an RSV protein, and 3) polyethylamine  
(PEI), wherein the MAA, PEI and nucleic acid form a complex. Also  
provided by the present invention is a method of preventing respiratory  
syncytial virus (RSV) infection in a subject comprising administering to  
the subject an amount of a composition of this invention.

ACCESSION NUMBER: 2004:13381 USPATFULL  
TITLE: Macroaggregated **albumin**-polyethyleneimine  
(MAA-PEI) lung-targeted delivery of respiratory  
syncytial virus DNA vaccines  
INVENTOR(S): Tripp, Ralph A., Decatur, GA, UNITED STATES  
Harcourt, Jennifer L., Lilburn, GA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009903	A1	20040115
APPLICATION INFO.:	US 2003-453219	A1	20030602 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-384586P	20020531 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	NEEDLE & ROSENBERG, P.C., SUITE 1000, 999 PEACHTREE STREET, ATLANTA, GA, 30309-3915	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	10 Drawing Page(s)	
LINE COUNT:	1297	

=> d his

(FILE 'HOME' ENTERED AT 18:21:39 ON 29 JAN 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA' ENTERED AT 18:21:55

ON 29 JAN 2004

L1 5340 S TIMP-1  
L2 1 S CEREBUS PROTEIN  
L3 10853 S BRAIN DERIVED NEUROTROPHIC FACTOR OR BDNF  
L4 41802 S INTERFERON ALPHA  
L5 14602 S INTERFERON BETA  
L6 258098 S ALBUMIN  
L7 30354 S L6 AND FUSION  
L8 214 S L7 AND L1  
L9 0 S L7 AND L2  
L10 636 S L7 AND L3  
L11 1550 S L7 AND L4  
L12 1361 S L7 AND L5  
L13 0 S L6 AND L2

=> d l12 ti abs ibib 1-20

L12 ANSWER 1 OF 1361 MEDLINE on STN

TI An IFN-beta-**albumin fusion** protein that displays improved pharmacokinetic and pharmacodynamic properties in nonhuman primates.

AB The long half-life and stability of human serum **albumin** (HSA) make it an attractive candidate for **fusion** to short-lived therapeutic proteins. Albuferon (Human Genome Sciences [HGS], Inc., Rockville, MD) beta is a novel recombinant protein derived from a gene **fusion** of **interferon-beta** (IFN-beta) and HSA. In vitro, Albuferon beta displays antiviral and antiproliferative activities and triggers the IFN-stimulated response element (ISRE) signal transduction pathway. Array analysis of 5694 independent genes in Daudi-treated cells revealed that Albuferon beta and IFN-beta induce the expression of an identical set of 30 genes, including 9 previously not identified. In rhesus monkeys administered a dose of 50 microg/kg intravenously (i.v.) or subcutaneously (s.c.) or 300 microg/kg s.c., Albuferon beta demonstrated favorable pharmacokinetic properties. Subcutaneous bioavailability was 87%, plasma clearance at 4.7-5.7 ml/h/kg was approximately 140-fold lower than that of IFN-beta, and the terminal half-life was 36-40 h compared with 8 h for IFN-beta. Importantly, Albuferon beta induced sustained increases in serum neopterin levels and 2',5' mRNA expression. At a molar dose equivalent to one-half the dose of IFN-beta, Albuferon beta elicited comparable neopterin responses and significantly higher 2',5'-OAS mRNA levels in rhesus monkeys. The enhanced in vivo pharmacologic properties of IFN-beta when fused to serum **albumin** suggest a clinical opportunity for improved IFN-beta therapy.

ACCESSION NUMBER: 2003128795 MEDLINE

DOCUMENT NUMBER: 22526967 PubMed ID: 12639296

TITLE: An IFN-beta-**albumin fusion** protein that displays improved pharmacokinetic and pharmacodynamic properties in nonhuman primates.

AUTHOR: Sung Cynthia; Nardelli Bernardetta; LaFleur David W; Blatter Erich; Corcoran Marta; Olsen Henrik S; Birse Charles E; Pickeral Oxana K; Zhang Junli; Shah Devanshi; Moody Gordon; Gentz Solange; Beebe Lisa; Moore Paul A

CORPORATE SOURCE: Human Genome Sciences, Inc, Rockville, MD 20850, USA.

SOURCE: JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, (2003 Jan) 23 (1) 25-36.

Journal code: 9507088. ISSN: 1079-9907.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200309

ENTRY DATE: Entered STN: 20030320

Last Updated on STN: 20030928

Entered Medline: 20030926



L12 ANSWER 2 OF 1361 USPATFULL on STN

TI Methods and compositions for interferon therapy

AB Methods and pharmaceutical compositions for administering interferon therapy to tissues or organs having an epithelial cell layer are provided. A recombinant adenoviral vector encoding an interferon gene is administered to the target tissue or organ in combination with treatment with a delivery enhancing agent which increases the transduction of the cells of the target tissues or organs by the vector. The methods and combinations are useful in the treatment of cancers and other conditions responsive to interferon therapy. An exemplary method comprises the transurethral intravesical administration to the bladder of a therapeutically effective amount of a pharmaceutical composition comprising an adenoviral vector encoding alpha-interferon and SYN3 or a SYN3 homolog or analog. In the urinary bladder, as much as a 1,000 to 10,000 fold increase in interferon gene expression has been achieved by use of the combination of SYN3 with the recombinant adenoviral vector as compared to the use of the vector without SYN3.

ACCESSION NUMBER: 2004:19405 USPATFULL

TITLE: Methods and compositions for interferon therapy

INVENTOR(S): Engler, Heidrun, San Diego, CA, UNITED STATES  
Nagabhushan, Tattanahalli L., Parsippany, NJ, UNITED STATES

PATENT ASSIGNEE(S): Youngster, Stephen, Piscataway, NJ, UNITED STATES  
Canji, Inc., San Diego, CA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004014709	A1	20040122
APPLICATION INFO.:	US 2003-455215	A1	20030604 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-55863, filed on 22 Jan 2002, PENDING Continuation of Ser. No. US 1998-112074, filed on 8 Jul 1998, GRANTED, Pat. No. US 6392069 Continuation-in-part of Ser. No. US 1997-889355, filed on 8 Jul 1997, PENDING Continuation-in-part of Ser. No. US 1996-584077, filed on 8 Jan 1996, GRANTED, Pat. No. US 5789244 Continuation-in-part of Ser. No. US 2003-454662, filed on 3 Jun 2003, PENDING Continuation of Ser. No. US 2000-650359, filed on 28 Aug 2000, ABANDONED Continuation of Ser. No. US 1997-779627, filed on 7 Jan 1997, GRANTED, Pat. No. US 6165779 Continuation-in-part of Ser. No. US 1996-584077, filed on 8 Jan 1996, GRANTED, Pat. No. US 5789244		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834		
NUMBER OF CLAIMS:	58		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	7 Drawing Page(s)		
LINE COUNT:	2411		

L12 ANSWER 3 OF 1361 USPATFULL on STN

TI Polynucleotide encoding a novel cysteine protease of the calpain superfamily, Protease-42

AB The present invention provides novel polynucleotides encoding Protease-42 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel Protease-42 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists

and antagonists of the polynucleotides and polypeptides of the present invention.

ACCESSION NUMBER: 2004:18791 USPATFULL  
TITLE: Polynucleotide encoding a novel cysteine protease of the calpain superfamily, Protease-42  
INVENTOR(S): Duclos, Franck, Washington Crossing, PA, UNITED STATES  
Chen, Jian, Princeton, NJ, UNITED STATES  
Feder, John N., Belle Mead, NJ, UNITED STATES  
Nayeem, Akbar, Newtown, PA, UNITED STATES  
Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004014093	A1	20040122
APPLICATION INFO.:	US 2003-390585	A1	20030314 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-364941P	20020314 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	19 Drawing Page(s)	
LINE COUNT:	19269	

L12 ANSWER 4 OF 1361 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:18737 USPATFULL  
TITLE: Nucleic acids, proteins, and antibodies  
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Ruben, Steven M., Olney, MD, UNITED STATES  
Barash, Steven C., Rockville, MD, UNITED STATES  
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004014039	A1	20040122
APPLICATION INFO.:	US 2002-158057	A1	20020531 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-764890, filed on 17 Jan 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)

US 2000-217487P	20000711 (60)
US 2000-225758P	20000814 (60)
US 2000-220963P	20000726 (60)
US 2000-217496P	20000711 (60)
US 2000-225447P	20000814 (60)
US 2000-218290P	20000714 (60)
US 2000-225757P	20000814 (60)
US 2000-226868P	20000822 (60)
US 2000-216647P	20000707 (60)
US 2000-225267P	20000814 (60)
US 2000-216880P	20000707 (60)
US 2000-225270P	20000814 (60)
US 2000-251869P	20001208 (60)
US 2000-235834P	20000927 (60)
US 2000-234274P	20000921 (60)
US 2000-234223P	20000921 (60)
US 2000-228924P	20000830 (60)
US 2000-224518P	20000814 (60)
US 2000-236369P	20000929 (60)
US 2000-224519P	20000814 (60)
US 2000-220964P	20000726 (60)
US 2000-241809P	20001020 (60)
US 2000-249299P	20001117 (60)
US 2000-236327P	20000929 (60)
US 2000-241785P	20001020 (60)
US 2000-244617P	20001101 (60)
US 2000-225268P	20000814 (60)
US 2000-236368P	20000929 (60)
US 2000-251856P	20001208 (60)
US 2000-251868P	20001208 (60)
US 2000-229344P	20000901 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-229345P	20000901 (60)
US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)

US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)

US 2000-209467P 20000607 (60)  
 US 2000-205515P 20000519 (60)  
 US 2001-259678P 20010105 (60)  
 DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
 ROCKVILLE, MD, 20850  
 NUMBER OF CLAIMS: 24  
 EXEMPLARY CLAIM: 1  
 LINE COUNT: 26776

L12 ANSWER 5 OF 1361 USPATFULL on STN

TI Immunoreactive peptides from Epstein-Barr virus  
 AB Epstein-Barr virus (EBV) specific polypeptides are disclosed. Also  
 disclosed are the use of these polypeptides for the production of  
 polypeptide-specific antibodies and the diagnosis and treatment of  
 EBV-associated disease.

ACCESSION NUMBER: 2004:18363 USPATFULL  
 TITLE: Immunoreactive peptides from Epstein-Barr virus  
 INVENTOR(S): Smith, Richard S., Salt Lake City, UT, UNITED STATES  
 Pearson, Gary R., Sedona, AZ, UNITED STATES  
 Parks, D. Elliot, Del Mar, CA, UNITED STATES  
 Varghese, Susan Pothan, Melrose, MA, UNITED STATES  
 PATENT ASSIGNEE(S): Ortho Diagnostic Systems, Inc. (U.S. corporation)  
 Georgetown University (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004013665	A1	20040122
APPLICATION INFO.:	US 2003-442456	A1	20030521 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 1996-392934, filed on 28 Oct 1996, PENDING A 371 of International Ser. No. WO 1993-US8699, filed on 15 Sep 1993, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	EMMA R. DAILEY, WOODCOCK WASHBURN LLP, ONE LIBERTY PLACE 46TH FLOOR, PHILADELPHIA, PA, 19103		
NUMBER OF CLAIMS:	36		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	7 Drawing Page(s)		
LINE COUNT:	1490		

L12 ANSWER 6 OF 1361 USPATFULL on STN

TI Tumor necrosis factor receptors 6 alpha & 6 beta  
 AB The present invention relates to novel Tumor Necrosis Factor Receptor proteins. In particular, isolated nucleic acid molecules are provided encoding the human TNFR-6 $\alpha$  & -6 $\beta$  proteins. TNFR-6 $\alpha$  & -6 $\beta$  polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TNFR-6 $\alpha$  & -6 $\beta$  activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.

ACCESSION NUMBER: 2004:18362 USPATFULL  
 TITLE: Tumor necrosis factor receptors 6 alpha & 6 beta  
 INVENTOR(S): Gentz, Reiner L., Belo Horizonte-Mg, BRAZIL  
 Yu, Guo-Liang, Berkeley, CA, UNITED STATES  
 Ni, Jian, Germantown, MD, UNITED STATES  
 Ebner, Reinhard, Gaithersburg, MD, UNITED STATES  
 Feng, Ping, Germantown, MD, UNITED STATES  
 Ruben, Steven M., Brookeville, MD, UNITED STATES

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 2004013664 A1 20040122  
 APPLICATION INFO.: US 2003-418242 A1 20030418 (10)  
 RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-935727, filed  
 on 24 Aug 2001, PENDING Continuation-in-part of Ser.  
 No. US 2000-518931, filed on 3 Mar 2000, PENDING  
 Continuation-in-part of Ser. No. US 1998-6352, filed on  
 13 Jan 1998, PENDING Continuation-in-part of Ser. No.  
 US 2000-518931, filed on 3 Mar 2000, PENDING  
 Continuation-in-part of Ser. No. US 1998-6352, filed on  
 13 Jan 1998, PENDING Continuation-in-part of Ser. No.  
 US 1998-6352, filed on 13 Jan 1998, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-373604P	20020419 (60)
	US 2001-303224P	20010706 (60)
	US 2000-252131P	20001121 (60)
	US 2000-227598P	20000825 (60)
	US 1999-168235P	19991201 (60)
	US 1999-146371P	19990802 (60)
	US 1999-131964P	19990430 (60)
	US 1999-131279P	19990427 (60)
	US 1999-124092P	19990312 (60)
	US 1999-121774P	19990304 (60)
	US 1997-35496P	19970114 (60)
	US 1999-168235P	19991201 (60)
	US 1999-146371P	19990802 (60)
	US 1999-131964P	19990430 (60)
	US 1999-131279P	19990427 (60)
	US 1999-124092P	19990312 (60)
	US 1999-121774P	19990304 (60)
	US 1997-35496P	19970114 (60)
	US 1997-35496P	19970114 (60)

DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
 ROCKVILLE, MD, 20850  
 NUMBER OF CLAIMS: 40  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 23 Drawing Page(s)  
 LINE COUNT: 13403

L12 ANSWER 7 OF 1361 USPATFULL on STN

TI **Interferon beta**-like molecules  
 AB The invention relates to a conjugate exhibiting **interferon .**  
**beta.** (IFNB) activity and comprising at least one first  
 non-polypeptide moiety covalently attached to an IFNB polypeptide, the  
 amino acid sequence of which differs from that of wildtype human IFNB in  
 at least one introduced and at least one removed amino acid residue  
 comprising an attachment group for said first non-polypeptide moiety.  
 The first non-polypeptide moiety is e.g. a polymer molecule or a sugar  
 moiety. The conjugate finds particular use in therapy. The invention  
 also relates to a glycosylated variant of a parent IFNB polypeptide  
 comprising at least one in vivo glycosylation site, wherein an amino  
 acid residue of said parent polypeptide located close to said  
 glycosylation site has been modified to obtain the variant polypeptide  
 having an increased glycosylation as compared to the glycosylation of  
 the parent polypeptide.

ACCESSION NUMBER: 2004:18342 USPATFULL  
 TITLE: **Interferon beta**-like molecules  
 INVENTOR(S): Rasmussen, Poul Baad, Soeberg, DENMARK  
 Drustrup, Joern, Farum, DENMARK  
 Rasmussen, Grethe, Farum, DENMARK

PATENT ASSIGNEE(S): Pedersen, Anders Hjelholt, Lyngby, DENMARK  
 Schambye, Hans Thalsgard, Frederiksberg C., DENMARK  
 Andersen, Kim Vilbourn, Broenshoej, DENMARK  
 Bornaes, Claus, Hellerup, DENMARK  
 Maxygen ApS (non-U.S. corporation)  
 Maxygen Holdings Ltd. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004013644	A1	20040122
APPLICATION INFO.:	US 2003-609296	A1	20030627 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2002-84706, filed on 26 Feb 2002, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	DK 2001-333	20010301
	DK 1999-1197	19990827
	DK 1999-1691	19991126
	DK 2000-194	20000207
	US 2001-272116P	20010227 (60)
	US 2001-343436P	20011221 (60)
	US 2001-302140P	20010629 (60)
	US 2001-316170P	20010830 (60)
	US 2002-357945P	20020219 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	CANDESCENT TECHNOLOGIES, 6320 SAN IGNACIO AVE., SAN JOSE, CA, 95119	
NUMBER OF CLAIMS:	87	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	5448	

L12 ANSWER 8 OF 1361 USPATFULL on STN

TI **Albumin fusion** proteins  
 AB The present invention encompasses **albumin fusion** proteins. Nucleic acid molecules encoding the **albumin fusion** proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the **albumin fusion** proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising **albumin fusion** proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using **albumin fusion** proteins of the invention.

ACCESSION NUMBER: 2004:13611 USPATFULL  
 TITLE: **Albumin fusion** proteins  
 INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
 Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010134	A1	20040115
APPLICATION INFO.:	US 2001-833245	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	

LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850  
NUMBER OF CLAIMS: 29  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 18 Drawing Page(s)  
LINE COUNT: 25066

L12 ANSWER 9 OF 1361 USPATFULL on STN

TI 53 human secreted proteins

AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

ACCESSION NUMBER: 2004:13609 USPATFULL  
TITLE: 53 human secreted proteins  
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Brewer, Laurie A., St. Paul, MN, UNITED STATES  
Duan, Roxanne D., Bethesda, MD, UNITED STATES  
Ruben, Steven M., Olney, MD, UNITED STATES  
Florence, Kimberly A., Rockville, MD, UNITED STATES  
Greene, John M., Gaithersburg, MD, UNITED STATES  
Young, Paul E., Gaithersburg, MD, UNITED STATES  
Ferrie, Ann M., Painted Post, NY, UNITED STATES  
Yu, Guo-Liang, Berkeley, CA, UNITED STATES  
Florence, Charles, Rockville, MD, UNITED STATES  
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES  
Olsen, Henrik, Gaithersburg, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010132	A1	20040115
APPLICATION INFO.:	US 2001-984429	A1	20011030 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-288143, filed on 8 Apr 1999, GRANTED, Pat. No. US 6433139		
	Continuation-in-part of Ser. No. WO 1998-US21142, filed on 8 Oct 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-244591P	20001101 (60)
	US 1997-61463P	19971009 (60)
	US 1997-61529P	19971009 (60)
	US 1997-71498P	19971009 (60)
	US 1997-61527P	19971009 (60)
	US 1997-61536P	19971009 (60)
	US 1997-61532P	19971009 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 24  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 4 Drawing Page(s)  
LINE COUNT: 27480

L12 ANSWER 10 OF 1361 USPATFULL on STN

TI 7 Human ovarian and ovarian cancer associated proteins

AB This invention relates to newly identified ovarian or ovarian cancer related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "ovarian cancer antigens", and the use of such ovarian antigens for detecting disorders of the



reproductive system, particularly the presence of ovarian cancer and ovarian cancer metastases. This invention relates to ovarian cancer antigens as well as vectors, host cells, antibodies directed to ovarian cancer antigens and the recombinant methods and synthetic methods for producing the same. Also provided are diagnostic methods for detecting, treating, preventing and/or prognosing disorders related to the ovary, including ovarian cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of ovarian cancer antigens of the invention. The present invention further relates to inhibiting the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:13598 USPATFULL  
 TITLE: 7 Human ovarian and ovarian cancer associated proteins  
 INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES  
 Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010121	A1	20040115
APPLICATION INFO.:	US 2003-333900	A1	20030124 (10)
	WO 2001-US8585		20010316
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850		
NUMBER OF CLAIMS:	23		
EXEMPLARY CLAIM:	1		
LINE COUNT:	16023		

L12 ANSWER 11 OF 1361 USPATFULL on STN

TI Methods of enhancing immune induction involving MDA-7  
 AB The present invention relates to compositions and methods for the enhancing or inducing an immune response against an immunogenic molecule by indirectly activating PKR. More specifically, immunotherapy is improved by co-administering a MDA-7 polypeptide with an immunogenic molecule against which an immune response is desired. Such immunotherapies include cancer vaccines, and compositions thereof are described.

ACCESSION NUMBER: 2004:13417 USPATFULL  
 TITLE: Methods of enhancing immune induction involving MDA-7  
 INVENTOR(S): Chada, Sunil, Missouri City, TX, UNITED STATES  
 Pataer, Abujiang, Houston, TX, UNITED STATES  
 Mhashilkar, Abner, Houston, TX, UNITED STATES  
 Ramesh, Rajagopal, Sugarland, TX, UNITED STATES  
 Roth, Jack, Houston, TX, UNITED STATES  
 Swisher, Steve, Fresno, TX, UNITED STATES  
 PATENT ASSIGNEE(S): Board of Regent, The University of Texas System (U.S. corporation)  
 Introgen Therapeutics, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009939	A1	20040115
APPLICATION INFO.:	US 2003-378590	A1	20030303 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-404932P	20020821 (60)
	US 2002-370335P	20020405 (60)
	US 2002-361755P	20020305 (60)

DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: Gina N. Shishima, Fulbright & Jaworski L.L.P., Suite

2400, 600 Congress Avenue, Austin, TX, 78701  
NUMBER OF CLAIMS: 76  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 73 Drawing Page(s)  
LINE COUNT: 6371

L12 ANSWER 12 OF 1361 USPATFULL on STN

TI Polynucleotides encoding a novel intracellular chloride channel-related polypeptide  
AB The present invention describes the novel human intracellular chloride ion channel-related protein HCLI and its encoding polynucleotide. Also described are expression vectors, host cells, antisense molecules, and antibodies associated with the HCLI polynucleotide and/or polypeptide of this invention. In addition, methods for treating, diagnosing, preventing, and screening for disorders or diseases associated with abnormal biological activity of HCLI are described, as are methods for screening for modulators, e.g., agonists or antagonists, of HCLI activity and/or function.

ACCESSION NUMBER: 2004:13393 USPATFULL  
TITLE: Polynucleotides encoding a novel intracellular chloride channel-related polypeptide  
INVENTOR(S): Chang, Han, Princeton Junction, NJ, UNITED STATES  
Feder, John N., Belle Mead, NJ, UNITED STATES  
Lee, Liana M., Somerset, NJ, UNITED STATES  
Rich, Adam, Yardley, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009915	A1	20040115
APPLICATION INFO.:	US 2003-384919	A1	20030306 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-362257P	20020306 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	21 Drawing Page(s)	
LINE COUNT:	7702	

L12 ANSWER 13 OF 1361 USPATFULL on STN

TI Novel 27411, 23413, 22438, 23553, 25278, 26212, NARC SC1, NARC 10A, NARC 1, NARC 12, NARC 13, NARC17, NARC 25, NARC 3, NARC 4, NARC 7, NARC 8, NARC 11, NARC 14A, NARC 15, NARC 16, NARC 19, NARC 20, NARC 26, NARC 27, NARC 28, NARC 30, NARC 5, NARC 6, NARC 9, NARC 10C, NARC 8B, NARC 9, NARC2A, NARC 16B, NARC 1C, NARC1A, NARC 25, 86604 and 32222 molecules and uses therefor  
AB The invention provides isolated nucleic acids molecules and proteins, designated 27411, 23413, 22438, 23553, 25278, 26212, NARC SC1, NARC 10A, NARC 1, NARC 12, NARC 13, NARC 17, NARC 25, NARC 3, NARC 4, NARC 7, NARC 8, NARC 11, NARC 14A, NARC 15, NARC 16, NARC 19, NARC 20, NARC 26, NARC 27, NARC 28, NARC 30, NARC 5, NARC 6, NARC 9, NARC 10C, NARC 8B, NARC 9, NARC2A, NARC 16B, NARC 1C, NARC 1A, NARC 25, 86604 and 32222 nucleic acid molecules and proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing said nucleic acid molecules, host cells into which the expression vectors have been introduced, nonhuman transgenic animals in which a said genes have been introduced or disrupted, **fusion** proteins, antigenic peptides and antibodies to said proteins. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

ACCESSION NUMBER: 2004:13033 USPATFULL

TITLE: Novel 27411, 23413, 22438, 23553, 25278, 26212, NARC SC1, NARC 10A, NARC 1, NARC 12, NARC 13, NARC17, NARC 25, NARC 3, NARC 4, NARC 7, NARC 8, NARC 11, NARC 14A, NARC 15, NARC 16, NARC 19, NARC 20, NARC 26, NARC 27, NARC 28, NARC 30, NARC 5, NARC 6, NARC 9, NARC 10C, NARC 8B, NARC 9, NARC2A, NARC 16B, NARC 1C, NARC1A, NARC 25, 86604 and 32222 molecules and uses therefor

INVENTOR(S): Glucksmann, Maria A., Lexington, MA, UNITED STATES  
Williamson, Mark J., Saugus, MA, UNITED STATES  
Tsai, Fong-Ying, Newton, MA, UNITED STATES  
Rudolph-Owen, Laura A., Medford, MA, UNITED STATES  
Kapeller-Libermann, Rosanna, Chestnut Hill, MA, UNITED STATES  
Meyers, Rachel E., Newton, MA, UNITED STATES  
Chiang, Lillian Wei-Ming, Edison, NJ, UNITED STATES  
Hunter, John Joseph, Somerville, MA, UNITED STATES

PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009553	A1	20040115
APPLICATION INFO.:	US 2003-426776	A1	20030430 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-229662, filed on 28 Aug 2002, PENDING Division of Ser. No. US 2001-795691, filed on 28 Feb 2001, GRANTED, Pat. No. US 6465230 Continuation-in-part of Ser. No. US 2002-105992, filed on 25 Mar 2002, PENDING Continuation of Ser. No. US 1999-406045, filed on 27 Sep 1999, GRANTED, Pat. No. US 6451994 Continuation-in-part of Ser. No. US 2002-314881, filed on 9 Dec 2002, PENDING Continuation of Ser. No. US 2001-773426, filed on 31 Jan 2001, GRANTED, Pat. No. US 6534302 Continuation-in-part of Ser. No. US 2000-495823, filed on 31 Jan 2000, PENDING Continuation-in-part of Ser. No. US 2000-692785, filed on 20 Oct 2000, PENDING Continuation-in-part of Ser. No. US 2002-284014, filed on 30 Oct 2002, PENDING Continuation-in-part of Ser. No. US 2002-284059, filed on 30 Oct 2002, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-185517P	20000228 (60)
	US 1999-161188P	19991022 (60)
	US 2001-335003P	20011031 (60)
	US 2001-335037P	20011031 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
LINE COUNT:	24534	

L12 ANSWER 14 OF 1361 USPATFULL on STN

TI Export and modification of (poly)peptides in the lantibiotic way

AB The invention includes a method for harvesting a polypeptide produced by a host cell, wherein the polypeptide has not undergone intra-cellular post-translational modification, such as dehydration of a serine or a threonine, and/or thioether bridge formation. The invention also includes a method for producing thioether containing peptides and dehydroalanine/dehydrobutyrine-containing peptides, wherein extracellularly thioether rings may be formed.

ACCESSION NUMBER: 2004:13030 USPATFULL

TITLE: Export and modification of (poly)peptides in the  
lantibiotic way  
INVENTOR(S): Moll, Gert Nikolaas, Groningen, NETHERLANDS  
Leenhouts, Cornelis Johannes, Haren, NETHERLANDS

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009550	A1	20040115
APPLICATION INFO.:	US 2003-360101	A1	20030207 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	EP 2002-77060	20020524
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	TRASK BRITT, P.O. BOX 2550, SALT LAKE CITY, UT, 84110	
NUMBER OF CLAIMS:	13	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	9 Drawing Page(s)	
LINE COUNT:	3337	

L12 ANSWER 15 OF 1361 USPATFULL on STN

TI Novel 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 molecules and uses therefor

AB The invention provides isolated nucleic acids molecules, designated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 gene has been introduced or disrupted. The invention still further provides isolated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 proteins, fusion proteins, antigenic peptides and anti-25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

ACCESSION NUMBER: 2004:12981 USPATFULL

TITLE: Novel 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 molecules and uses therefor

INVENTOR(S): Curtis, Rory A. J., Ashland, MA, UNITED STATES  
Logan, Thomas Joseph, Springfield, PA, UNITED STATES  
Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES  
Meyers, Rachel E., Newton, MA, UNITED STATES  
Williamson, Mark J., Saugus, MA, UNITED STATES  
Rudolph-Owen, Laura A., Medford, MA, UNITED STATES  
Chun, Miyoung, Belmont, MA, UNITED STATES  
Tsai, Fong-Ying, Newton, MA, UNITED STATES

PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009501	A1	20040115
APPLICATION INFO.:	US 2003-377072	A1	20030227 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-895860, filed on 29 Jun 2001, PENDING Continuation-in-part of Ser. No. US 2000-723806, filed on 28 Nov 2000, PENDING Continuation-in-part of Ser. No. US 2001-843297, filed on 25 Apr 2001, GRANTED, Pat. No. US 6569667 Continuation-in-part of Ser. No. US 2001-861801, filed		

on 21 May 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-816494, filed on 23 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2001-888911, filed on 25 Jun 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-908664, filed on 17 Jul 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-935291, filed on 21 Aug 2001, ABANDONED

	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	US 2000-215370P	20000629 (60)
	US 2000-187455P	20000307 (60)
	US 2000-199801P	20000426 (60)
	US 2000-205508P	20000519 (60)
	US 2000-213688P	20000623 (60)
	US 2000-218675P	20000717 (60)
	US 2000-250932P	20001130 (60)
	US 2000-226504P	20000821 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Jean M. Silveri, 75 Sidney Street, Cambridge, MA, 02139	
NUMBER OF CLAIMS:	19	
EXEMPLARY CLAIM:	1	
LINE COUNT:	16123	

L12 ANSWER 16 OF 1361 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel polynucleotides associated with the plasma membrane, the polypeptides encoded by these polynucleotides herein collectively referred to as "plasma membrane associated antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such plasma membrane associated polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders related to these novel polypeptides. More specifically, isolated nucleic acid molecules are provided encoding novel plasma membrane associated polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing these plasma membrane associated polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the novel polypeptides of the invention. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

ACCESSION NUMBER: 2004:12971 USPATFULL  
 TITLE: Nucleic acids, proteins, and antibodies  
 INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES  
 Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
	-----	-----	-----
PATENT INFORMATION:	US 2004009491	A1	20040115
APPLICATION INFO.:	US 2002-264237	A1	20021004 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2001-US16450, filed on 18 May 2001, PENDING		

	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	US 2000-205515P	20000519 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	

LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850  
NUMBER OF CLAIMS: 24  
EXEMPLARY CLAIM: 1  
LINE COUNT: 18144

L12 ANSWER 17 OF 1361 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel musculoskeletal system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "musculoskeletal system antigens," and the use of such musculoskeletal system antigens for detecting disorders of the musculoskeletal system, particularly the presence of cancer and cancer metastases. More specifically, isolated musculoskeletal system associated nucleic acid molecules are provided encoding novel musculoskeletal system associated polypeptides. Novel musculoskeletal system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human musculoskeletal system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the musculoskeletal system, including cancer of musculoskeletal tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:12968 USPATFULL  
TITLE: Nucleic acids, proteins, and antibodies  
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Ruben, Steven M., Olney, MD, UNITED STATES  
Barash, Steven C., Rockville, MD, UNITED STATES  
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009488	A1	20040115
APPLICATION INFO.:	US 2002-242515	A1	20020913 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-764877, filed on 17 Jan 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)

US 2000-228924P	20000830 (60)
US 2000-224518P	20000814 (60)
US 2000-236369P	20000929 (60)
US 2000-224519P	20000814 (60)
US 2000-220964P	20000726 (60)
US 2000-241809P	20001020 (60)
US 2000-249299P	20001117 (60)
US 2000-236327P	20000929 (60)
US 2000-241785P	20001020 (60)
US 2000-244617P	20001101 (60)
US 2000-225268P	20000814 (60)
US 2000-236368P	20000929 (60)
US 2000-251856P	20001208 (60)
US 2000-251868P	20001208 (60)
US 2000-229344P	20000901 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-229345P	20000901 (60)
US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)

US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850  
NUMBER OF CLAIMS: 24  
EXEMPLARY CLAIM: 1  
LINE COUNT: 32038

L12 ANSWER 18 OF 1361 USPATFULL on STN

TI Compositions, kits, and methods for identification, assessment,  
prevention, and therapy of human prostate cancer

AB The invention relates to compositions, kits, and methods for diagnosing,  
staging, prognosing, monitoring and treating human prostate cancers. A



variety of marker genes are provided, wherein changes in the levels of expression of one or more of the marker genes is correlated with the presence of prostate cancer.

ACCESSION NUMBER: 2004:12961 USPATFULL  
TITLE: Compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer  
INVENTOR(S): Schlegel, Robert, Auburndale, MA, UNITED STATES  
Endege, Wilson O., Norwood, MA, UNITED STATES  
PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., Cambridge, MA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009481	A1	20040115
APPLICATION INFO.:	US 2002-166883	A1	20020611 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-297285P	20010611 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	LAHIVE & COCKFIELD, 28 STATE STREET, BOSTON, MA, 02109	
NUMBER OF CLAIMS:	27	
EXEMPLARY CLAIM:	1	
LINE COUNT:	15572	

L12 ANSWER 19 OF 1361 USPATFULL on STN

TI Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases  
AB Methods of diagnosing or monitoring an autoimmune or chronic inflammatory disease, particularly SLE in a patient by detecting the expression level of one or more genes or surrogates derived therefrom in the patient are described. Diagnostic oligonucleotides for diagnosing or monitoring chronic inflammatory disease, particularly SLE infection and kits or systems containing the same are also described.

ACCESSION NUMBER: 2004:12959 USPATFULL  
TITLE: Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases  
INVENTOR(S): Wohlgemuth, Jay, Palo Alto, CA, UNITED STATES  
Fry, Kirk, Palo Alto, CA, UNITED STATES  
Woodward, Robert, Pleasanton, CA, UNITED STATES  
Ly, Ngoc, San Bruno, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009479	A1	20040115
APPLICATION INFO.:	US 2002-131827	A1	20020424 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-6290, filed on 22 Oct 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-296764P	20010608 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Michael R. Ward, Morrison & Foerster LLP, 425 Market Street, San Francisco, CA, 94105-2482	
NUMBER OF CLAIMS:	19	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	12 Drawing Page(s)	
LINE COUNT:	19677	

L12 ANSWER 20 OF 1361 USPATFULL on STN

TI Multimeric binding complexes

AB The invention provides multimeric receptor-binding complexes, including chemokine tetramers, useful for recognizing and binding receptors bound to the surface of a wide variety of cells. The binding complexes are useful for identifying and isolating cells according to their specific receptors, screening for cells having a specific receptor or constellation of receptors, and introducing exogenous molecules (e.g., nucleic acids and toxins) into cells. Methods of producing the complexes and other uses are also described.

ACCESSION NUMBER: 2004:12631 USPATFULL

TITLE: Multimeric binding complexes

INVENTOR(S): Altman, John D., Decatur, GA, UNITED STATES  
Ravkov, Eugene, Tucker, GA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009149	A1	20040115
APPLICATION INFO.:	US 2003-376887	A1	20030227 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-360724P	20020227 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FISH & RICHARDSON PC, 225 FRANKLIN ST, BOSTON, MA, 02110	
NUMBER OF CLAIMS:	36	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	16 Drawing Page(s)	
LINE COUNT:	1909	

=> d his

(FILE 'HOME' ENTERED AT 18:21:39 ON 29 JAN 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA' ENTERED AT 18:21:55 ON 29 JAN 2004

L1 5340 S TIMP-1  
L2 1 S CEREBUS PROTEIN  
L3 10853 S BRAIN DERIVED NEUROTROPHIC FACTOR OR BDNF  
L4 41802 S INTERFERON ALPHA  
L5 14602 S INTERFERON BETA  
L6 258098 S ALBUMIN  
L7 30354 S L6 AND FUSION  
L8 214 S L7 AND L1  
L9 0 S L7 AND L2  
L10 636 S L7 AND L3  
L11 1550 S L7 AND L4  
L12 1361 S L7 AND L5  
L13 0 S L6 AND L2

=> s albumin fusion protein () interferon alpha

L14 5 ALBUMIN FUSION PROTEIN (W) INTERFERON ALPHA

=> d l14 ti abs ibib tot

L14 ANSWER 1 OF 5 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and

methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

ACCESSION NUMBER: 2004:13611 USPATFULL  
TITLE: Albumin fusion proteins  
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010134	A1	20040115
APPLICATION INFO.:	US 2001-833245	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850  
NUMBER OF CLAIMS: 29  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 18 Drawing Page(s)  
LINE COUNT: 25066

L14 ANSWER 2 OF 5 USPATFULL on STN

TI Albumin fusion proteins  
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:312278 USPATFULL  
TITLE: Albumin fusion proteins  
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003219875	A1	20031127
APPLICATION INFO.:	US 2001-833118	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850  
NUMBER OF CLAIMS: 29

EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 18 Drawing Page(s)  
LINE COUNT: 15415  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 3 OF 5 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:282700 USPATFULL  
TITLE: Albumin fusion proteins  
INVENTOR(S): Ballance, David J., Berwyn, PA, UNITED STATES  
Sleep, Darrell, West Bridgford, UNITED KINGDOM  
Prior, Christopher P., Rosemont, PA, UNITED STATES  
Sadeghi, Homayoun, Doylestown, PA, UNITED STATES  
Turner, Andrew J., Eagleville, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003199043	A1	20031023
APPLICATION INFO.:	US 2001-832501	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 60  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 18 Drawing Page(s)  
LINE COUNT: 14339  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 4 OF 5 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:244853 USPATFULL  
TITLE: Albumin fusion proteins  
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Sadeghi, Homayoun, Doylestown, PA, UNITED STATES

Prior, Christopher P., Rosemont, PA, UNITED STATES  
Turner, Andrew J., Eagleville, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003171267	A1	20030911
APPLICATION INFO.:	US 2001-833117	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	59	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	20 Drawing Page(s)	
LINE COUNT:	13208	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L14 ANSWER 5 OF 5 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:181414 USPATFULL  
TITLE: Albumin fusion proteins  
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003125247	A1	20030703
APPLICATION INFO.:	US 2001-833041	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	29	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	20 Drawing Page(s)	
LINE COUNT:	15235	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

=> d his

(FILE 'HOME' ENTERED AT 18:21:39 ON 29 JAN 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA' ENTERED AT 18:21:55  
ON 29 JAN 2004

L1 5340 S TIMP-1  
L2 1 S CEREBUS PROTEIN  
L3 10853 S BRAIN DERIVED NEUROTROPHIC FACTOR OR BDNF  
L4 41802 S INTERFERON ALPHA  
L5 14602 S INTERFERON BETA  
L6 258098 S ALBUMIN  
L7 30354 S L6 AND FUSION  
L8 214 S L7 AND L1  
L9 0 S L7 AND L2  
L10 636 S L7 AND L3  
L11 1550 S L7 AND L4  
L12 1361 S L7 AND L5  
L13 0 S L6 AND L2  
L14 5 S ALBUMIN FUSION PROTEIN () INTERFERON ALPHA

=> s albumin fusion protein () interferon beta

L15 5 ALBUMIN FUSION PROTEIN (W) INTERFERON BETA

=> d l15 ti abs ibib tot

L15 ANSWER 1 OF 5 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

ACCESSION NUMBER: 2004:13611 USPATFULL

TITLE: Albumin fusion proteins

INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010134	A1	20040115
APPLICATION INFO.:	US 2001-833245	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 29

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 18 Drawing Page(s)

LINE COUNT: 25066

L15 ANSWER 2 OF 5 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also

encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:312278 USPATFULL  
TITLE: Albumin fusion proteins  
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003219875	A1	20031127
APPLICATION INFO.:	US 2001-833118	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 29  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 18 Drawing Page(s)  
LINE COUNT: 15415

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 3 OF 5 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:282700 USPATFULL  
TITLE: Albumin fusion proteins  
INVENTOR(S): Ballance, David J., Berwyn, PA, UNITED STATES  
Sleep, Darrell, West Bridgford, UNITED KINGDOM  
Prior, Christopher P., Rosemont, PA, UNITED STATES  
Sadeghi, Homayoun, Doylestown, PA, UNITED STATES  
Turner, Andrew J., Eagleville, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003199043	A1	20031023
APPLICATION INFO.:	US 2001-832501	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)

US 2000-199384P 20000425 (60)  
US 2000-229358P 20000412 (60)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850  
NUMBER OF CLAIMS: 60  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 18 Drawing Page(s)  
LINE COUNT: 14339  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 4 OF 5 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:244853 USPATFULL  
TITLE: Albumin fusion proteins  
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Sadeghi, Homayoun, Doylestown, PA, UNITED STATES  
Prior, Christopher P., Rosemont, PA, UNITED STATES  
Turner, Andrew J., Eagleville, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003171267	A1	20030911
APPLICATION INFO.:	US 2001-833117	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850  
NUMBER OF CLAIMS: 59  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 20 Drawing Page(s)  
LINE COUNT: 13208  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 5 OF 5 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.



CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:181414 USPATFULL  
TITLE: Albumin fusion proteins  
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003125247	A1	20030703
APPLICATION INFO.:	US 2001-833041	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 29  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 20 Drawing Page(s)  
LINE COUNT: 15235

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 18:21:39 ON 29 JAN 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA' ENTERED AT 18:21:55  
ON 29 JAN 2004

L1 5340 S TIMP-1  
L2 1 S CEREBUS PROTEIN  
L3 10853 S BRAIN DERIVED NEUROTROPHIC FACTOR OR BDNF  
L4 41802 S INTERFERON ALPHA  
L5 14602 S INTERFERON BETA  
L6 258098 S ALBUMIN  
L7 30354 S L6 AND FUSION  
L8 214 S L7 AND L1  
L9 0 S L7 AND L2  
L10 636 S L7 AND L3  
L11 1550 S L7 AND L4  
L12 1361 S L7 AND L5  
L13 0 S L6 AND L2  
L14 5 S ALBUMIN FUSION PROTEIN () INTERFERON ALPHA  
L15 5 S ALBUMIN FUSION PROTEIN () INTERFERON BETA

=> s albumin fusion protein () BDNF  
L16 1 ALBUMIN FUSION PROTEIN (W) BDNF

=> d l16 ti abs ibib tot

L16 ANSWER 1 OF 1 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or

ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:312278 USPATFULL  
TITLE: Albumin fusion proteins  
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003219875	A1	20031127
APPLICATION INFO.:	US 2001-833118	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850  
NUMBER OF CLAIMS: 29  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 18 Drawing Page(s)  
LINE COUNT: 15415  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s albumin fusion protein () TIMP-1  
5 FILES SEARCHED...  
L17 5 ALBUMIN FUSION PROTEIN (W) TIMP-1  
=> d l17 ti abs ibib tot

L17 ANSWER 1 OF 5 USPATFULL on STN

TI Albumin fusion proteins  
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

ACCESSION NUMBER: 2004:13611 USPATFULL  
TITLE: Albumin fusion proteins  
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010134	A1	20040115
APPLICATION INFO.:	US 2001-833245	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)
DOCUMENT TYPE:	Utility	

FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850  
NUMBER OF CLAIMS: 29  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 18 Drawing Page(s)  
LINE COUNT: 25066

L17 ANSWER 2 OF 5 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:312278 USPATFULL  
TITLE: Albumin fusion proteins  
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003219875	A1	20031127
APPLICATION INFO.:	US 2001-833118	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850  
NUMBER OF CLAIMS: 29  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 18 Drawing Page(s)  
LINE COUNT: 15415  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 3 OF 5 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:282700 USPATFULL  
TITLE: Albumin fusion proteins  
INVENTOR(S): Ballance, David J., Berwyn, PA, UNITED STATES  
Sleep, Darrell, West Bridgford, UNITED KINGDOM

Prior, Christopher P., Rosemont, PA, UNITED STATES  
Sadeghi, Homayoun, Doylestown, PA, UNITED STATES  
Turner, Andrew J., Eagleville, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003199043	A1	20031023
APPLICATION INFO.:	US 2001-832501	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 60  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 18 Drawing Page(s)  
LINE COUNT: 14339  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 4 OF 5 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:244853 USPATFULL  
TITLE: Albumin fusion proteins  
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Sadeghi, Homayoun, Doylestown, PA, UNITED STATES  
Prior, Christopher P., Rosemont, PA, UNITED STATES  
Turner, Andrew J., Eagleville, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003171267	A1	20030911
APPLICATION INFO.:	US 2001-833117	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 59  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 20 Drawing Page(s)  
LINE COUNT: 13208  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 5 OF 5 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:181414 USPATFULL

TITLE: Albumin fusion proteins

INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES

Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003125247	A1	20030703
APPLICATION INFO.:	US 2001-833041	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 29

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 20 Drawing Page(s)

LINE COUNT: 15235

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 18:21:39 ON 29 JAN 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA' ENTERED AT 18:21:55 ON 29 JAN 2004

L1 5340 S TIMP-1  
L2 1 S CEREBUS PROTEIN  
L3 10853 S BRAIN DERIVED NEUROTROPHIC FACTOR OR BDNF  
L4 41802 S INTERFERON ALPHA  
L5 14602 S INTERFERON BETA  
L6 258098 S ALBUMIN  
L7 30354 S L6 AND FUSION  
L8 214 S L7 AND L1  
L9 0 S L7 AND L2  
L10 636 S L7 AND L3  
L11 1550 S L7 AND L4  
L12 1361 S L7 AND L5  
L13 0 S L6 AND L2  
L14 5 S ALBUMIN FUSION PROTEIN () INTERFERON ALPHA  
L15 5 S ALBUMIN FUSION PROTEIN () INTERFERON BETA  
L16 1 S ALBUMIN FUSION PROTEIN () BDNF  
L17 5 S ALBUMIN FUSION PROTEIN () TIMP-1

=> s abluamin fusion protein

L18 0 ABLUMIN FUSION PROTEIN

=> s albumin fusion protein

L19 2840 ALBUMIN FUSION PROTEIN

=> d l19 ti abs ibib 1-30

L19 ANSWER 1 OF 2840 MEDLINE on STN

TI An IFN-beta-**albumin fusion protein** that displays improved pharmacokinetic and pharmacodynamic properties in nonhuman primates.

AB The long half-life and stability of human serum albumin (HSA) make it an attractive candidate for fusion to short-lived therapeutic proteins. Albuferon (Human Genome Sciences [HGS], Inc., Rockville, MD) beta is a novel recombinant protein derived from a gene fusion of interferon-beta (IFN-beta) and HSA. In vitro, Albuferon beta displays antiviral and antiproliferative activities and triggers the IFN-stimulated response element (ISRE) signal transduction pathway. Array analysis of 5694 independent genes in Daudi-treated cells revealed that Albuferon beta and IFN-beta induce the expression of an identical set of 30 genes, including 9 previously not identified. In rhesus monkeys administered a dose of 50 microg/kg intravenously (i.v.) or subcutaneously (s.c.) or 300 microg/kg s.c., Albuferon beta demonstrated favorable pharmacokinetic properties. Subcutaneous bioavailability was 87%, plasma clearance at 4.7-5.7 ml/h/kg was approximately 140-fold lower than that of IFN-beta, and the terminal half-life was 36-40 h compared with 8 h for IFN-beta. Importantly, Albuferon beta induced sustained increases in serum neopterin levels and 2',5' mRNA expression. At a molar dose equivalent to one-half the dose of IFN-beta, Albuferon beta elicited comparable neopterin responses and significantly higher 2',5'-OAS mRNA levels in rhesus monkeys. The enhanced in vivo pharmacologic properties of IFN-beta when fused to serum albumin suggest a clinical opportunity for improved IFN-beta therapy.

ACCESSION NUMBER: 2003128795 MEDLINE

DOCUMENT NUMBER: 22526967 PubMed ID: 12639296

TITLE: An IFN-beta-**albumin fusion protein** that displays improved pharmacokinetic and pharmacodynamic properties in nonhuman primates.

AUTHOR: Sung Cynthia; Nardelli Bernardetta; LaFleur David W; Blatter Erich; Corcoran Marta; Olsen Henrik S; Birse Charles E; Pickeral Oxana K; Zhang Junli; Shah Devanshi; Moody Gordon; Gentz Solange; Beebe Lisa; Moore Paul A

CORPORATE SOURCE: Human Genome Sciences, Inc, Rockville, MD 20850, USA.

SOURCE: JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, (2003 Jan) 23 (1) 25-36.

Journal code: 9507088. ISSN: 1079-9907.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200309

ENTRY DATE: Entered STN: 20030320

Last Updated on STN: 20030928

Entered Medline: 20030926

L19 ANSWER 2 OF 2840 MEDLINE on STN

TI Pharmaceutical strategies utilizing recombinant human serum albumin.

AB Gene manipulation techniques open up the possibility of making recombinant human serum albumin (rHSA) or mutants with desirable therapeutic properties and for protein fusion products. rHSA can serve as a carrier in synthetic heme protein, thus reversibly carrying oxygen. Myristoylation of insulin results in a prolonged half-life because of self aggregation and increased albumin binding. Preferential albumin uptake by tumor cells serves as the basis for albumin-anticancer drug conjugate formulation. Furthermore, drug targeting can be achieved by incorporating drugs into albumin microspheres whereas liver targeting can be achieved by

conjugating drug with galactosylated or mannosylated albumin. Microspheres and nanoparticles of different sizes can, with or without drugs and/or radioisotopes, be used for drug delivery or diagnostic purposes. In vivo implantation of **albumin fusion protein** expressing cells encapsulated in HSA-alginate coated beads showed promising results compared to organoids in rats. Chimeric peptide strategy with cationized albumin as the transport can deliver drugs via receptor mediated transcytosis through the blood brain barrier. Gene bearing, albumin microbubbles containing ultrasound contrast agents can non-invasively deliver gene after destruction by ultrasound. Various site-directed mutants of HSA can be tailor made depending on the application required.

ACCESSION NUMBER: 2002326620 MEDLINE  
 DOCUMENT NUMBER: 22064084 PubMed ID: 12069157  
 TITLE: Pharmaceutical strategies utilizing recombinant human serum albumin.  
 AUTHOR: Chuang Victor Tuan Giam; Kragh-Hansen Ulrich; Otagiri Masaki  
 CORPORATE SOURCE: Faculty of Pharmaceutical Sciences, Kumamoto University, Japan.  
 SOURCE: PHARMACEUTICAL RESEARCH, (2002 May) 19 (5) 569-77. Ref: 91  
 Journal code: 8406521. ISSN: 0724-8741.  
 PUB. COUNTRY: United States  
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW, TUTORIAL)  
 LANGUAGE: English  
 FILE SEGMENT: Priority Journals  
 ENTRY MONTH: 200302  
 ENTRY DATE: Entered STN: 20020619  
 Last Updated on STN: 20030214  
 Entered Medline: 20030213

L19 ANSWER 3 OF 2840 MEDLINE on STN

TI A barbourin-**albumin fusion protein** that is slowly cleared in vivo retains the ability to inhibit platelet aggregation in vitro.

AB Barbourin is a 73 amino acid venom protein that inhibits platelet aggregation. Recombinant barbourin (BARH6), rabbit serum albumin (RSAH6), and a barbourin-RSA fusion protein (barbourin-linker-albumin; BLAH6) were secreted from *Pichia pastoris* yeast, and purified by nickel-chelate affinity chromatography via their C-terminal hexahistidine (H6) tags. BARH6 and BLAH6 did not differ in their IC50s for inhibition of platelet aggregation using either human platelets stimulated with thrombin or ADP, or rabbit platelets stimulated with ADP. BARH6 and BLAH6 were also effective in inhibiting platelet aggregation in whole blood, and formed complexes with platelet integrin  $\alpha$ IIb $\beta$ 3. The terminal catabolic half-life of BLAH6 approached that of RSAH6 [3.4 +/- 0.2 versus 4.0 +/- 0.1 days (n = 4 +/- SD)], but was substantially increased relative to that of BARH6 [0.15 +/- 0.03 days (n = 3 +/- SD)]. Our results suggest that fusion to albumin slows the clearance of barbourin in vivo, while preserving its ability to inhibit platelet aggregation.

ACCESSION NUMBER: 2001535476 MEDLINE  
 DOCUMENT NUMBER: 21467016 PubMed ID: 11583325  
 TITLE: A barbourin-**albumin fusion protein** that is slowly cleared in vivo retains the ability to inhibit platelet aggregation in vitro.  
 AUTHOR: Marques J A; George J K; Smith I J; Bhakta V; Sheffield W P  
 CORPORATE SOURCE: Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada.  
 SOURCE: THROMBOSIS AND HAEMOSTASIS, (2001 Sep) 86 (3) 902-8.  
 Journal code: 7608063. ISSN: 0340-6245.  
 PUB. COUNTRY: Germany: Germany, Federal Republic of  
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
 LANGUAGE: English

FILE SEGMENT: Priority Journals  
ENTRY MONTH: 200204  
ENTRY DATE: Entered STN: 20011004  
Last Updated on STN: 20020409  
Entered Medline: 20020408

L19 ANSWER 4 OF 2840 MEDLINE on STN

TI Prolonged in vivo anticoagulant activity of a hirudin-**albumin fusion protein** secreted from *Pichia pastoris*.

AB Hirudin is a small, proteinaceous thrombin inhibitor that clears rapidly from the circulation. A hexahistidine-tagged hirudin-rabbit serum albumin (RSA) fusion protein, HLAH6, was characterized following secretion from *Pichia pastoris*. HLAH6 bound to immobilized nickel, anti-RSA, and anti-hexahistidine antibodies, and contained the expected (ITYTD) N-terminus. Its spectrometric mass was 74,490 (versus the theoretical mass of 74,410 and sodium dodecyl sulfate-polyacrylamide gel electrophoresis mobility of 84 kDa). The terminal catabolic half-life in rabbits of HLAH6, recombinant *Pichia*-derived His-tagged RSA, or plasma-derived RSA did not differ. Injection of 2 mg/kg HLAH6 into rabbits raised the activated partial thromboplastin time (aPTT) above initial values for 4-24 h, while the equimolar dose of unfused hirudin was without significant effect. A higher dose of HLAH6 (3 mg/kg functional HLAH6, equivalent to 37.6 thrombin-inhibitory units/g) raised the aPTT by 2.0- to 2.5-fold; the elevation persisted for > 48 h. Importantly, both HLAH6 and unfused hirudin inhibited clot-bound thrombin. Our results suggest that HLAH6 exhibits not only delayed clearance, but also prolonged biological activity in vivo compared with unfused hirudin.

ACCESSION NUMBER: 2001506683 MEDLINE  
DOCUMENT NUMBER: 21439005 PubMed ID: 11555696  
TITLE: Prolonged in vivo anticoagulant activity of a hirudin-**albumin fusion protein** secreted from *Pichia pastoris*.  
AUTHOR: Sheffield W P; Smith I J; Syed S; Bhakta V  
CORPORATE SOURCE: Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ont., Canada.. sheffield@mcmaster.ca  
SOURCE: BLOOD COAGULATION AND FIBRINOLYSIS, (2001 Sep) 12 (6) 433-43.  
Journal code: 9102551. ISSN: 0957-5235.  
PUB. COUNTRY: England: United Kingdom  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 200112  
ENTRY DATE: Entered STN: 20010917  
Last Updated on STN: 20020122  
Entered Medline: 20011204

L19 ANSWER 5 OF 2840 USPATFULL on STN

TI Tumor necrosis factor receptors 6 alpha & 6 beta

AB The present invention relates to novel Tumor Necrosis Factor Receptor proteins. In particular, isolated nucleic acid molecules are provided encoding the human TNFR-6 $\alpha$  & -6 $\beta$  proteins. TNFR-6 $\alpha$  & -6 $\beta$  polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TNFR-6 $\alpha$  & -6 $\beta$  activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.

ACCESSION NUMBER: 2004:18362 USPATFULL  
TITLE: Tumor necrosis factor receptors 6 alpha & 6 beta  
INVENTOR(S): Gentz, Reiner L., Belo Horizonte-Mg, BRAZIL  
Yu, Guo-Liang, Berkeley, CA, UNITED STATES  
Ni, Jian, Germantown, MD, UNITED STATES  
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES



Feng, Ping, Germantown, MD, UNITED STATES  
Ruben, Steven M., Brookeville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004013664	A1	20040122
APPLICATION INFO.:	US 2003-418242	A1	20030418 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-935727, filed on 24 Aug 2001, PENDING Continuation-in-part of Ser. No. US 2000-518931, filed on 3 Mar 2000, PENDING Continuation-in-part of Ser. No. US 1998-6352, filed on 13 Jan 1998, PENDING Continuation-in-part of Ser. No. US 2000-518931, filed on 3 Mar 2000, PENDING Continuation-in-part of Ser. No. US 1998-6352, filed on 13 Jan 1998, PENDING Continuation-in-part of Ser. No. US 1998-6352, filed on 13 Jan 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-373604P	20020419 (60)
	US 2001-303224P	20010706 (60)
	US 2000-252131P	20001121 (60)
	US 2000-227598P	20000825 (60)
	US 1999-168235P	19991201 (60)
	US 1999-146371P	19990802 (60)
	US 1999-131964P	19990430 (60)
	US 1999-131279P	19990427 (60)
	US 1999-124092P	19990312 (60)
	US 1999-121774P	19990304 (60)
	US 1997-35496P	19970114 (60)
	US 1999-168235P	19991201 (60)
	US 1999-146371P	19990802 (60)
	US 1999-131964P	19990430 (60)
	US 1999-131279P	19990427 (60)
	US 1999-124092P	19990312 (60)
	US 1999-121774P	19990304 (60)
	US 1997-35496P	19970114 (60)
	US 1997-35496P	19970114 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850  
NUMBER OF CLAIMS: 40  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 23 Drawing Page(s)  
LINE COUNT: 13403

L19 ANSWER 6 OF 2840 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

ACCESSION NUMBER: 2004:13611 USPATFULL  
TITLE: Albumin fusion proteins  
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010134	A1	20040115
APPLICATION INFO.:	US 2001-833245	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850  
NUMBER OF CLAIMS: 29  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 18 Drawing Page(s)  
LINE COUNT: 25066

L19 ANSWER 7 OF 2840 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:312278 USPATFULL  
TITLE: Albumin fusion proteins  
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003219875	A1	20031127
APPLICATION INFO.:	US 2001-833118	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850  
NUMBER OF CLAIMS: 29  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 18 Drawing Page(s)  
LINE COUNT: 15415

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 8 OF 2840 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using

these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:282700 USPATFULL  
TITLE: Albumin fusion proteins  
INVENTOR(S): Ballance, David J., Berwyn, PA, UNITED STATES  
Sleep, Darrell, West Bridgford, UNITED KINGDOM  
Prior, Christopher P., Rosemont, PA, UNITED STATES  
Sadeghi, Homayoun, Doylestown, PA, UNITED STATES  
Turner, Andrew J., Eagleville, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003199043	A1	20031023
APPLICATION INFO.:	US 2001-832501	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	60	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	18 Drawing Page(s)	
LINE COUNT:	14339	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 9 OF 2840 USPATFULL on STN

TI Binding polypeptides for B lymphocyte stimulator protein (BLyS)  
AB Binding polypeptides comprising specific amino acid sequences are disclosed that bind B Lymphocyte Stimulator (BLyS) protein or BLyS-like polypeptides. The binding polypeptides can be used in methods of the invention for detecting or isolating BLyS protein or BLyS-like polypeptides in solutions or mixtures, such as blood, tissue samples, or conditioned media.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:276718 USPATFULL  
TITLE: Binding polypeptides for B lymphocyte stimulator protein (BLyS)  
INVENTOR(S): Beltzer, James P., Carlisle, MA, UNITED STATES  
Potter, M. Daniel, Acton, MA, UNITED STATES  
Potter, Marilou, Acton, MA, UNITED STATES LR  
Fleming, Tony J., Waltham, MA, UNITED STATES  
Ladner, Robert Charles, Ijamsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003194743	A1	20031016
APPLICATION INFO.:	US 2001-932322	A1	20010817 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-226489P	20000818 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Leon R. Yankwich, Esq., YANKWICH & ASSOCIATES, 201	

Broadway, Cambridge, MA, 02139  
NUMBER OF CLAIMS: 38  
EXEMPLARY CLAIM: 1  
LINE COUNT: 6942  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 10 OF 2840 USPATFULL on STN

TI Neutrokin-alpha and neutrokin-alpha splice variant  
AB The present invention relates to nucleic acid molecules encoding Neutrokin-alpha and/or Neutrokin-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokin-alpha and/or Neutrokin-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to antibodies or portions thereof that specifically bind Neutrokin-alpha and/or Neutrokin-alphaSV and diagnostic and therapeutic methods using these antibodies. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders using the compositions of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:250423 USPATFULL  
TITLE: Neutrokin-alpha and neutrokin-alpha splice variant  
INVENTOR(S): Yu, Guo-Liang, Berkeley, CA, UNITED STATES  
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES  
Ni, Jian, Germantown, MD, UNITED STATES  
Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Ullrich, Stephen, Rockville, MD, UNITED STATES  
Laird, Michael, Germantown, MD, UNITED STATES  
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003175208	A1	20030918
APPLICATION INFO.:	US 2002-270487	A1	20021016 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-929493, filed on 15 Aug 2001, PENDING Continuation-in-part of Ser. No. US 2000-588947, filed on 8 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-589285, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-589286, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-589287, filed on 8 Jun 2000, GRANTED, Pat. No. US 6403770 Continuation-in-part of Ser. No. US 2000-589288, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-507968, filed on 22 Feb 2000, PENDING Continuation-in-part of Ser. No. US 1999-255794, filed on 23 Feb 1999, PENDING Continuation-in-part of Ser. No. US 2000-588947, filed on 8 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-589285, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-589286, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-589288, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-507968, filed on 22 Feb 2000, PENDING Continuation-in-part of Ser. No. US 1999-255794, filed on 23 Feb 1999, PENDING Continuation-in-part of Ser. No. US 1998-5874, filed on 12 Jan 1998, PENDING Continuation-in-part of Ser. No. WO 1996-US17957, filed on 25 Oct 1996, PENDING Continuation-in-part of Ser. No. US 1999-255794, filed on 23 Feb 1999, PENDING Continuation-in-part of Ser. No. US 1998-5874, filed on 12 Jan 1998, PENDING		

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2001-329508P	20011017	(60)
	US 2001-329747P	20011018	(60)
	US 2001-330835P	20011031	(60)
	US 2001-331478P	20011116	(60)
	US 2001-336726P	20011207	(60)
	US 2002-368548P	20020401	(60)
	US 2000-225628P	20000815	(60)
	US 2000-227008P	20000823	(60)
	US 2000-234338P	20000922	(60)
	US 2000-240806P	20001017	(60)
	US 2000-250020P	20001130	(60)
	US 2001-276248P	20010316	(60)
	US 2001-293499P	20010525	(60)
	US 2001-296122P	20010607	(60)
	US 2001-304809P	20010713	(60)
	US 1999-122388P	19990302	(60)
	US 1999-124097P	19990312	(60)
	US 1999-126599P	19990326	(60)
	US 1999-127598P	19990402	(60)
	US 1999-130412P	19990416	(60)
	US 1999-130696P	19990423	(60)
	US 1999-131278P	19990427	(60)
	US 1999-131673P	19990429	(60)
	US 1999-136784P	19990528	(60)
	US 1999-142659P	19990706	(60)
	US 1999-145824P	19990727	(60)
	US 1999-167239P	19991124	(60)
	US 1999-168624P	19991203	(60)
	US 1999-171108P	19991216	(60)
	US 1999-171626P	19991223	(60)
	US 2000-176015P	20000114	(60)
	US 1999-122388P	19990302	(60)
	US 1999-124097P	19990312	(60)
	US 1999-126599P	19990326	(60)
	US 1999-127598P	19990402	(60)
	US 1999-130412P	19990416	(60)
	US 1999-130696P	19990423	(60)
	US 1999-131278P	19990427	(60)
	US 1999-131673P	19990429	(60)
	US 1999-136784P	19990528	(60)
	US 1999-142659P	19990706	(60)
	US 1999-145824P	19990727	(60)
	US 1999-167239P	19991124	(60)
	US 1999-168624P	19991203	(60)
	US 1999-171108P	19991216	(60)
	US 1999-171626P	19991223	(60)
	US 2000-176015P	20000114	(60)
	US 1997-36100P	19970114	(60)

DOCUMENT TYPE:

Utility

FILE SEGMENT:

APPLICATION

LEGAL REPRESENTATIVE:

HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850

NUMBER OF CLAIMS:

44

EXEMPLARY CLAIM:

1

NUMBER OF DRAWINGS:

27 Drawing Page(s)

LINE COUNT:

18884

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 11 OF 2840 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic

acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:244853 USPATFULL  
 TITLE: Albumin fusion proteins  
 INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
 Sadeghi, Homayoun, Doylestown, PA, UNITED STATES  
 Prior, Christopher P., Rosemont, PA, UNITED STATES  
 Turner, Andrew J., Eagleville, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003171267	A1	20030911
APPLICATION INFO.:	US 2001-833117	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
 ROCKVILLE, MD, 20850  
 NUMBER OF CLAIMS: 59  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 20 Drawing Page(s)  
 LINE COUNT: 13208

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 12 OF 2840 USPATFULL on STN

TI Death domain containing receptors  
 AB The present invention relates to novel Death Domain Containing Receptor (DR3 and DR3-V1) proteins that are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR3 and DR3-V1 proteins. DR3 and DR3-V1 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of DR3 and DR3-V1 activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:243794 USPATFULL  
 TITLE: Death domain containing receptors  
 INVENTOR(S): Yu, Guo-Liang, Berkeley, CA, UNITED STATES  
 Ni, Jian, Germantown, MD, UNITED STATES  
 Gentz, Reiner L., Belo Horizonte, BRAZIL  
 Dillon, Patrick J., Carlsbad, CA, UNITED STATES  
 PATENT ASSIGNEE(S): Human Genome Sciences, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003170203	A1	20030911
APPLICATION INFO.:	US 2002-189189	A1	20020705 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-557908, filed on 21 Apr 2000, PENDING Continuation-in-part of Ser. No. US 1997-815469, filed on 11 Mar 1997, GRANTED, Pat. No. US 6153402		

	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	US 2001-314314P	20010824 (60)
	US 2001-303155P	20010706 (60)
	US 1999-136741P	19990528 (60)
	US 1999-130488P	19990422 (60)
	US 1997-37341P	19970206 (60)
	US 1996-28711P	19961017 (60)
	US 1996-13285P	19960312 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., 1100 NEW YORK AVENUE, N.W., SUITE 600, WASHINGTON, DC, 20005-3934	
NUMBER OF CLAIMS:	83	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	10 Drawing Page(s)	
LINE COUNT:	9858	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L19 ANSWER 13 OF 2840 USPATFULL on STN

TI Chemokine beta-1 fusion proteins

AB The present invention relates to novel chemokine polypeptides and encoding nucleic acids. More specifically, therapeutic compositions and methods are provided using isolated nucleic acid molecules encoding a human chemokine beta-1 (Ck $\beta$ -1 or Ckb1) polypeptide (previously termed monocyte-colony inhibitory factor (M-CIF), MIP1- $\gamma$ , and Hemofiltrate CC chemokine-1 (HCC-1)), and Ckb1 polypeptides themselves, as are vectors, host cells and recombinant methods for producing the same. Also provided are methods of treating, preventing, ameliorating diseases using such compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:206834 USPATFULL

TITLE: Chemokine beta-1 fusion proteins

INVENTOR(S): Bell, Adam, Germantown, MD, UNITED STATES  
Ruben, Steven M., Olney, MD, UNITED STATES

	NUMBER	KIND	DATE
	-----	-----	-----
PATENT INFORMATION:	US 2003143191	A1	20030731
APPLICATION INFO.:	US 2002-153604	A1	20020524 (10)

	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	US 2001-293212P	20010525 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	21 Drawing Page(s)	
LINE COUNT:	15446	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L19 ANSWER 14 OF 2840 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising

albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:181414 USPATFULL  
TITLE: Albumin fusion proteins  
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003125247	A1	20030703
APPLICATION INFO.:	US 2001-833041	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 29  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 20 Drawing Page(s)  
LINE COUNT: 15235

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 15 OF 2840 USPATFULL on STN

TI Binding polypeptides and methods based thereon  
AB Binding polypeptides that specifically bind BLYS protein or BLYS-like polypeptides can be used in methods of the invention for detecting, diagnosing, or prognosing a disease or disorder associated with aberrant BLYS or BLYS receptor expression or inappropriate function of BLYS or BLYS receptor, comprising BLYS binding polypeptides or fragments or variants thereof, that specifically bind to BLYS. The present invention further relates to methods and compositions for preventing, treating or ameliorating a disease or disorder associated with aberrant BLYS or BLYS receptor expression or inappropriate BLYS function or BLYS receptor function, comprising administering to an animal, preferably a human, an effective amount of one or more BLYS binding polypeptides or fragments or variants thereof, that specifically bind to BLYS.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:133480 USPATFULL  
TITLE: Binding polypeptides and methods based thereon  
INVENTOR(S): Beltzer, James P., Carlisle, MA, UNITED STATES  
Potter, M. Daniel, UNITED STATES  
Potter, Marilou, Acton, MA, UNITED STATES LR  
Fleming, Tony J., Waltham, MA, UNITED STATES  
Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003091565	A1	20030515
APPLICATION INFO.:	US 2001-932613	A1	20010817 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-226700P	20000818 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: Leon R. Yankwich, Esq., Yankwich & Associates, 130



Bishop Allen Drive, Cambridge, MA, 02139

NUMBER OF CLAIMS: 71  
EXEMPLARY CLAIM: 1  
LINE COUNT: 11834  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 16 OF 2840 USPATFULL on STN

TI Use of the KAL protein and treatment with the KAL protein in treatment of retinal, renal, neuronal and neural injury  
AB KAL protein is identified as the active agent in a therapeutic composition for treatment of injury to nerve tissue, including spinal cord tissue, as well as support of treatment for renal grafts. Additionally, therapeutic treatment of renal injury, and kidney transplantation and renal surgery, is effected by administration of KAL protein. The therapeutic agent may be administered locally, or intravenously. Retinal disorders may be similarly treated.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:102360 USPATFULL  
TITLE: Use of the KAL protein and treatment with the KAL protein in treatment of retinal, renal, neuronal and neural injury  
INVENTOR(S): Petit, Christine, Le Plessis-Robinson, FRANCE  
Soussi-Yanticostas, Nadia, Paris, FRANCE  
Hardelin, Jean-Pierre, Paris, FRANCE  
Sarailh, Catherine, Marseille, FRANCE  
Rougon, Genevieve, Marseille, FRANCE  
Legouis, Renaud, Strasbourg, FRANCE  
Ardouin, Olivier, Issy-les-Mou-lineaux, FRANCE  
Mazie, Jean-Claude, Asnieres, FRANCE  
PATENT ASSIGNEE(S): Institut Pasteur, Paris, FRANCE (non-U.S. corporation)  
Centre National de la Recherche Scientifique, Paris, FRANCE (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6548475	B1	20030415
APPLICATION INFO.:	US 2000-576967		20000524 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1996-761136, filed on 6 Dec 1996, now patented, Pat. No. US 6121231		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Ulm, John		
ASSISTANT EXAMINER:	Chernyshev, Olga N.		
LEGAL REPRESENTATIVE:	Obion, Spivak, McClelland, Maier & Neustadt, P.C.		
NUMBER OF CLAIMS:	5		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	24 Drawing Figure(s); 17 Drawing Page(s)		
LINE COUNT:	1338		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 17 OF 2840 USPATFULL on STN

TI Serum albumin binding moieties  
AB Compositions comprising non-naturally occurring serum albumin binding moieties are described, together with methods of use thereof, e.g., for detecting or isolating serum albumin molecules in a solution, for blood circulation imaging, and for linking therapeutics or other molecules to albumin. Preferred serum albumin binding peptides having a high affinity for human serum albumin are particularly disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:100284 USPATFULL  
TITLE: Serum albumin binding moieties  
INVENTOR(S): Sato, Aaron K., Somerville, MA, UNITED STATES  
Ley, Arthur C., Newton, MA, UNITED STATES

Cohen, Edward H., Belmont, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003069395	A1	20030410
APPLICATION INFO.:	US 2002-94401	A1	20020308 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-331352P	20010309 (60)
	US 2001-292975P	20010523 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	LEON R. YANKWICH, YANKWICH & ASSOCIATES, 201 BROADWAY, CAMBRIDGE, MA, 02139	
NUMBER OF CLAIMS:	54	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Page(s)	
LINE COUNT:	4384	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 18 OF 2840 USPATFULL on STN

TI Use of the KAL protein and treatment with the KAL protein in treatment of retinal, renal, neuronal and neural injury

AB KAL protein is identified the active agent in a therapeutic composition for treatment of injury to nerve tissue, including spinal cord tissue, as well as support of treatment for renal grafts. Additionally, therapeutic treatment of renal injury, and kidney transplantation and renal surgery, is effected by administration of KAL protein. The therapeutic agent may be administered locally, or intravenously. Retinal disorders may be similarly treated.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:86793 USPATFULL

TITLE: Use of the KAL protein and treatment with the KAL protein in treatment of retinal, renal, neuronal and neural injury

INVENTOR(S): Petit, Christine, Le Plessis-Robinson, FRANCE  
Soussi-Yanticostas, Nadia, Paris, FRANCE  
Hardelin, Jean-Pierre, Paris, FRANCE  
Sarailh, Catherine, Marseille, FRANCE  
Rougon, Genevieve, Marseille, FRANCE  
Legouis, Renaud, Strasbourg, FRANCE  
Ardouin, Olivier, Issy-les-Mou-lineaux, FRANCE  
Mazie, Jean-Claude, Asnieres, FRANCE

PATENT ASSIGNEE(S): INSTITUT PASTEUR, PARIS CEDEX, FRANCE (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003060401	A1	20030327
APPLICATION INFO.:	US 2002-219541	A1	20020816 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-576967, filed on 24 May 2000, PENDING Division of Ser. No. US 1996-761136, filed on 6 Dec 1996, GRANTED, Pat. No. US 6121231		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C., 1940 DUKE STREET, ALEXANDRIA, VA, 22314		
NUMBER OF CLAIMS:	31		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	17 Drawing Page(s)		
LINE COUNT:	1363		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 19 OF 2840 USPATFULL on STN

TI Tumor necrosis factor receptors 6alpha & 6beta  
AB The present invention relates to novel Tumor Necrosis Factor Receptor proteins. In particular, isolated nucleic acid molecules are provided encoding the human TNFR-6 $\alpha$  & -6 $\beta$  proteins. TNFR-6 $\alpha$  & -6 $\beta$  polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TNFR-6 $\alpha$  & -6 $\beta$  activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:272468 USPATFULL  
TITLE: Tumor necrosis factor receptors 6alpha & 6beta  
INVENTOR(S): Gentz, Reiner L., Rockville, MD, UNITED STATES  
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES  
Yu, Guo-Liang, Berkeley, CA, UNITED STATES  
Ruben, Steven M., Olney, MD, UNITED STATES  
Ni, Jian, Germantown, MD, UNITED STATES  
Feng, Ping, Gaithersburg, MD, UNITED STATES  
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002150583	A1	20021017
APPLICATION INFO.:	US 2001-935727	A1	20010824 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1998-6352, filed on 13 Jan 1998, PENDING Continuation-in-part of Ser. No. US 2000-518931, filed on 3 Mar 2000, PENDING Continuation-in-part of Ser. No. US 1998-6352, filed on 13 Jan 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-303224P	20010706 (60)
	US 2000-252131P	20001121 (60)
	US 2000-227598P	20000825 (60)
	US 1999-168235P	19991201 (60)
	US 1999-146371P	19990802 (60)
	US 1999-131964P	19990430 (60)
	US 1999-131270P	19990427 (60)
	US 1999-124092P	19990312 (60)
	US 1999-121774P	19990304 (60)
	US 1997-35496P	19970114 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 48  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 23 Drawing Page(s)  
LINE COUNT: 12989  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 20 OF 2840 USPATFULL on STN

TI Therapeutic composition comprising the KAL protein and use of the KAL protein for the treatment of retinal, renal, neuronal and neural injury  
AB KAL protein is identified the active agent in a therapeutic composition for treatment of injury to nerve tissue including spinal cord tissue, as well as support of treatment for renal grafts. Additionally, therapeutic treatment of renal injury, and kidney transplantation and renal surgery, is effected by administration of KAL protein. The therapeutic agent may be administered locally, or intravenously. Retinal disorders may be

similarly treated.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:228307 USPATFULL  
TITLE: Therapeutic composition comprising the KAL protein and  
use of the KAL protein for the treatment of retinal,  
renal, neuronal and neural injury  
INVENTOR(S): Petit, Christine, Le Plessis-Robinson, FRANCE  
Soussi-Yanicostas, Nadia, Paris, FRANCE  
Hardelin, Jean-Pierre, Paris, FRANCE  
Sarailh, Catherine, Marseille, FRANCE  
Rougon, Genevieve, Marseille, FRANCE  
Legouis, Renaud, Strasbourg, FRANCE  
Ardouin, Olivier, Issy Les Moulineaux, FRANCE  
Mazie, Jean-Claude, Asnieres, FRANCE  
PATENT ASSIGNEE(S): INSTITUT PASTEUR, Paris Cedex, FRANCE, 75724 (non-U.S.  
individual)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002123467	A1	20020905
APPLICATION INFO.:	US 2002-119714	A1	20020411 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-319236, filed on 2 Sep 1999, PENDING A 371 of International Ser. No. WO 1997-EP6806, filed on 5 Dec 1997, UNKNOWN		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	OBLON SPIVAK MCCLELLAND MAIER & NEUSTADT PC, FOURTH FLOOR, 1755 JEFFERSON DAVIS HIGHWAY, ARLINGTON, VA, 22202		
NUMBER OF CLAIMS:	32		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	21 Drawing Page(s)		
LINE COUNT:	1904		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 21 OF 2840 USPATFULL on STN

TI Hyaluronan receptor protein  
AB The present invention relates to a novel hyaluronan receptor protein  
involved in cell locomotion or motility and in cell proliferation and  
transformation and to DNA sequences encoding this protein. The protein  
is designated Receptor for Hyaluronic Acid Mediated Motility or RHAMM.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:194945 USPATFULL  
TITLE: Hyaluronan receptor protein  
INVENTOR(S): Turley, Eva Ann, #5 - 375 Wellington Crescent,  
Winnipeg, Manitoba, CANADA L2M 0A1  
Zhang, Shuwen, 143 Branson Crescent, Winnipeg,  
Manitoba, CANADA R2P 9N9  
Entwistle, Jocelyn, 380 Linden Wood Drive East,  
Winnipeg, Manitoba, CANADA R3P 2H1

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6429291	B1	20020806
APPLICATION INFO.:	US 1995-477831		19950607 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1994-20740	19941014
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Kemmerer, Elizabeth	
LEGAL REPRESENTATIVE:	Fish & Neave, Pierri, Margaret A., Mayrand, Shawn-Marie	

NUMBER OF CLAIMS: 3  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 123 Drawing Figure(s); 70 Drawing Page(s)  
LINE COUNT: 3544  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 22 OF 2840 USPATFULL on STN

TI Use of the KAL protein and treatment with the KAL protein in treatment of retinal, renal, neuromal and neural injury  
AB KAL protein is identified the active agent in a therapeutic composition for treatment of injury to nerve tissue, including spinal cord tissue, as well as support of treatment for renal grafts. Additionally, therapeutic treatment of renal injury, and kidney transplantation and renal surgery, is effected by administration of KAL protein. The therapeutic agent may be administered locally, or intravenously. Retinal disorders may be similarly treated.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2000:125008 USPATFULL  
TITLE: Use of the KAL protein and treatment with the KAL protein in treatment of retinal, renal, neuromal and neural injury  
INVENTOR(S): Petit, Christine, Le Plessis-Robinson, France  
Soussi-Yanticostas, Nadia, Paris, France  
Hardelin, Jean-Pierre, Paris, France  
Sarailh, Catherine, Marseilles, France  
Rougon, Genevieve, Marseilles, France  
Legouis, Renaud, Strasbourg, France  
Ardouin, Olivier, Issy-les-Mou-lineaux, France  
Mazie, Jean-Claude, Asnieres, France  
PATENT ASSIGNEE(S): Institut Pasteur, Paris, France (non-U.S. corporation)  
Centre Nationale de la Recherche Scientifique, Paris, France (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6121231		20000919
APPLICATION INFO.:	US 1996-761136		19961206 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Duffy, Patricia A.		
LEGAL REPRESENTATIVE:	Oblon, Spivak, McClelland, Maier & Neustadt, P.C.		
NUMBER OF CLAIMS:	4		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	23 Drawing Figure(s); 17 Drawing Page(s)		
LINE COUNT:	1334		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 23 OF 2840 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN

TI New **albumin fusion protein** for diagnosing, preventing or treating diseases (e.g. HIV, cancer, atherosclerosis or stroke) comprises a therapeutic protein (e.g. cathepsin K or vascular endothelial growth factor) and an albumin.  
AN ADD68074 protein DGENE  
AB The present invention relates to albumin fusion proteins comprising any of the therapeutic proteins listed in the specification, or their fragments or variants, and an albumin protein or its fragments or variants. The invention also discloses pharmaceutical compositions comprising the albumin fusion proteins, a kit comprising the albumin fusion proteins, and methods for treating a disease or disorder in a patient, that is modulated by the therapeutic protein or its fragment or variant. The compositions and methods of the invention are useful in diagnosing, preventing, treating or ameliorating diseases or disorders, such as HIV, osteoporosis, cancer, wounds, autoimmune diseases, cardiovascular diseases, hepatitis, multiple sclerosis, psoriasis, graft-

versus-host disease, stroke, atherosclerosis and inflammation. The present sequence represents a human therapeutic protein.

ACCESSION NUMBER: ADD68074 protein DGENE  
TITLE: New **albumin fusion protein** for  
diagnosing, preventing or treating diseases (e.g. HIV,  
cancer, atherosclerosis or stroke) comprises a therapeutic  
protein (e.g. cathepsin K or vascular endothelial growth  
factor) and an albumin.  
INVENTOR: Rosen C A; Haseltine W A  
PATENT ASSIGNEE: (ROSE-I)ROSEN C A.  
(HASE-I) HASELTINE W A.  
PATENT INFO: US 2003125247 A1 20030703 180p  
APPLICATION INFO: US 2001-833041 20010412  
PRIORITY INFO: US 2000-229358P 20000412  
US 2000-199384P 20000425  
US 2000-256931P 20001221  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
OTHER SOURCE: 2003-810996 [76]  
DESCRIPTION: Human therapeutic protein #4.

L19 ANSWER 24 OF 2840 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN

TI New **albumin fusion protein** for diagnosing,  
preventing or treating diseases (e.g. HIV, cancer, atherosclerosis or  
stroke) comprises a therapeutic protein (e.g. cathepsin K or vascular  
endothelial growth factor) and an albumin.

AN ADD68075 protein DGENE

AB The present invention relates to albumin fusion proteins comprising any  
of the therapeutic proteins listed in the specification, or their  
fragments or variants, and an albumin protein or its fragments or  
variants. The invention also discloses pharmaceutical compositions  
comprising the albumin fusion proteins, a kit comprising the albumin  
fusion proteins, and methods for treating a disease or disorder in a  
patient, that is modulated by the therapeutic protein or its fragment or  
variant. The compositions and methods of the invention are useful in  
diagnosing, preventing, treating or ameliorating diseases or disorders,  
such as HIV, osteoporosis, cancer, wounds, autoimmune diseases,  
cardiovascular diseases, hepatitis, multiple sclerosis, psoriasis, graft-  
versus-host disease, stroke, atherosclerosis and inflammation. The  
present sequence represents a human therapeutic protein.

ACCESSION NUMBER: ADD68075 protein DGENE  
TITLE: New **albumin fusion protein** for  
diagnosing, preventing or treating diseases (e.g. HIV,  
cancer, atherosclerosis or stroke) comprises a therapeutic  
protein (e.g. cathepsin K or vascular endothelial growth  
factor) and an albumin.  
INVENTOR: Rosen C A; Haseltine W A  
PATENT ASSIGNEE: (ROSE-I)ROSEN C A.  
(HASE-I) HASELTINE W A.  
PATENT INFO: US 2003125247 A1 20030703 180p  
APPLICATION INFO: US 2001-833041 20010412  
PRIORITY INFO: US 2000-229358P 20000412  
US 2000-199384P 20000425  
US 2000-256931P 20001221  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
OTHER SOURCE: 2003-810996 [76]  
DESCRIPTION: Human therapeutic protein #5.

L19 ANSWER 25 OF 2840 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN

TI New **albumin fusion protein** for diagnosing,  
preventing or treating diseases (e.g. HIV, cancer, atherosclerosis or  
stroke) comprises a therapeutic protein (e.g. cathepsin K or vascular  
endothelial growth factor) and an albumin.

AN ADD68073 protein DGENE

AB The present invention relates to albumin fusion proteins comprising any of the therapeutic proteins listed in the specification, or their fragments or variants, and an albumin protein or its fragments or variants. The invention also discloses pharmaceutical compositions comprising the albumin fusion proteins, a kit comprising the albumin fusion proteins, and methods for treating a disease or disorder in a patient, that is modulated by the therapeutic protein or its fragment or variant. The compositions and methods of the invention are useful in diagnosing, preventing, treating or ameliorating diseases or disorders, such as HIV, osteoporosis, cancer, wounds, autoimmune diseases, cardiovascular diseases, hepatitis, multiple sclerosis, psoriasis, graft-versus-host disease, stroke, atherosclerosis and inflammation. The present sequence represents a human therapeutic protein.

ACCESSION NUMBER: ADD68073 protein DGENE

TITLE: New **albumin fusion protein** for diagnosing, preventing or treating diseases (e.g. HIV, cancer, atherosclerosis or stroke) comprises a therapeutic protein (e.g. cathepsin K or vascular endothelial growth factor) and an albumin.

INVENTOR: Rosen C A; Haseltine W A

PATENT ASSIGNEE: (ROSE-I)ROSEN C A.

(HASE-I) HASELTINE W A.

PATENT INFO: US 2003125247 A1 20030703 180p

APPLICATION INFO: US 2001-833041 20010412

PRIORITY INFO: US 2000-229358P 20000412

US 2000-199384P 20000425

US 2000-256931P 20001221

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2003-810996 [76]

DESCRIPTION: Human therapeutic protein #3.

L19 ANSWER 26 OF 2840 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN

TI New **albumin fusion protein** for diagnosing, preventing or treating diseases (e.g. HIV, cancer, atherosclerosis or stroke) comprises a therapeutic protein (e.g. cathepsin K or vascular endothelial growth factor) and an albumin.

AN ADD68072 protein DGENE

AB The present invention relates to albumin fusion proteins comprising any of the therapeutic proteins listed in the specification, or their fragments or variants, and an albumin protein or its fragments or variants. The invention also discloses pharmaceutical compositions comprising the albumin fusion proteins, a kit comprising the albumin fusion proteins, and methods for treating a disease or disorder in a patient, that is modulated by the therapeutic protein or its fragment or variant. The compositions and methods of the invention are useful in diagnosing, preventing, treating or ameliorating diseases or disorders, such as HIV, osteoporosis, cancer, wounds, autoimmune diseases, cardiovascular diseases, hepatitis, multiple sclerosis, psoriasis, graft-versus-host disease, stroke, atherosclerosis and inflammation. The present sequence represents a human therapeutic protein.

ACCESSION NUMBER: ADD68072 protein DGENE

TITLE: New **albumin fusion protein** for diagnosing, preventing or treating diseases (e.g. HIV, cancer, atherosclerosis or stroke) comprises a therapeutic protein (e.g. cathepsin K or vascular endothelial growth factor) and an albumin.

INVENTOR: Rosen C A; Haseltine W A

PATENT ASSIGNEE: (ROSE-I)ROSEN C A.

(HASE-I) HASELTINE W A.

PATENT INFO: US 2003125247 A1 20030703 180p

APPLICATION INFO: US 2001-833041 20010412

PRIORITY INFO: US 2000-229358P 20000412

US 2000-199384P 20000425

US 2000-256931P 20001221

DOCUMENT TYPE: Patent  
LANGUAGE: English  
OTHER SOURCE: 2003-810996 [76]  
DESCRIPTION: Human therapeutic protein #2.

L19 ANSWER 27 OF 2840 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN

TI New **albumin fusion protein** for diagnosing, preventing or treating diseases (e.g. HIV, cancer, atherosclerosis or stroke) comprises a therapeutic protein (e.g. cathepsin K or vascular endothelial growth factor) and an albumin.

AN ADD68005 peptide DGENE

AB The present invention relates to albumin fusion proteins comprising any of the therapeutic proteins listed in the specification, or their fragments or variants, and an albumin protein or its fragments or variants. The invention also discloses pharmaceutical compositions comprising the albumin fusion proteins, a kit comprising the albumin fusion proteins, and methods for treating a disease or disorder in a patient, that is modulated by the therapeutic protein or its fragment or variant. The compositions and methods of the invention are useful in diagnosing, preventing, treating or ameliorating diseases or disorders, such as HIV, osteoporosis, cancer, wounds, autoimmune diseases, cardiovascular diseases, hepatitis, multiple sclerosis, psoriasis, graft-versus-host disease, stroke, atherosclerosis and inflammation. The present sequence is used in the examples of the present invention.

ACCESSION NUMBER: ADD68005 peptide DGENE

TITLE: New **albumin fusion protein** for diagnosing, preventing or treating diseases (e.g. HIV, cancer, atherosclerosis or stroke) comprises a therapeutic protein (e.g. cathepsin K or vascular endothelial growth factor) and an albumin.

INVENTOR: Rosen C A; Haseltine W A

PATENT ASSIGNEE: (ROSE-I)ROSEN C A.  
(HASE-I) HASELTINE W A.

PATENT INFO: US 2003125247 A1 20030703 180p

APPLICATION INFO: US 2001-833041 20010412

PRIORITY INFO: US 2000-229358P 20000412

US 2000-199384P 20000425

US 2000-256931P 20001221

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2003-810996 [76]

DESCRIPTION: Yeast invertase (SU2) leader-hGH N-terminal fusion peptide.

L19 ANSWER 28 OF 2840 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN

TI New **albumin fusion protein** for diagnosing, preventing or treating diseases (e.g. HIV, cancer, atherosclerosis or stroke) comprises a therapeutic protein (e.g. cathepsin K or vascular endothelial growth factor) and an albumin.

AN ADD68077 protein DGENE

AB The present invention relates to albumin fusion proteins comprising any of the therapeutic proteins listed in the specification, or their fragments or variants, and an albumin protein or its fragments or variants. The invention also discloses pharmaceutical compositions comprising the albumin fusion proteins, a kit comprising the albumin fusion proteins, and methods for treating a disease or disorder in a patient, that is modulated by the therapeutic protein or its fragment or variant. The compositions and methods of the invention are useful in diagnosing, preventing, treating or ameliorating diseases or disorders, such as HIV, osteoporosis, cancer, wounds, autoimmune diseases, cardiovascular diseases, hepatitis, multiple sclerosis, psoriasis, graft-versus-host disease, stroke, atherosclerosis and inflammation. The present sequence represents a human therapeutic protein.

ACCESSION NUMBER: ADD68077 protein DGENE

TITLE: New **albumin fusion protein** for diagnosing, preventing or treating diseases (e.g. HIV,



cancer, atherosclerosis or stroke) comprises a therapeutic protein (e.g. cathepsin K or vascular endothelial growth factor) and an albumin.

INVENTOR: Rosen C A; Haseltine W A  
 PATENT ASSIGNEE: (ROSE-I)ROSEN C A.  
 (HASE-I) HASELTINE W A.  
 PATENT INFO: US 2003125247 A1 20030703 180p  
 APPLICATION INFO: US 2001-833041 20010412  
 PRIORITY INFO: US 2000-229358P 20000412  
 US 2000-199384P 20000425  
 US 2000-256931P 20001221  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 OTHER SOURCE: 2003-810996 [76]  
 DESCRIPTION: Human therapeutic protein #7.

L19 ANSWER 29 OF 2840 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN

TI New **albumin fusion protein** for diagnosing, preventing or treating diseases (e.g. HIV, cancer, atherosclerosis or stroke) comprises a therapeutic protein (e.g. cathepsin K or vascular endothelial growth factor) and an albumin.

AN ADD68076 protein DGENE

AB The present invention relates to albumin fusion proteins comprising any of the therapeutic proteins listed in the specification, or their fragments or variants, and an albumin protein or its fragments or variants. The invention also discloses pharmaceutical compositions comprising the albumin fusion proteins, a kit comprising the albumin fusion proteins, and methods for treating a disease or disorder in a patient, that is modulated by the therapeutic protein or its fragment or variant. The compositions and methods of the invention are useful in diagnosing, preventing, treating or ameliorating diseases or disorders, such as HIV, osteoporosis, cancer, wounds, autoimmune diseases, cardiovascular diseases, hepatitis, multiple sclerosis, psoriasis, graft-versus-host disease, stroke, atherosclerosis and inflammation. The present sequence represents a human therapeutic protein.

ACCESSION NUMBER: ADD68076 protein DGENE

TITLE: New **albumin fusion protein** for diagnosing, preventing or treating diseases (e.g. HIV, cancer, atherosclerosis or stroke) comprises a therapeutic protein (e.g. cathepsin K or vascular endothelial growth factor) and an albumin.

INVENTOR: Rosen C A; Haseltine W A

PATENT ASSIGNEE: (ROSE-I)ROSEN C A.

(HASE-I) HASELTINE W A.

PATENT INFO: US 2003125247 A1 20030703 180p

APPLICATION INFO: US 2001-833041 20010412

PRIORITY INFO: US 2000-229358P 20000412

US 2000-199384P 20000425

US 2000-256931P 20001221

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2003-810996 [76]

DESCRIPTION: Human therapeutic protein #6.

L19 ANSWER 30 OF 2840 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN

TI New **albumin fusion protein** for diagnosing, preventing or treating diseases (e.g. HIV, cancer, atherosclerosis or stroke) comprises a therapeutic protein (e.g. cathepsin K or vascular endothelial growth factor) and an albumin.

AN ADD68071 peptide DGENE

AB The present invention relates to albumin fusion proteins comprising any of the therapeutic proteins listed in the specification, or their fragments or variants, and an albumin protein or its fragments or variants. The invention also discloses pharmaceutical compositions comprising the albumin fusion proteins, a kit comprising the albumin

fusion proteins, and methods for treating a disease or disorder in a patient, that is modulated by the therapeutic protein or its fragment or variant. The compositions and methods of the invention are useful in diagnosing, preventing, treating or ameliorating diseases or disorders, such as HIV, osteoporosis, cancer, wounds, autoimmune diseases, cardiovascular diseases, hepatitis, multiple sclerosis, psoriasis, graft-versus-host disease, stroke, atherosclerosis and inflammation. The present sequence represents a human therapeutic protein.

ACCESSION NUMBER: ADD68071 peptide DGENE  
 TITLE: New **albumin fusion protein** for  
 diagnosing, preventing or treating diseases (e.g. HIV,  
 cancer, atherosclerosis or stroke) comprises a therapeutic  
 protein (e.g. cathepsin K or vascular endothelial growth  
 factor) and an albumin.  
 INVENTOR: Rosen C A; Haseltine W A  
 PATENT ASSIGNEE: (ROSE-I)ROSEN C A.  
 (HASE-I) HASELTINE W A.  
 PATENT INFO: US 2003125247 A1 20030703 180p  
 APPLICATION INFO: US 2001-833041 20010412  
 PRIORITY INFO: US 2000-229358P 20000412  
 US 2000-199384P 20000425  
 US 2000-256931P 20001221  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 OTHER SOURCE: 2003-810996 [76]  
 DESCRIPTION: Human therapeutic protein #1.

=> log y  
 COST IN U.S. DOLLARS SINCE FILE TOTAL  
 ENTRY SESSION  
 FULL ESTIMATED COST 272.52 272.73

STN INTERNATIONAL LOGOFF AT 18:31:43 ON 29 JAN 2004

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal653hxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
 NEWS 2 "Ask CAS" for self-help around the clock  
 NEWS 3 SEP 09 CA/Caplus records now contain indexing from 1907 to the  
 present  
 NEWS 4 DEC 08 INPADOC: Legal Status data reloaded  
 NEWS 5 SEP 29 DISSABS now available on STN  
 NEWS 6 OCT 10 PCTFULL: Two new display fields added  
 NEWS 7 OCT 21 BIOSIS file reloaded and enhanced  
 NEWS 8 OCT 28 BIOSIS file segment of TOXCENTER reloaded and enhanced  
 NEWS 9 NOV 24 MSDS-CCOHS file reloaded  
 NEWS 10 DEC 08 CABA reloaded with left truncation  
 NEWS 11 DEC 08 IMS file names changed  
 NEWS 12 DEC 09 Experimental property data collected by CAS now available

in REGISTRY

NEWS 13 DEC 09 STN Entry Date available for display in REGISTRY and CA/Caplus

NEWS 14 DEC 17 DGENE: Two new display fields added

NEWS 15 DEC 18 BIOTECHNO no longer updated

NEWS 16 DEC 19 CROPU no longer updated; subscriber discount no longer available

NEWS 17 DEC 22 Additional INPI reactions and pre-1907 documents added to CAS databases

NEWS 18 DEC 22 IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields

NEWS 19 DEC 22 ABI-INFORM now available on STN

NEWS 20 JAN 27 Source of Registration (SR) information in REGISTRY updated and searchable

NEWS 21 JAN 27 A new search aid, the Company Name Thesaurus, available in CA/Caplus

NEWS EXPRESS DECEMBER 28 CURRENT WINDOWS VERSION IS V7.00, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS INTER General Internet Information

NEWS LOGIN Welcome Banner and News Items

NEWS PHONE Direct Dial and Telecommunication Network Access to STN

NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 17:28:33 ON 30 JAN 2004

=> file medline, uspatful, dgene, embase, wpids, fsta, biosis,  
 COST IN U.S. DOLLARS SINCE FILE TOTAL  
 ENTRY SESSION  
 FULL ESTIMATED COST 0.21 0.21

FILE 'MEDLINE' ENTERED AT 17:28:55 ON 30 JAN 2004

FILE 'USPATFULL' ENTERED AT 17:28:55 ON 30 JAN 2004  
 CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 17:28:55 ON 30 JAN 2004  
 COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'EMBASE' ENTERED AT 17:28:55 ON 30 JAN 2004  
 COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'WPIDS' ENTERED AT 17:28:55 ON 30 JAN 2004  
 COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'FSTA' ENTERED AT 17:28:55 ON 30 JAN 2004  
 COPYRIGHT (C) 2004 International Food Information Service

FILE 'BIOSIS' ENTERED AT 17:28:55 ON 30 JAN 2004  
 COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC. (R)

=> s GLP-1  
 5 FILES SEARCHED...  
 L1 7447 GLP-1

```
=> s l1 and analog
L2      514 L1 AND ANALOG

=> s l2 and (7-34)
L3      61 L2 AND (7-34)

=> s l3 and tonicity modifier
L4      1 L3 AND TONICITY MODIFIER
```

```
=> d l4 ti abs ibib tot
```

```
L4  ANSWER 1 OF 1  USPATFULL on STN
TI   Peptide pharmaceutical formulations
AB   A pharmaceutical composition for administration to a mammal is
      disclosed. The composition includes a therapeutically effective amount
      of a peptide, such as a GLP-1 molecule, a PTH
      molecule, or a GRF molecule. The composition further includes a buffer
      including a weak acid having an acid dissociation constant value of
      greater than about 1+10.sup.-5, such as acetic acid. The
      composition also includes an excipient for making the composition
      generally isotonic, such as D-mannitol.
```

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

```
ACCESSION NUMBER: 2002:119850  USPATFULL
TITLE:           Peptide pharmaceutical formulations
INVENTOR(S):     Holmquist, Barton, Lincoln, NE, UNITED STATES
                  Dormady, Daniel C., Omaha, NE, UNITED STATES
```

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002061838	A1	20020523
APPLICATION INFO.:	US 2001-858880	A1	20010517 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-205377P	20000517 (60)
	US 2000-205262P	20000519 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Beth A. Burrous, FOLEY & LARDNER, Suite 500, 3000 K Street, N.W., Washington, DC, 20007-5109	
NUMBER OF CLAIMS:	14	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	
LINE COUNT:	929	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

```
=> d his
```

(FILE 'HOME' ENTERED AT 17:28:33 ON 30 JAN 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, BIOSIS' ENTERED AT 17:28:55 ON 30 JAN 2004

```
L1      7447 S GLP-1
L2      514 S L1 AND ANALOG
L3      61 S L2 AND (7-34)
L4      1 S L3 AND TONICITY MODIFIER
```

```
=> s l3 and solution
L5      61 L3 AND SOLUTION
```

```
=> s l5 and (7-35)
L6      52 L5 AND (7-35)
```

=> s l6 and (7-37)  
L7 48 L6 AND (7-37)

=> s l7 and (7-36)  
L8 48 L7 AND (7-36)

=> s l8 and pH  
L9 48 L8 AND PH

=> s l8 and basic pH  
L10 4 L8 AND BASIC PH

=> d l10 ti abs ibib tot

L10 ANSWER 1 OF 4 USPATFULL on STN

TI Indole carboxylic acids as thyroid receptor ligands

AB A compound of the formula ##STR1##

wherein W, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8 and R.sup.13 are as defined herein, useful in the treatment of obesity, overweight condition, hyperlipidemia, glaucoma, cardiac arrhythmias, skin disorders, thyroid disease, hypothyroidism, thyroid cancer and related disorders and diseases such as diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, congestive heart failure, hypercholesteremia, depression, osteoporosis and hair loss.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:113548 USPATFULL

TITLE: Indole carboxylic acids as thyroid receptor ligands

INVENTOR(S): Aspnes, Gary E., Rockville, RI, UNITED STATES  
Chiang, Yuan-Ching P., East Lyme, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003078289	A1	20030424
APPLICATION INFO.:	US 2002-255180	A1	20020924 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-325385P	20010926 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PFIZER INC., PATENT DEPARTMENT, MS8260-1611, EASTERN POINT ROAD, GROTON, CT, 06340	
NUMBER OF CLAIMS:	36	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3688	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 2 OF 4 USPATFULL on STN

TI Process for solubilizing glucagon-like peptide 1 compounds

AB Disclosed is a method of preparing a GLP-1 compound that is soluble in aqueous **solution** at pH 7.4 from a GLP-1 compound that is substantially insoluble in aqueous **solution** at pH 7.4. The insoluble GLP-1 compound is dissolved in aqueous base or in aqueous acid to form a GLP-1 **solution**. The GLP-1 **solution** is then neutralized to a pH at which substantially no amino acid racemization of the GLP-1 compounds occurs, after which the soluble GLP-1 compound is isolated from the neutralized **solution**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:86804 USPATFULL  
TITLE: Process for solubilizing glucagon-like peptide  
1compounds  
INVENTOR(S): Prouty, Walter Francis, JR., Indianapolis, IN, UNITED  
STATES  
Rinella, Joseph Vincent, JR., Ypsilanti, MI, UNITED  
STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003060412	A1	20030327
APPLICATION INFO.:	US 2002-169657	A1	20020628 (10)
	WO 2001-US10		20010116
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	ELI LILLY AND COMPANY, PATENT DIVISION, P.O. BOX 6288, INDIANAPOLIS, IN, 46206-6288		
NUMBER OF CLAIMS:	30		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Page(s)		
LINE COUNT:	1103		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 3 OF 4 USPATFULL on STN  
TI Glucagon-like peptide-1 crystals  
AB The invention provides individual tetragonal flat rod shaped or  
plate-like crystals of glucagon-like peptide-1 related molecules,  
processes for their preparation, compositions and methods of use. The  
crystal preparations exhibit extended time action in vivo and are useful  
for treating diabetes, obesity and related conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:65340 USPATFULL  
TITLE: Glucagon-like peptide-1 crystals  
INVENTOR(S): Hermeling, Ronald Norbert, Indianapolis, IN, UNITED  
STATES  
Hoffmann, James Arthur, Greenwood, IN, UNITED STATES  
Narasimhan, Chakravarthy, Carmel, IN, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003045464	A1	20030306
	US 6555521	B2	20030429
APPLICATION INFO.:	US 2001-997792	A1	20011130 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-209799, filed on 11 Dec 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-69728P	19971216 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ELI LILLY AND COMPANY, LILLY CORPORATE CENTER, DROP CODE 1104, INDIANAPOLIS, IN, 46285	
NUMBER OF CLAIMS:	25	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1128	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 4 OF 4 USPATFULL on STN  
TI GLUCAGON-LIKE PEPTIDE-1 CRYSTALS  
AB The invention provides individual tetragonal flat rod shaped or  
plate-like crystals of glucagon-like peptide-1 related molecules,  
processes for their preparation, compositions and methods of use. The  
crystal preparations exhibit extended time action in vivo and are useful

for treating diabetes, obesity and related conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:134217 USPATFULL  
TITLE: GLUCAGON-LIKE PEPTIDE-1 CRYSTALS  
INVENTOR(S): HERMELING, RONALD NORBERT, INDIANAPOLIS, IN, United States  
HOFFMANN, JAMES ARTHUR, GREENWOOD, IN, United States  
NARASIMHAN, CHAKAVARTHY, CARMEL, IN, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001014666	A1	20010816
	US 6380357	B2	20020430
APPLICATION INFO.:	US 1998-209799	A1	19981211 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	ROBERT A CONRAD, ELI LILLY AND COMPANY, PATENT DIVISION/RSM, LILLY CORPORATE CENTER, INDIANAPOLIS, IN, 46285		
NUMBER OF CLAIMS:	25		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1106		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 17:28:33 ON 30 JAN 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, BIOSIS' ENTERED AT  
17:28:55 ON 30 JAN 2004

L1 7447 S GLP-1  
L2 514 S L1 AND ANALOG  
L3 61 S L2 AND (7-34)  
L4 1 S L3 AND TONICITY MODIFIER  
L5 61 S L3 AND SOLUTION  
L6 52 S L5 AND (7-35)  
L7 48 S L6 AND (7-37)  
L8 48 S L7 AND (7-36)  
L9 48 S L8 AND PH  
L10 4 S L8 AND BASIC PH

=> s l9 and preservative

L11 12 L9 AND PRESERVATIVE

=> d l11 ti abs ibib tot

L11 ANSWER 1 OF 12 USPATFULL on STN

TI Inhibition of beta cell degeneration

AB This invention relates to a method for modulating, inhibiting or decreasing or preventing beta cell degeneration, loss of beta cell function, beta cell dysfunction, and/or death of beta cells, such as necrosis or apoptosis of beta cells in a subject comprising administering a GLP-1 agonist to said subject.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:312646 USPATFULL  
TITLE: Inhibition of beta cell degeneration  
INVENTOR(S): Knudsen, Liselotte Bjerre, Valby, DENMARK  
Godtfredsen, Carsten Foged, Herlev, DENMARK  
Petersen, Jacob Sten, Copenhagen O, DENMARK  
Carr, Richard David, Vaerloose, DENMARK

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 2003220251 A1 20031127  
 APPLICATION INFO.: US 2003-372485 A1 20030224 (10)  
 RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-709856, filed on 10  
 Nov 2000, GRANTED, Pat. No. US 6569832

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1999-1628	19991112
	DK 2000-270	20000222
	US 1999-166800P	19991122 (60)
	US 2000-185845P	20000229 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Reza Green, Esq., Novo Nordisk Pharmaceuticals, Inc., 100 College Road West, Princeton, NJ, 08540	
NUMBER OF CLAIMS:	8	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2373	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L11 ANSWER 2 OF 12 USPATFULL on STN

TI Derivatives of GLP-1 analogs

AB The present invention relates to a pharmaceutical composition comprising  
a GLP-1 derivative having a lipophilic substituent; and a surfactant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:283328 USPATFULL  
 TITLE: Derivatives of GLP-1 analogs  
 INVENTOR(S): Knudsen, Liselotte Bjerre, Valby, DENMARK  
 Huusfeldt, Per Olaf, Kobenhavn K, DENMARK  
 Nielsen, Per Franklin, Vaerloose, DENMARK  
 Kaarsholm, Niels C., Vanlose, DENMARK  
 Olsen, Helle Birk, Allerod, DENMARK  
 Bjorn, Soren Erik, Lyngby, DENMARK  
 Pedersen, Freddy Zimmerdahl, Vaerloose, DENMARK  
 Madsen, Kjeld, Vaerloose, DENMARK

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003199672	A1	20031023
APPLICATION INFO.:	US 2002-285079	A1	20020819 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-398111, filed on 16 Sep 1999, GRANTED, Pat. No. US 6458924		
	Continuation-in-part of Ser. No. US 1999-265141, filed on 8 Mar 1999, GRANTED, Pat. No. US 6384016		
	Continuation-in-part of Ser. No. US 1999-258750, filed on 26 Feb 1999, GRANTED, Pat. No. US 6268343		
	Continuation-in-part of Ser. No. US 1998-38432, filed on 11 Mar 1998, ABANDONED Continuation-in-part of Ser. No. US 1997-918810, filed on 26 Aug 1997, ABANDONED		
	Continuation-in-part of Ser. No. WO 1997-DK340, filed on 22 Aug 1997, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1996-931	19960830
	DK 1996-1259	19961108
	DK 1996-1470	19961220
	DK 1998-263	19980227
	DK 1998-264	19980227
	DK 1998-268	19980227
	EP 1998-610006	19980313
	DK 1998-507	19980408
	DK 1998-272	19980227



DK 1998-274	19980227
DK 1998-508	19980408
DK 1998-509	19980408
US 1997-35904P	19970124 (60)
US 1997-36226P	19970125 (60)
US 1997-36255P	19970124 (60)

DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: Reza Green, Esq., Novo Nordisk of North America, Inc.,  
 Suite 6400, 405 Lexington Avenue, New York, NY,  
 10174-6401  
 NUMBER OF CLAIMS: 238  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 1 Drawing Page(s)  
 LINE COUNT: 19138  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 3 OF 12 USPATFULL on STN

TI Protein formulations

AB The present invention discloses a stable, soluble formulation comprising  
 a medically useful peptide or protein, a hydrophobic  
**preservative**, and nicotinamide. Said storage-stable, soluble  
 formulation is useful as a multi-use pharmaceutical product.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:100072 USPATFULL  
 TITLE: Protein formulations  
 INVENTOR(S): Rinella, Vincent Joseph, JR., Brownsburg, IN, UNITED  
 STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003069182	A1	20030410
	US 6573237	B2	20030603
APPLICATION INFO.:	US 2002-170301	A1	20020612 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-787500, filed on 16 Mar 2001, GRANTED, Pat. No. US 6440930		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	ELI LILLY AND COMPANY, PATENT DIVISION, P.O. BOX 6288, INDIANAPOLIS, IN, 46206-6288		
NUMBER OF CLAIMS:	13		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Page(s)		
LINE COUNT:	700		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 4 OF 12 USPATFULL on STN

TI Glucagon-like peptide-1 crystals

AB The invention provides individual tetragonal flat rod shaped or  
 plate-like crystals of glucagon-like peptide-1 related molecules,  
 processes for their preparation, compositions and methods of use. The  
 crystal preparations exhibit extended time action in vivo and are useful  
 for treating diabetes, obesity and related conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:65340 USPATFULL  
 TITLE: Glucagon-like peptide-1 crystals  
 INVENTOR(S): Hermeling, Ronald Norbert, Indianapolis, IN, UNITED  
 STATES  
 Hoffmann, James Arthur, Greenwood, IN, UNITED STATES  
 Narasimhan, Chakravarthy, Carmel, IN, UNITED STATES

NUMBER	KIND	DATE
-----	-----	-----

PATENT INFORMATION: US 2003045464 A1 20030306  
US 6555521 B2 20030429  
APPLICATION INFO.: US 2001-997792 A1 20011130 (9)  
RELATED APPLN. INFO.: Continuation of Ser. No. US 1998-209799, filed on 11  
Dec 1998, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-69728P	19971216 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ELI LILLY AND COMPANY, LILLY CORPORATE CENTER, DROP CODE 1104, INDIANAPOLIS, IN, 46285	
NUMBER OF CLAIMS:	25	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1128	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 5 OF 12 USPATFULL on STN

TI Use of glycogen phosphorylase inhibitors

AB The invention provides methods of treating prophylactically an individual in whom Type 2 diabetes mellitus has not yet presented, but in whom there is an increased risk of developing such condition, which methods comprise administering to an individual in need thereof an effective amount of a glycogen phosphorylase inhibitor; effective amounts of a glycogen phosphorylase inhibitor and a non-glycogen phosphorylase inhibiting anti-diabetic agent; or effective amounts of a glycogen phosphorylase inhibitor and an anti-obesity agent.

The invention further provides methods of treating prophylactically an individual in whom Type 2 diabetes mellitus has not yet presented, but in whom there is an increased risk of developing such condition, which methods comprise administering to an individual in need thereof a pharmaceutical composition comprising effective amounts of a glycogen phosphorylase inhibitor and a non-glycogen phosphorylase inhibiting anti-diabetic agent; or effective amounts of a glycogen phosphorylase inhibitor and an anti-obesity agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:4123 USPATFULL  
TITLE: Use of glycogen phosphorylase inhibitors  
INVENTOR(S): Treadway, Judith L., Mystic, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003004162	A1	20030102
APPLICATION INFO.:	US 2001-813335	A1	20010320 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-191381P	20000322 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Gregg C. Benson, Pfizer Inc., Patent Department, MS 4159,, Eastern Point Road, Groton, CT, 06340	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
LINE COUNT:	4011	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 6 OF 12 USPATFULL on STN

TI GLP-1 formulations

AB Methods and formulations are presented that provide for a) the oral absorption of GLP-1 peptides that bind surfactants; and b) long-term storage of formulations containing these peptides. For

example, a **GLP-1**/DSS complex is administered orally instead of parenterally, which is much more convenient for, and facilitates compliance with diabetic patients and persons with other **GLP-1** treated conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:228306 USPATFULL  
TITLE: **GLP-1** formulations  
INVENTOR(S): Hoffmann, James Arthur, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002123466	A1	20020905
APPLICATION INFO.:	US 2002-72540	A1	20020208 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-573809, filed on 18 May 2000, GRANTED, Pat. No. US 6410513 Continuation of Ser. No. WO 1998-US25515, filed on 2 Dec 1998, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-67600P	19971205 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ELI LILLY AND COMPANY, PATENT DIVISION, P.O. BOX 6288, INDIANAPOLIS, IN, 46206-6288	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
LINE COUNT:	546	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 7 OF 12 USPATFULL on STN

TI Protein formulations

AB The present invention discloses a stable, soluble formulation comprising a medically useful peptide or protein, a hydrophobic **preservative**, and nicotinamide. Said storage-stable, soluble formulation is useful as a multi-use pharmaceutical product.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:217237 USPATFULL  
TITLE: Protein formulations  
INVENTOR(S): Rinella, Jr., Vincent Joseph, Brownsburg, IN, United States  
PATENT ASSIGNEE(S): Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6440930	B1	20020827
	WO 2000015224		20000323
APPLICATION INFO.:	US 2001-787500		20010316 (9)
	WO 1999-US21055		19990914
			20010316 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-100687P	19980917 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Henley, III, Raymond	
LEGAL REPRESENTATIVE:	Stewart, Mark J., Davis, Paula K.	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)	
LINE COUNT:	715	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 8 OF 12 USPATFULL on STN

TI Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders

AB The present invention relates to methods for prevention and treatment of bone-related or nutrition-related disorders using a GLP molecule or GLP activator either alone or in combination with another therapeutic. The present invention also encompasses methods of diagnosing or monitoring the progression of a disorder. The invention also encompasses methods of monitoring the effectiveness of treatment of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:67183 USPATFULL

TITLE: Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders

INVENTOR(S): Henriksen, Dennis Bang, Alleroed, DENMARK

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002037836	A1	20020328
APPLICATION INFO.:	US 2001-954304	A1	20010918 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2000-22844	20000918
	GB 2000-29920	20001207
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PENNIE AND EDMONDS, 1155 AVENUE OF THE AMERICAS, NEW YORK, NY, 100362711	
NUMBER OF CLAIMS:	57	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	2814	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 9 OF 12 USPATFULL on STN

TI **GLP-1** formulations

AB Methods and formulations are presented that provide for a) the oral absorption of **GLP-1** peptides that bind surfactants; and b) long-term storage of formulations containing these peptides. For example, a **GLP-1**/DSS complex is administered orally instead of parenterally, which is much more convenient for, and facilitates compliance with diabetic patients and persons with other **GLP-1** treated conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:57761 USPATFULL

TITLE: **GLP-1** formulations

INVENTOR(S): Hoffmann, James Arthur, Greenwood, IN, United States

PATENT ASSIGNEE(S): Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6358924	B1	20020319
APPLICATION INFO.:	US 2000-585181		20000601 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 1998-US25515, filed on 2 Dec 1998		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-67600P	19971205 (60)
DOCUMENT TYPE:	Utility	

FILE SEGMENT: GRANTED  
PRIMARY EXAMINER: Russel, Jeffrey E.  
LEGAL REPRESENTATIVE: Stewart, Mark J., Cox, Gregory A.  
NUMBER OF CLAIMS: 11  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)  
LINE COUNT: 490  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 10 OF 12 USPATFULL on STN  
TI GLUCAGON-LIKE PEPTIDE-1 CRYSTALS  
AB The invention provides individual tetragonal flat rod shaped or plate-like crystals of glucagon-like peptide-1 related molecules, processes for their preparation, compositions and methods of use. The crystal preparations exhibit extended time action in vivo and are useful for treating diabetes, obesity and related conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:134217 USPATFULL  
TITLE: GLUCAGON-LIKE PEPTIDE-1 CRYSTALS  
INVENTOR(S): HERMELING, RONALD NORBERT, INDIANAPOLIS, IN, United States  
HOFFMANN, JAMES ARTHUR, GREENWOOD, IN, United States  
NARASIMHAN, CHAKAVARTHY, CARMEL, IN, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001014666	A1	20010816
	US 6380357	B2	20020430
APPLICATION INFO.:	US 1998-209799	A1	19981211 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	ROBERT A CONRAD, ELI LILLY AND COMPANY, PATENT DIVISION/RSM, LILLY CORPORATE CENTER, INDIANAPOLIS, IN, 46285		
NUMBER OF CLAIMS:	25		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1106		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 11 OF 12 USPATFULL on STN  
TI DERIVATIVES OF GLP-1 ANALOGS  
AB The present invention relates to a pharmaceutical composition comprising a GLP-1 derivative having a lipophilic substituent; and a surfactant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:123563 USPATFULL  
TITLE: DERIVATIVES OF GLP-1 ANALOGS  
INVENTOR(S): KNUDSEN, LISELOTTE BJERRE, VALBY, Denmark  
HUUSFELDT, PER OLAF, KOBENHAVN K, Denmark  
NIELSEN, PER FRANKLIN, VARLOSE, Denmark  
KAARSHOLM, NIELS C., VANLOSE, Denmark  
OLSEN, HELLE BIRK, ALLEROD, Denmark  
BJORN, SOREN ERIK, LYNGBY, Denmark  
PEDERSEN, FREDDY ZIMMERDAHL, VARLOSE, Denmark  
MADSEN, KJELD, VARLOSE, Denmark

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001011071	A1	20010802
	US 6458924	B2	20021001
APPLICATION INFO.:	US 1999-398111	A1	19990916 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-265141, filed on 8 Mar 1999, PENDING		
	Continuation-in-part of Ser. No. US 1999-258750, filed on 26 Feb 1999, PENDING		

Continuation-in-part of Ser. No. US 1998-38432, filed on 11 Mar 1998, ABANDONED Continuation-in-part of Ser. No. US 1997-918810, filed on 26 Aug 1997, ABANDONED A 371 of International Ser. No. WO 1997-DK340, filed on 22 Aug 1997, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1996-931	19960830
	DK 1996-1259	19961108
	DK 1996-1470	19961220
	DK 1998-263	19980227
	DK 1998-264	19980227
	DK 1998-268	19980227
	EP 1998-610006	19980313
	DK 1998-507	19980408
	DK 1998-272	19980227
	DK 1998-274	19980227
	DK 1998-508	19980408
	DK 1998-509	19980408
	US 1997-35904P	19970124 (60)
	US 1997-36226P	19970125 (60)
	US 1997-36255P	19970124 (60)
	US 1998-78422P	19980318 (60)
	US 1998-82478P	19980421 (60)
	US 1998-82479P	19980421 (60)
	US 1998-82480P	19980421 (60)
	US 1998-82802P	19980423 (60)
	US 1998-84357P	19980505 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STEVE T ZELSON, NOVO NORDISK OF NORTH AMERICA INC, 405 LEXINGTON AVENUE, SUITE 6400, NEW YORK, NY, 101746401	
NUMBER OF CLAIMS:	238	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	15340	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L11 ANSWER 12 OF 12 USPATFULL on STN

TI Derivatives of GLP-1 analogs

AB The present invention relates to GLP-1 derivatives having a lipophilic substituent, pharmaceutical compositions comprising same, and methods of making an using same. The GLP-1 derivatives of the present invention have a protracted profile of action.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:121450 USPATFULL

TITLE: Derivatives of GLP-1 analogs

INVENTOR(S): Knudsen, Liselotte Bjerre, Valby, Denmark  
Huusfeldt, Per Olaf, K.o slashed.benhavn K, Denmark  
Nielsen, Per Franklin, V.ae butted.rl.o slashed.se, Denmark  
Kaarsholm, Niels C., Vanl.o slashed.se, Denmark  
Olsen, Helle Birk, Aller.o slashed.d, Denmark  
Bj.o slashed.rn, S.o slashed.ren Erik, Lyngby, Denmark  
Pedersen, Freddy Zimmerdahl, V.ae butted.rl.o slashed.se, Denmark  
Madsen, Kjeld, V.ae butted.rl.o slashed.se, Denmark  
PATENT ASSIGNEE(S): Novo Nordisk A/S, Bagsvaerd, Denmark (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6268343	B1	20010731

APPLICATION INFO.: US 1999-258750 19990226 (9)  
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1998-38432, filed  
on 11 Mar 1998, now abandoned Continuation-in-part of  
Ser. No. US 1997-918810, filed on 26 Aug 1997, now  
abandoned Continuation-in-part of Ser. No. WO  
1997-DK340, filed on 22 Aug 1997

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1996-931	19960830
	DK 1996-1259	19961108
	DK 1996-1470	19961220
	DK 1998-263	19980227
	DK 1998-264	19980227
	DK 1998-268	19980227
	DK 1998-272	19980227
	DK 1998-274	19980227
	DK 1998-508	19980408
	DK 1998-509	19980408
	US 1997-35904P	19970124 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Borin, Michael	
LEGAL REPRESENTATIVE:	Zelson, Esq., Steve T., Lambiris, Esq., Elias J.	
NUMBER OF CLAIMS:	40	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	14165	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

=> d his

(FILE 'HOME' ENTERED AT 17:28:33 ON 30 JAN 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, BIOSIS' ENTERED AT  
17:28:55 ON 30 JAN 2004

L1	7447 S GLP-1
L2	514 S L1 AND ANALOG
L3	61 S L2 AND (7-34)
L4	1 S L3 AND TONICITY MODIFIER
L5	61 S L3 AND SOLUTION
L6	52 S L5 AND (7-35)
L7	48 S L6 AND (7-37)
L8	48 S L7 AND (7-36)
L9	48 S L8 AND PH
L10	4 S L8 AND BASIC PH
L11	12 S L9 AND PRESERVATIVE

=> s l9 and TRIS

L12 31 L9 AND TRIS

=> s l12 and BRIJ-35

L13 2 L12 AND BRIJ-35

=> d l13 ti abs ibib tot

L13 ANSWER 1 OF 2 USPATFULL on STN

TI Derivatives of GLP-1 analogs

AB The present invention relates to a pharmaceutical composition comprising  
a GLP-1 derivative having a lipophilic substituent; and a surfactant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:283328 USPATFULL

TITLE: Derivatives of GLP-1 analogs

INVENTOR(S): Knudsen, Liselotte Bjerre, Valby, DENMARK  
Huusfeldt, Per Olaf, Kobenhavn K, DENMARK  
Nielsen, Per Franklin, Vaerloose, DENMARK  
Kaarsholm, Niels C., Vanlose, DENMARK  
Olsen, Helle Birk, Allerod, DENMARK  
Bjorn, Soren Erik, Lyngby, DENMARK  
Pedersen, Freddy Zimmerdahl, Vaerloose, DENMARK  
Madsen, Kjeld, Vaerloose, DENMARK

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003199672	A1	20031023
APPLICATION INFO.:	US 2002-285079	A1	20020819 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-398111, filed on 16 Sep 1999, GRANTED, Pat. No. US 6458924		
	Continuation-in-part of Ser. No. US 1999-265141, filed on 8 Mar 1999, GRANTED, Pat. No. US 6384016		
	Continuation-in-part of Ser. No. US 1999-258750, filed on 26 Feb 1999, GRANTED, Pat. No. US 6268343		
	Continuation-in-part of Ser. No. US 1998-38432, filed on 11 Mar 1998, ABANDONED		
	Continuation-in-part of Ser. No. US 1997-918810, filed on 26 Aug 1997, ABANDONED		
	Continuation-in-part of Ser. No. WO 1997-DK340, filed on 22 Aug 1997, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1996-931	19960830
	DK 1996-1259	19961108
	DK 1996-1470	19961220
	DK 1998-263	19980227
	DK 1998-264	19980227
	DK 1998-268	19980227
	EP 1998-610006	19980313
	DK 1998-507	19980408
	DK 1998-272	19980227
	DK 1998-274	19980227
	DK 1998-508	19980408
	DK 1998-509	19980408
	US 1997-35904P	19970124 (60)
	US 1997-36226P	19970125 (60)
	US 1997-36255P	19970124 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: Reza Green, Esq., Novo Nordisk of North America, Inc., Suite 6400, 405 Lexington Avenue, New York, NY, 10174-6401

NUMBER OF CLAIMS: 238  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 1 Drawing Page(s)  
LINE COUNT: 19138  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 2 OF 2 USPATFULL on STN  
TI DERIVATIVES OF GLP-1 ANALOGS  
AB The present invention relates to a pharmaceutical composition comprising a GLP-1 derivative having a lipophilic substituent; and a surfactant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:123563 USPATFULL  
TITLE: DERIVATIVES OF GLP-1 ANALOGS  
INVENTOR(S): KNUDSEN, LISELOTTE BJERRE, VALBY, Denmark  
HUUSFELDT, PER OLAF, KOBENHAVN K, Denmark  
NIELSEN, PER FRANKLIN, VARLOSE, Denmark  
KAARSHOLM, NIELS C., VANLOSE, Denmark



OLSEN, HELLE BIRK, ALLEROD, Denmark  
BJORN, SOREN ERIK, LYNGBY, Denmark  
PEDERSEN, FREDDY ZIMMERDAHL, VARLOSE, Denmark  
MADSEN, KJELD, VARLOSE, Denmark

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001011071	A1	20010802
	US 6458924	B2	20021001
APPLICATION INFO.:	US 1999-398111	A1	19990916 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-265141, filed on 8 Mar 1999, PENDING Continuation-in-part of Ser. No. US 1999-258750, filed on 26 Feb 1999, PENDING Continuation-in-part of Ser. No. US 1998-38432, filed on 11 Mar 1998, ABANDONED Continuation-in-part of Ser. No. US 1997-918810, filed on 26 Aug 1997, ABANDONED A 371 of International Ser. No. WO 1997-DK340, filed on 22 Aug 1997, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1996-931	19960830
	DK 1996-1259	19961108
	DK 1996-1470	19961220
	DK 1998-263	19980227
	DK 1998-264	19980227
	DK 1998-268	19980227
	EP 1998-610006	19980313
	DK 1998-507	19980408
	DK 1998-272	19980227
	DK 1998-274	19980227
	DK 1998-508	19980408
	DK 1998-509	19980408
	US 1997-35904P	19970124 (60)
	US 1997-36226P	19970125 (60)
	US 1997-36255P	19970124 (60)
	US 1998-78422P	19980318 (60)
	US 1998-82478P	19980421 (60)
	US 1998-82479P	19980421 (60)
	US 1998-82480P	19980421 (60)
	US 1998-82802P	19980423 (60)
	US 1998-84357P	19980505 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STEVE T ZELSON, NOVO NORDISK OF NORTH AMERICA INC, 405 LEXINGTON AVENUE, SUITE 6400, NEW YORK, NY, 101746401	
NUMBER OF CLAIMS:	238	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	15340	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

=> d his

(FILE 'HOME' ENTERED AT 17:28:33 ON 30 JAN 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, BIOSIS' ENTERED AT 17:28:55 ON 30 JAN 2004

L1 7447 S GLP-1  
L2 514 S L1 AND ANALOG  
L3 61 S L2 AND (7-34)  
L4 1 S L3 AND TONICITY MODIFIER  
L5 61 S L3 AND SOLUTION  
L6 52 S L5 AND (7-35)

L7 48 S L6 AND (7-37)  
 L8 48 S L7 AND (7-36)  
 L9 48 S L8 AND PH  
 L10 4 S L8 AND BASIC PH  
 L11 12 S L9 AND PRESERVATIVE  
 L12 31 S L9 AND TRIS  
 L13 2 S L12 AND BRIJ-35

=> d l12 ti abs ibib 1-15

L12 ANSWER 1 OF 31 USPATFULL on STN  
 TI Novel glucagon antagonists/inverse agonists  
 AB Novel compounds that act to antagonize the action of the glucagon peptide hormone on the glucagon receptor. More particularly, it relates to glucagon antagonists or inverse agonists.

ACCESSION NUMBER: 2004:19485 USPATFULL  
 TITLE: Novel glucagon antagonists/inverse agonists  
 INVENTOR(S): Lau, Jesper, Farum, DENMARK  
 Christensen, Inge Thoger, Lyngby, DENMARK  
 Madsen, Peter, Bagsvaerd, DENMARK  
 Bloch, Paw, Taastrup, DENMARK  
 Behrens, Carsten, Kobenhavn, DENMARK  
 Kodra, Janos Tibor, Kobenhavn, DENMARK  
 Nielsen, Poul Enrico, Borup, DENMARK

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004014789	A1	20040122
APPLICATION INFO.:	US 2003-448529	A1	20030530 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	DK 2001-1789	20011203
	DK 2002-1006	20020627
	DK 2002-1927	20021217
	US 2002-394145P	20020703 (60)
	US 2002-434255P	20021218 (60)

DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: Reza Green, Esq., Novo Nordisk Pharmaceuticals, Inc.,  
 100 College Road West, Princeton, NJ, 08540  
 NUMBER OF CLAIMS: 36  
 EXEMPLARY CLAIM: 1  
 LINE COUNT: 4435

L12 ANSWER 2 OF 31 USPATFULL on STN  
 TI Modified transferrin fusion proteins  
 AB Modified fusion proteins of transferrin and therapeutic proteins or peptides including soluble toxin receptors, with increased serum half-life or serum stability are disclosed. Preferred fusion proteins include those modified so that the transferrin moiety exhibits no or reduced glycosylation, binding to iron and/or binding to the transferrin receptor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:313593 USPATFULL  
 TITLE: Modified transferrin fusion proteins  
 INVENTOR(S): Prior, Christopher P., King of Prussia, PA, UNITED STATES  
 Lai, Char-Huei, King of Prussia, PA, UNITED STATES  
 Sadeghi, Homayoun, King of Prussia, PA, UNITED STATES  
 Turner, Andrew, King of Prussia, PA, UNITED STATES  
 PATENT ASSIGNEE(S): BIOREXIS PHARMACEUTICAL CORPORATION (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003221201	A1	20031127
APPLICATION INFO.:	US 2003-378094	A1	20030304 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-231494, filed on 30 Aug 2002, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-315745P	20010830 (60)
	US 2001-334059P	20011130 (60)
	US 2002-406977P	20020830 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MORGAN LEWIS & BOCKIUS LLP, 1111 PENNSYLVANIA AVENUE NW, WASHINGTON, DC, 20004	
NUMBER OF CLAIMS:	86	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	6 Drawing Page(s)	
LINE COUNT:	5075	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L12 ANSWER 3 OF 31 USPATFULL on STN

TI Glucagon antagonists/inverse agonists

AB A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any glucagon-mediated conditions and diseases such as hyperglycemia, Type 1 diabetes, Type 2 diabetes and obesity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:312745 USPATFULL

TITLE: Glucagon antagonists/inverse agonists

INVENTOR(S): Lau, Jesper, Farum, DENMARK  
Madsen, Peter, Bagsvaerd, DENMARK  
Sams, Christian, Frederiksberg, DENMARK  
Behrens, Carsten, Copenhagen N, DENMARK  
Vagner, Josef, Oro Valley, AZ, UNITED STATES  
Christensen, Inge Thoger, Lyngby, DENMARK  
Lundt, Behrend Frederik, Kokkedal, DENMARK  
Sidelmann, Ulla Grove, Vedbaek, DENMARK  
Thogersen, Henning, Farum, DENMARK  
Ling, Anthony L., San Diego, CA, UNITED STATES  
Plewe, Michael Bruno, San Diego, CA, UNITED STATES  
Truesdale, Larry Kenneth, San Diego, CA, UNITED STATES  
Jogensen, Anker Steen, Copenhagen, DENMARK  
Kodra, Janos Tibor, Copenhagen, DENMARK  
Shi, Shenghua, San Diego, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003220350	A1	20031127
APPLICATION INFO.:	US 2002-233851	A1	20020830 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-572553, filed on 16 May 2000, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1999-684	19990517
	DK 2000-478	20000321
	US 1999-134415P	19990517 (60)
	US 2000-191685P	20000323 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	

LEGAL REPRESENTATIVE: Reza Green, Esq., Novo Nordisk of North America, Inc.,  
Suite 6400, 405 Lexington, New York, NY, 10174-6400  
NUMBER OF CLAIMS: 88  
EXEMPLARY CLAIM: 1  
LINE COUNT: 13924  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 4 OF 31 USPATFULL on STN  
TI Derivatives of GLP-1 analogs  
AB The present invention relates to a pharmaceutical composition comprising  
a GLP-1 derivative having a lipophilic substituent; and a surfactant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:283328 USPATFULL  
TITLE: Derivatives of GLP-1 analogs  
INVENTOR(S): Knudsen, Liselotte Bjerre, Valby, DENMARK  
Huusfeldt, Per Olaf, Kobenhavn K, DENMARK  
Nielsen, Per Franklin, Vaerlose, DENMARK  
Kaarsholm, Niels C., Vanlose, DENMARK  
Olsen, Helle Birk, Allerod, DENMARK  
Bjorn, Soren Erik, Lyngby, DENMARK  
Pedersen, Freddy Zimmerdahl, Vaerlose, DENMARK  
Madsen, Kjeld, Vaerlose, DENMARK

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003199672	A1	20031023
APPLICATION INFO.:	US 2002-285079	A1	20020819 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-398111, filed on 16 Sep 1999, GRANTED, Pat. No. US 6458924		
	Continuation-in-part of Ser. No. US 1999-265141, filed on 8 Mar 1999, GRANTED, Pat. No. US 6384016		
	Continuation-in-part of Ser. No. US 1999-258750, filed on 26 Feb 1999, GRANTED, Pat. No. US 6268343		
	Continuation-in-part of Ser. No. US 1998-38432, filed on 11 Mar 1998, ABANDONED Continuation-in-part of Ser. No. US 1997-918810, filed on 26 Aug 1997, ABANDONED		
	Continuation-in-part of Ser. No. WO 1997-DK340, filed on 22 Aug 1997, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1996-931	19960830
	DK 1996-1259	19961108
	DK 1996-1470	19961220
	DK 1998-263	19980227
	DK 1998-264	19980227
	DK 1998-268	19980227
	EP 1998-610006	19980313
	DK 1998-507	19980408
	DK 1998-272	19980227
	DK 1998-274	19980227
	DK 1998-508	19980408
	DK 1998-509	19980408
	US 1997-35904P	19970124 (60)
	US 1997-36226P	19970125 (60)
	US 1997-36255P	19970124 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: Reza Green, Esq., Novo Nordisk of North America, Inc.,  
Suite 6400, 405 Lexington Avenue, New York, NY,  
10174-6401  
NUMBER OF CLAIMS: 238  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 1 Drawing Page(s)

LINE COUNT: 19138  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 5 OF 31 USPATFULL on STN

TI Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins  
AB The present invention provides a means for increasing the serum half-life of a selected biologically active agent by utilizing transthyretin (TTR) as a fusion partner with a biologically active agent. Specifically, the present invention provides substantially homogenous preparations of TTR (or a TTR variant)-biologically active agent fusions and PEG-TTR (PEG-TTR variant)-biologically active agent fusions. As compared to the biologically active agent alone, the TTR-biologically active agent fusion and/or PEG-TTR-biologically active agent fusion has substantially increased serum half-life.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:277127 USPATFULL  
TITLE: Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins  
INVENTOR(S): Walker, Kenneth, Newbury Park, CA, UNITED STATES  
Xiong, Fei, Thousand Oaks, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003195154	A1	20031016
APPLICATION INFO.:	US 2003-407078	A1	20030403 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-117109, filed on 4 Apr 2002, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	AMGEN INCORPORATED, MAIL STOP 27-4-A, ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA, 91320-1799		
NUMBER OF CLAIMS:	37		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	15 Drawing Page(s)		
LINE COUNT:	3042		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 6 OF 31 USPATFULL on STN

TI Crystallisation of a GLP-1 analogue  
AB Crystals of glucagon-like peptide-1 (GLP-1) and GLP-1 analogues, and processes for preparation of crystals of GLP-1 and GLP-1 analogues.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:265841 USPATFULL  
TITLE: Crystallisation of a GLP-1 analogue  
INVENTOR(S): Arentsen, Anne Charlotte, Holte, DENMARK

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003186858	A1	20031002
APPLICATION INFO.:	US 2001-769692	A1	20010125 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	NL 2000-156	20000131
	US 2000-183300P	20000217 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Steve T. Zelson, Esq., Novo Nordisk of North America, Inc., Suite 6400, 405 Lexington Avenue, New York, NY,	

10174-6400  
NUMBER OF CLAIMS: 15  
EXEMPLARY CLAIM: 1  
LINE COUNT: 1159  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 7 OF 31 USPATFULL on STN

TI C-aryl glucoside SGLT2 inhibitors and method  
AB A method is provided for treating diabetes and related diseases  
employing an SGLT2 inhibiting amount of a compound of the formula  
##STR1##

alone or in combination with one or more other antidiabetic agent(s) or  
other therapeutic agent(s).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:166532 USPATFULL  
TITLE: C-aryl glucoside SGLT2 inhibitors and method  
INVENTOR(S): Washburn, William N., Titusville, NJ, UNITED STATES  
Ellsworth, Bruce, Princeton, NJ, UNITED STATES  
Meng, Wei, Pennington, NJ, UNITED STATES  
Wu, Gang, Princeton, NJ, UNITED STATES  
Sher, Philip M., Plainsboro, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003114390	A1	20030619
APPLICATION INFO.:	US 2002-264410	A1	20021004 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-805341, filed on 13 Mar 2001, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000		
NUMBER OF CLAIMS:	24		
EXEMPLARY CLAIM:	1		
LINE COUNT:	2410		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 8 OF 31 USPATFULL on STN

TI Heterocyclic compounds that are inhibitors of the enzyme DPP-IV  
AB The present invention relates to therapeutically active and selective  
inhibitors of the enzyme DPP-IV of formula I, pharmaceutical  
compositions comprising the compounds and the use of such compounds for  
and the manufacture of medicaments for treating diseases that are  
associated with proteins that are subject to inactivation by DPP-IV,  
such as type 2 diabetes and obesity. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:153409 USPATFULL  
TITLE: Heterocyclic compounds that are inhibitors of the  
enzyme DPP-IV  
INVENTOR(S): Kanstrup, Anders Bendtz, Espergaerde, DENMARK  
Sams, Christian Klarner, Frederiksberg C, DENMARK  
Lundbeck, Jane Marie, Glostrup, DENMARK  
Christiansen, Lise Brown, Lyngby, DENMARK  
Kristiansen, Marit, Soborg, DENMARK

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003105077	A1	20030605
APPLICATION INFO.:	US 2002-186498	A1	20020628 (10)

NUMBER	DATE
-----	-----

PRIORITY INFORMATION: DK 2001-1049 20010703  
DK 2002-180 20020206  
US 2001-309621P 20010802 (60)  
US 2002-356631P 20020208 (60)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: Reza Green, Esq.,, Novo Nordisk of North America,  
Inc.,, Suite 6400, 405 Lexington Avenue, New York, NY,  
10174-6401  
NUMBER OF CLAIMS: 53  
EXEMPLARY CLAIM: 1  
LINE COUNT: 2972  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 9 OF 31 USPATFULL on STN

TI Substituted acid derivatives useful as antidiabetic and antiobesity  
agents and method

AB Compounds are provided which have the structure ##STR1##

wherein Q is C or N, A is O or S, Z is O or a bond, X is CH or N and  
R.sup.1, R.sup.2, R.sup.2a, R.sup.2b, R.sup.2c, R.sup.3, Y, x, m, and n  
are as defined herein, which compounds are useful as antidiabetic,  
hypolipidemic, and antiobesity agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:141004 USPATFULL  
TITLE: Substituted acid derivatives useful as antidiabetic and  
antiobesity agents and method  
INVENTOR(S): Cheng, Peter T., Princeton, NJ, UNITED STATES  
Devasthale, Pratik, Plainsboro, NJ, UNITED STATES  
Jeon, Yoon, Belle Mead, NJ, UNITED STATES  
Chen, Sean, Princeton, NJ, UNITED STATES  
Zhang, Hao, Belle Mead, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003096846	A1	20030522
	US 6653314	B2	20031125
APPLICATION INFO.:	US 2002-80981	A1	20020222 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-812960, filed on 20 Mar 2001, GRANTED, Pat. No. US 6414002 Continuation-in-part of Ser. No. US 2000-664598, filed on 18 Sep 2000, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-155400P	19990922 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000	
NUMBER OF CLAIMS:	54	
EXEMPLARY CLAIM:	1	
LINE COUNT:	5718	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 10 OF 31 USPATFULL on STN

TI Substituted acid derivatives useful as antidiabetic and antiobesity  
agents and method

AB Compounds are provided which have the structure ##STR1##

wherein Q is C or N, A is O or S, Z is O or a bond, X is CH or N and  
R.sup.1, R.sup.2, R.sup.2a, R.sup.2b, R.sup.2c, R.sup.3, Y, x, m, and n  
are as defined herein, which compounds are useful as antidiabetic,  
hypolipidemic, and antiobesity agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:127720 USPATFULL  
TITLE: Substituted acid derivatives useful as antidiabetic and  
antiobesity agents and method  
INVENTOR(S): Cheng, Peter T., Princeton, NJ, UNITED STATES  
Devasthale, Pratik, Plainsboro, NJ, UNITED STATES  
Jeon, Yoon, Belle Mead, NJ, UNITED STATES  
Chen, Sean, Princeton, NJ, UNITED STATES  
Zhang, Hao, Belle Mead, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003087935	A1	20030508
APPLICATION INFO.:	US 2002-81075	A1	20020222 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2001-812960, filed on 20 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2000-664598, filed on 18 Sep 2000, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-155400P	19990922 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Stephen B. Davis, Bristol-Myers Squibb Company, Patent Department, P.O. Box 4000, Princeton, NJ, 08543-4000	
NUMBER OF CLAIMS:	54	
EXEMPLARY CLAIM:	1	
LINE COUNT:	5712	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 11 OF 31 USPATFULL on STN

TI Indole carboxylic acids as thyroid receptor ligands  
AB A compound of the formula ##STR1##

wherein W, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6,  
R.sup.7, R.sup.8 and R.sup.13 are as defined herein, useful in the  
treatment of obesity, overweight condition, hyperlipidemia, glaucoma,  
cardiac arrhythmias, skin disorders, thyroid disease, hypothyroidism,  
thyroid cancer and related disorders and diseases such as diabetes  
mellitus, atherosclerosis, hypertension, coronary heart disease,  
congestive heart failure, hypercholesteremia, depression, osteoporosis  
and hair loss.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:113548 USPATFULL  
TITLE: Indole carboxylic acids as thyroid receptor ligands  
INVENTOR(S): Aspnes, Gary E., Rockville, RI, UNITED STATES  
Chiang, Yuan-Ching P., East Lyme, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003078289	A1	20030424
APPLICATION INFO.:	US 2002-255180	A1	20020924 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-325385P	20010926 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PFIZER INC., PATENT DEPARTMENT, MS8260-1611, EASTERN POINT ROAD, GROTON, CT, 06340	
NUMBER OF CLAIMS:	36	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3688	



CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 12 OF 31 USPATFULL on STN

TI Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes

AB A combination therapy of at least one FBPase inhibitor and at least one other antidiabetic agent is disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:106816 USPATFULL

TITLE: Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes

INVENTOR(S): van Poelje, Paul D., La Jolla, CA, UNITED STATES

Erion, Mark D., Del Mar, CA, UNITED STATES

Fujiwara, Toshihiko, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003073728	A1	20030417
APPLICATION INFO.:	US 2001-900364	A1	20010705 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-216531P	20000706 (60)
	US 2000-215126P	20000629 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BROBECK, PHLEGER & HARRISON LLP, 12390 EL CAMINO REAL, SAN DIEGO, CA, 92130	
NUMBER OF CLAIMS:	114	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	12671	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 13 OF 31 USPATFULL on STN

TI Substituted acid derivatives useful as antidiabetic and antiobesity agents and method

AB Compounds are provided which have the structure ##STR1##

wherein Q is C or N, A is O or S, Z is O or a bond, X is CH or N and R.sup.1, R.sup.2, R.sup.2a, R.sup.2b, R.sup.2c, R.sup.3, Y, x, m, and n are as defined herein, which compounds are useful as antidiabetic, hypolipidemic, and antiobesity agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:100164 USPATFULL

TITLE: Substituted acid derivatives useful as antidiabetic and antiobesity agents and method

INVENTOR(S): Cheng, Peter T., Princeton, NJ, UNITED STATES

Devasthale, Pratik, Plainsboro, NJ, UNITED STATES

Jeon, Yoon, Belle Mead, NJ, UNITED STATES

Chen, Sean, Princeton, NJ, UNITED STATES

Zhang, Hao, Belle Mead, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003069275	A1	20030410
APPLICATION INFO.:	US 2002-80965	A1	20020222 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2001-812960, filed on 20 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2000-664598, filed on 18 Sep 2000, PENDING		

NUMBER	DATE
-----	-----

PRIORITY INFORMATION: US 1999-155400P 19990922 (60)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT  
DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000  
NUMBER OF CLAIMS: 54  
EXEMPLARY CLAIM: 1  
LINE COUNT: 5710  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 14 OF 31 USPATFULL on STN

TI Protein formulations

AB The present invention discloses a stable, soluble formulation comprising  
a medically useful peptide or protein, a hydrophobic preservative, and  
nicotinamide. Said storage-stable, soluble formulation is useful as a  
multi-use pharmaceutical product.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:100072 USPATFULL  
TITLE: Protein formulations  
INVENTOR(S): Rinella, Vincent Joseph, JR., Brownsburg, IN, UNITED  
STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003069182	A1	20030410
	US 6573237	B2	20030603
APPLICATION INFO.:	US 2002-170301	A1	20020612 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-787500, filed on 16 Mar 2001, GRANTED, Pat. No. US 6440930		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	ELI LILLY AND COMPANY, PATENT DIVISION, P.O. BOX 6288, INDIANAPOLIS, IN, 46206-6288		
NUMBER OF CLAIMS:	13		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Page(s)		
LINE COUNT:	700		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 15 OF 31 USPATFULL on STN

TI Glucagon-like peptide-1 crystals

AB The invention provides individual tetragonal flat rod shaped or  
plate-like crystals of glucagon-like peptide-1 related molecules,  
processes for their preparation, compositions and methods of use. The  
crystal preparations exhibit extended time action in vivo and are useful  
for treating diabetes, obesity and related conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:65340 USPATFULL  
TITLE: Glucagon-like peptide-1 crystals  
INVENTOR(S): Hermeling, Ronald Norbert, Indianapolis, IN, UNITED  
STATES  
Hoffmann, James Arthur, Greenwood, IN, UNITED STATES  
Narasimhan, Chakravarthy, Carmel, IN, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003045464	A1	20030306
	US 6555521	B2	20030429
APPLICATION INFO.:	US 2001-997792	A1	20011130 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-209799, filed on 11 Dec 1998, PENDING		

NUMBER	DATE
--------	------

```

-----
PRIORITY INFORMATION:  US 1997-69728P      19971216 (60)
DOCUMENT TYPE:         Utility
FILE SEGMENT:         APPLICATION
LEGAL REPRESENTATIVE:  ELI LILLY AND COMPANY, LILLY CORPORATE CENTER, DROP
                       CODE 1104, INDIANAPOLIS, IN, 46285
NUMBER OF CLAIMS:      25
EXEMPLARY CLAIM:       1
LINE COUNT:            1128
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

```

```

=> log y
COST IN U.S. DOLLARS                SINCE FILE      TOTAL
                                     ENTRY      SESSION
FULL ESTIMATED COST                78.48        78.69

```

STN INTERNATIONAL LOGOFF AT 17:35:18 ON 30 JAN 2004

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal653hxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

```

NEWS 1      Web Page URLs for STN Seminar Schedule - N. America
NEWS 2      "Ask CAS" for self-help around the clock
NEWS 3  SEP 09  CA/CAPLUS records now contain indexing from 1907 to the
               present
NEWS 4  DEC 08  INPADOC: Legal Status data reloaded
NEWS 5  SEP 29  DISSABS now available on STN
NEWS 6  OCT 10  PCTFULL: Two new display fields added
NEWS 7  OCT 21  BIOSIS file reloaded and enhanced
NEWS 8  OCT 28  BIOSIS file segment of TOXCENTER reloaded and enhanced
NEWS 9  NOV 24  MSDS-CCOHS file reloaded
NEWS 10 DEC 08  CABA reloaded with left truncation
NEWS 11 DEC 08  IMS file names changed
NEWS 12 DEC 09  Experimental property data collected by CAS now available
               in REGISTRY
NEWS 13 DEC 09  STN Entry Date available for display in REGISTRY and CA/CAPLUS
NEWS 14 DEC 17  DGENE: Two new display fields added
NEWS 15 DEC 18  BIOTECHNO no longer updated
NEWS 16 DEC 19  CROPU no longer updated; subscriber discount no longer
               available
NEWS 17 DEC 22  Additional INPI reactions and pre-1907 documents added to CAS
               databases
NEWS 18 DEC 22  IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
NEWS 19 DEC 22  ABI-INFORM now available on STN
NEWS 20 JAN 27  Source of Registration (SR) information in REGISTRY updated
               and searchable
NEWS 21 JAN 27  A new search aid, the Company Name Thesaurus, available in
               CA/CAPLUS

```

NEWS EXPRESS DECEMBER 28 CURRENT WINDOWS VERSION IS V7.00, CURRENT